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ABSTRACT 
 
 PAC-1 is an ortho-hydroxy-N-acylhydrazone that induces apoptosis by chelation of 
antiapoptotic labile zinc, relieving zinc-mediated inhibition of procaspase-3. Favorable results 
from cell culture and in vivo experiments with PAC-1 and its derivative S-PAC-1 have indicated 
the potential for translation to the clinic. However, several challenges exist in using PAC-1 in 
these experiments. This report describes the attempts to improve upon the process synthesis, 
potency, pharmacokinetics, and safety of PAC-1. 
The synthetic route to access PAC-1 was successful for the generation of batches of 
approximately 25 grams, but adaptation to multi-kilogram scale, as would be necessary for a 
human clinical trial, was not feasible using the existing route. In particular, the route included 
three chromatographic purification steps, as well as the use of anhydrous hydrazine. 
Optimization studies indicated that the active pharmaceutical ingredient could be synthesized 
without purification of any intermediates, and hydrazine monohydrate could be used in place of 
the anhydrous reagent. A batch of 155 grams of PAC-1 was synthesized using the improved 
route, and the route was scaled up to produce a batch of greater than 10 kilograms by a contract 
research organization. The lessons learned through this optimization effort were general and 
should be applicable if an alternative PAC-1 derivative is identified. 
In an effort to discover PAC-1 derivatives with improved potency, a combinatorial 
library of 837 compounds was synthesized. Each of 31 hydrazides was condensed with each of 
27 aldehydes. Because standard techniques for isolation and purification of products are 
impractical for libraries of this size, a solid-phase purification strategy was employed that 
yielded the library members with an average purity of 91%. Compounds were screened in cell 
culture, and six potent hits were identified. One of these compounds, B-PAC-1, was studied 
further in primary isolates from leukemia patients, and animal experiments are currently in 
progress. 
An additional challenge is the relatively rapid clearance of PAC-1 from circulation. 
Many sites of metabolism exist, giving metabolites that arise from oxidative N-dealkylation, 
olefin oxidation, and arene oxidation. Several derivatives were synthesized containing 
modifications that prevent the formation of these metabolites. The compounds were evaluated in 
cell culture, liver microsomes, and mice, and four lead compounds were identified. 
iii 
 
Pharmacokinetic analysis indicated that each of these four compounds displayed extended 
elimination half-lives compared to PAC-1 and S-PAC-1, making these compounds viable 
candidates as next-generation PAC-1 derivatives. 
One of the most significant challenges in working with PAC-1 in vivo is the 
neuroexcitation observed upon treatment with elevated doses of compound. Preliminary 
experiments suggested that the neurotoxicity was not related to the ability of the compound to 
bind zinc. In order to confirm these results and attempt to determine the portion of the molecule 
responsible for neurotoxicity, a series of compounds was designed and synthesized containing 
systematic modifications to PAC-1. Evaluation in cell culture and in vitro further defined the 
essential nature of the ortho-hydroxy-N-acylhydrazone for activity. Evaluation of the compounds 
in mice confirmed previous experiments that the neurotoxicity is most likely not a result of metal 
chelation, but no further conclusions could be drawn from these experiments, and further study 
will be necessary to fully define the observed neurotoxicity. 
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Chapter 1. Anticancer Activity of PAC-1 and Derivatives 
 
Portions of the text of this chapter are adapted with permission from literature (Hsu, D. C.; Roth, 
H. S.; West, D. C.; Botham, R. C.; Novotny, C. J.; Schmid, S. C.; Hergenrother, P. J. Parallel 
synthesis and biological evaluation of 837 analogues of Procaspase-Activating Compound 1 
(PAC-1). ACS Comb. Sci. 2012, 14, 44-50.
1
 Roth, H. S.; Botham, R. C.; Schmid, S. C.; Fan, T. 
M.; Dirikolu, L.; Hergenrother, P. J. Removal of metabolic liabilities enables development of 
derivatives of Procaspase-Activating Compound 1 (PAC-1) with improved pharmacokinetics. J. 
Med. Chem. 2015, 58(9), 4046-4065.
2
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1.1. Introduction: Procaspase-3 activation as an anticancer strategy 
Apoptosis is a process used by higher organisms to maintain homeostasis by removing 
cells that are in excess, damaged, or potentially dangerous.  Critical to apoptosis is the activation 
of caspase enzymes, a class of cysteine proteases that cleave cellular substrates after recognition 
sequences with C-terminal aspartate residues.
3
 There are two canonical apoptotic pathways, 
differing in that the apoptosis-initiating stimulus is intracellular (intrinsic pathway) or 
extracellular (extrinsic pathway).
4
 These pathways converge at the cleavage of procaspase-3 to 
form the active caspase-3, the key “executioner” caspase that catalyzes the hydrolysis of 
hundreds of protein substrates,
5-8
 leading to cell death. As one of the hallmarks of cancer is the 
ability to evade apoptosis,
9, 10
 many recent efforts to develop new anticancer drugs have focused 
on inhibition of antiapoptotic proteins, including MDM2,
11, 12
 Bcl-2,
13, 14
 and XIAP
15, 16
 (Figure 
1.1). The mutation and upregulation of these proteins provides targets that exist at much higher 
concentrations in cancer cells, reducing the potential for induction of apoptosis in healthy cells, 
which could lead to undesired toxicity. Similarly, small molecules capable of enhancing the 
activity of proapoptotic proteins hold promise for the treatment of cancer. One target that has 
received considerable attention is procaspase-3.
17-20
 The low frequency of procaspase-3 
mutations in cancer,
21
 its downstream location relative to apoptotic proteins that are frequently 
mutated,
4
 and the overexpression of procaspase-3 in a number of cancer types, including 
lymphoma,
22, 23
 leukemia,
24, 25
 melanoma,
26, 27
 glioblastoma,
28, 29
 pancreatic cancer,
30
 liver 
cancer,
31
 lung cancer,
32-34
 breast cancer,
35-38
 esophageal cancer,
39
 and colon cancer,
17, 40-42
 have 
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made the small molecule-mediated activation of procaspase-3 an attractive strategy for 
personalized medicine.
17-20
 
 
 
Figure 1.1. Representative small-molecule modulators of apoptotic regulators. 
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1.2. PAC-1 
 
1.2.1 Initial discovery of PAC-1 
 Procaspase Activating Compound 1 (PAC-1, 1.1, Figure 1.2) was discovered in the 
Hergenrother laboratory via a high-throughput screen of over 20,000 small molecules as a 
compound that could enhance the enzymatic activity of procaspase-3 in vitro, with an EC50 of 
0.22 µM for procaspase-3 activation. PAC-1 induced apoptosis in cancer cells in culture, with a 
72-hour IC50 of 0.92 µM against HL-60 (human leukemia) cells. PAC-1 is cytotoxic against a 
diverse array of cancer cells in culture, including cell lines derived from hematopoietic tumors 
(lymphoma,
1, 2, 17, 43-49
 leukemia,
2, 17, 45, 48-53
 and  multiple myeloma
53
), carcinomas of diverse 
origin (breast,
17, 45, 48-52, 54-56
 renal,
17
 adrenal,
17, 57
 colon, 
17, 48, 53, 55, 56, 58
 lung,
17, 48-56, 58-61
 
cervical,
45, 53
 gastric, 
48, 49, 53, 55, 56, 58
 ovarian,
53
 liver,
48, 49, 53
 prostate,
48, 49
 and gallbladder
48, 49
), 
and other solid tumor histologies (melanoma,
17, 45, 48, 49
 osteosarcoma,
53
 neuroblastoma,
17, 53, 55, 56
 
and glioblastoma
48, 49
).  PAC-1 and derivatives also induce apoptosis in patient-derived samples 
from colon cancer,
17
 and chronic lymphocytic leukemia,
25
 and anticancer efficacy has been 
observed in multiple murine tumor models
17, 48, 49, 54, 60-62
 and in pet dogs with cancer.
45
 In 
addition, PAC-1 displayed potent synergy with the antitumor agent paclitaxel,
60-62
 as well as the 
second reported procaspase-3 activator, 1541B,
54
 in various cell culture and in vivo models of 
cancer; a derivative of PAC-1 showed synergy with an investigational Smac mimetic in cell 
culture.
25
 The remainder of this chapter details studies of the structure-activity relationships 
(SAR) and the mechanism of action of PAC-1 performed by other members of the Hergenrother 
laboratory and by outside research groups. 
 
 
Figure 1.2. Structure of PAC-1 (1.1), with ortho-hydroxy-N-acylhydrazone highlighted in red.
17
 
 
An initial evaluation of SAR was undertaken with a small number of closely related 
compounds and synthetic intermediates (Table 1.1). PAC-1 was the most potent compound 
evaluated, while removal of the allyl group (1.2) led to a slight loss in potency. However, each of 
4 
 
the other compounds studied (1.3-1.10) was inactive in both procaspase-3 activation and 
cytotoxicity assays.
17
 
 
 
Table 1.1. Preliminary SAR studies of PAC-1.
17
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1.2.2. PAC-1 mechanism of action 
 One of the most informative results from the initial report on PAC-1 was that removal of 
the hydroxyl group (compound 1.3, also known as PAC-1a) abolished activity. This suggested 
the essential nature of the ortho-hydroxy-N-acylhydrazone moiety for anticancer activity of 
PAC-1. The ortho-hydroxy-N-acylhydrazone is known to chelate metals, including iron,
63
 
copper,
64
 and zinc,
65
 and many divalent metal cations are also known to inhibit procaspase
43
 and 
caspase
66-69
 enzymes. In particular, zinc from the labile zinc pool, which is bound loosely to 
certain proteins, has been shown to co-localize with procaspase-3
70
 and inhibit the enzymatic 
activity of both procaspase-3
43
 and caspase-3,
67
 as illustrated in Figure 1.1. In addition, a putative 
binding site on procaspase-3/caspase-3 for labile zinc ions has been identified.
71
 Based on this, 
the role of zinc in the mechanism of action of PAC-1 was investigated.
43
 PAC-1 was shown to 
bind zinc in a 1:1 ratio with a Kd of 52 ± 2 nM.
43, 44
 PAC-1 showed no activity toward 
procaspase-3 in a metal-free buffer; however, the addition of zinc inhibited procaspase-3 activity, 
and PAC-1 was able to restore this activity in a dose-dependent manner (Figure 1.3A). In 
addition, PAC-1 was shown to induce apoptosis in U-937 (human lymphoma) cells, but the 
addition of zinc to the cell culture medium abolished the ability of PAC-1 to induce apoptosis. 
Finally, PAC-1a displayed no affinity toward zinc and was unable to induce procaspase-3 
activation. Based on these results, a mechanism of action has been proposed for PAC-1 activity 
(Figure 1.3B). Zinc binds loosely to procaspase-3, inhibiting its activity and its ability to be 
cleaved to the active caspase-3. PAC-1 chelates the zinc from the labile pool, allowing for 
cleavage of procaspase-3 to caspase-3 and the initiation of the execution pathway of apoptosis.
43
 
The affinity of PAC-1 for zinc is not strong enough to disrupt proteins containing essential zinc 
ions; PAC-1 and several derivatives showed no inhibitory activity toward matrix 
metalloproteinases-9 and -14,
72
 as well as carboxypeptidase A and histone deacetylace,
25
 
enzymes containing active site zinc ions. 
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Figure 1.3. A. PAC-1 has no effect on procaspase-3 in a metal-free buffer but relieves zinc-
mediated inhibition of procaspase-3 in a dose-dependent manner. B. Proposed mechanism of 
action of PAC-1. PAC-1 chelates labile zinc from procaspase-3, facilitating activation to 
caspase-3. Figures adapted with permission from literature.
43
 
 
1.2.3. Structure-activity relationships 
 With a preliminary understanding of the mechanism of action of PAC-1, the SAR studies 
of the compound were initiated by members of the Hergenrother group.
44
 In order to investigate 
the SAR, four classes of PAC-1 derivatives were designed (Figure 1.4). Class I derivatives (1.2, 
1.3, 1.11a-h, and 1.12) contained modifications to the benzylidene group, Class II derivatives 
(1.13a-c and 1.14a-d) contained modifications to the benzyl group, and the single Class III 
derivative (1.15) contained modifications to both aromatic rings. Class IV derivatives (1.16a-b, 
1.17a-b, 1.18, 1.19, and 1.20) contained modifications to the four nitrogen atoms present in 
PAC-1. In total, 26 derivatives were synthesized and compared to PAC-1 in a series of 
experiments.
44
 
 
 
Figure 1.4. Four classes of PAC-1 derivatives synthesized for SAR determination.
44
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 The evaluation of the compounds is shown in Table 1.2. Compounds were evaluated for 
their ability to chelate zinc, relieve zinc-mediated inhibition of caspase-3, and induce cell death 
in U-937 cells. These experiments confirmed the essential nature of the ortho-hydroxy-N-
acylhydrazone for activity. Class I derivatives lacking the phenol showed significantly reduced 
activity compared to PAC-1 in these experiments, while the two Class I derivatives containing 
the phenol (1.2 and 1.11h) retained activity. However, modification of the benzyl group was 
tolerated, as Class II derivatives showed similar activity to PAC-1. The Class III derivative 
(1.15) was also active, suggesting that substitution of both aromatic rings could be tolerated, as 
long as the ortho-hydroxy-N-acylhydrazone remained intact. Class IV derivatives that contained 
the ortho-hydroxy-N-acylhydrazone (1.16a-b and 1.18) were capable of binding zinc and 
inducing cell death, although compounds 1.16a-b showed inhibitory activity toward caspase-3. 
Class IV derivatives containing modifications to the hydrazone (1.17a-b, 1.19, and 1.20) showed 
diminished activity relative to PAC-1. In order to further investigate the cellular effects of PAC-
1 and derivatives, U-937 cells were treated with PAC-1, 1.14a, or 1.18 at 50 µM for 12 hours, 
and cell death was assessed by flow cytometry with Annexin V-FITC/propidium iodide staining. 
Large populations of Annexin V-FITC positive, propidium iodide negative cells were present for 
each compound treatment, indicating that cell death proceeds through apoptosis.
44
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Table 1.2. Zinc chelation, in vitro caspase-3 activation, and cytotoxicity of PAC-1 and 
derivatives. 
a
 – These derivatives slightly inhibited caspase-3, masking any activation.44 
 
9 
 
An additional derivative of PAC-1 was synthesized containing a fluorophore conjugated 
to the benzyl ring through a triazole linker. This compound (AF350-PAC-1, 1.21, Figure 1.5) 
was found to bind zinc, activate caspase-3 in vitro, and induce cell death in culture. As shown in 
Figure 1.6, SK-MEL-5 cells were treated with 1.21 and FAM-DEVD-fmk, a covalent inhibitor 
for caspases-3 and -7 that covalently modifies the enzyme with a fluorophore. FAM-DEVD-fmk 
therefore represents a marker for sites of caspase-3/-7 activity within cells. Cells were treated for 
one hour, washed in phenol red-free medium, and incubated for an additional two hours. The 
cells were then visualized at emission wavelengths of 400 nm (1.21, pseudo-colored green) and 
520 nm (FAM-DEVD-fmk, pseudo-colored red). Treatment of cells with vehicle (Figure 1.6A, 
B, C) showed minimal fluorescence in either channel. Minimal increases in fluorescence were 
observed upon treatment with FAM-DEVD-fmk alone (Figure 1.6D, E, F). Treatment with 1.21 
alone (Figure 1.6G, H, I) showed punctate staining in the cytoplasm at 400 nm. Finally, cells 
treated with both 1.21 and FAM-DEVD-fmk (Figure 1.6J, K, L) showed punctate staining at 
both 400 nm and 520 nm, and the merged image (Figure 1.6L) shows overlap for the majority of 
these sites of fluorescence. This confirms that 1.21 induces activation of executioner caspases in 
cells and co-localizes with sites of caspase-3/-7 activity.
44
 
 
 
Figure 1.5. Structure of fluorescent PAC-1 derivative 1.21.
44
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Figure 1.6. Fluorescent PAC-1 derivative 1.21 co-localizes with sites of caspase-3/-7 activity in 
SK-MEL-5 cells. A-C. Background levels of fluorescence in cells treated with DMSO alone. D-
F. Minimal fluorescence over background in cells treated with FAM-DEVD-fmk alone. G-I. 
Cells treated with 1.21 show punctate staining in cytoplasm. J-L. Cells treated with FAM-
DEVD-fmk and 1.21 show sites of caspase activity, which co-localize with punctate staining of 
1.21. Figures adapted with permission from literature.
44
 
 
1.2.4 Relationship to other metal-binding compounds in medicine 
Given the increased attention paid to so-called “PAINS” (pan-assay interference 
compounds),
73
 a further discussion of PAC-1 and derivatives in relationship to PAINS 
compounds is warranted. The metal-binding ability of ortho-hydroxy-N-acylhydrazones can 
cause members of this class of compounds to appear as hits in screening assays due to 
interference with the assay screening system, rather than via specific interactions with biological 
targets.
73
 In these cases, attempts to validate such hits will fail because the apparent activity of 
1.21 1.21
11 
 
the screening hit is unrelated to the target. However, rather than interfering with the in vitro 
procaspase-3 enzymatic assay, the chelation of zinc from procaspase-3 in vitro by PAC-1 is 
highly biologically relevant; PAC-1 is directly modulating zinc, an endogenous inhibitor of 
procaspase-3, and a putative binding site on procaspase-3/caspase-3 for this inhibitory zinc has 
been identified.
71
 Through this “inhibiting the inhibitor” mechanism, PAC-1 is similar to 
compounds that bind to other endogenous apoptotic inhibitors and induce apoptosis, such as 
those binding MDM2
11
 and XIAP.
15
 PAC-1 shows minimal inhibitory activity towards zinc-
dependent enzymes, including matrix metalloproteinases-9 and -14,
72
 and a derivative of PAC-1 
showed minimal inhibition toward carboxypeptidase A and histone deacetylases.
25
 These results 
are consistent with the known modest affinity of PAC-1 for zinc,
43
 allowing for a high degree of 
selectivity for chelation of zinc ions from the labile pool over essential zinc ions in canonical 
zinc binding sites within metalloproteins. In addition, PAC-1 is stable in aqueous solution; 
degradation of PAC-1 is observed only when the compound is subjected to extremes in 
temperature and pH outside of relevant physiological ranges.
74
 
PAC-1 also chelates labile zinc in cancer cells in culture, as determined by detailed 
experiments with genetically encoded fluorescent sensors specific for zinc.
47
 This removal of 
zinc leads to the observed anticancer effect in cell culture. PAC-1 shows no activity toward 
several other enzymes as assessed by in vitro assays,
75
 PAC-1 and derivatives do not affect the 
activity of proteins that rely on tightly-bound zinc,
25, 72
 and PAC-1 derivatives that do not bind 
zinc in vitro are inactive in cells.
44
 As shown by multiple investigators, treatment of cells with 
PAC-1 or a derivative results in the cleavage of procaspase-3 prior to the cleavage of initiator 
procaspases-8 and -9,
48, 49
 and co-treatment of PAC-1 with a covalent inhibitor of caspase-9 does 
not prevent cleavage of procaspase-3,
76
 further supporting the hypothesis that the proapoptotic 
activity of PAC-1 is due to chelation of labile inhibitory zinc from procaspase-3, leading to the 
activation of procaspase-3 without the intermediacy of caspase-9, and subsequent apoptotic cell 
death. 
While many metal chelators will interfere with in vitro enzyme assays, it would be 
inappropriate to disregard all metal chelators from consideration as drug candidates due to this in 
vitro artifact. Indeed, metal chelators have a rich history in drug discovery and have made a 
positive impact on many diseases through a diverse range of mechanisms and targets.
77
 The 
marketed drugs vorinostat (Zn
2+
),
78
 penicillamine (Cu
2+
),
77
 and the entire class of 
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bisphosphonates (Ca
2+
),
79
 as well as the experimental therapeutics elesclomol (Cu
2+
),
77
 ML-
133/Apto-253 (Zn
2+
),
80
 and triapine (Fe
3+
/Fe
2+
),
81
 among other small molecules, all rely on metal 
chelation in vivo for their mechanism of action. It is safe to say that many of these compounds 
would interfere with certain in vitro assays that are contingent upon metal-bound proteins. While 
it is reasonable for metal chelators and metal-chelating motifs to be structural alerts when 
examining screening hits, if the desired biological activity is metal chelation, then metal 
chelation is the precise trait to look for in a screening hit. 
 
1.3. Diaryl urea conjugates 
 With the goal of improving upon PAC-1, several classes of derivatives were synthesized 
and evaluated. One approach toward improving the potency of PAC-1 explored by Gong and 
coworkers involved the conjugation of fragments derived from sorafenib (1.22), a diaryl urea 
that inhibits several kinases, including VEGFR, PDGFR, and B-Raf, to PAC-1.
50-52
 Initially, two 
series of compounds were synthesized (Table 1.3).
50
 In the first series (1.23a-k), diaryl ureas 
were conjugated via a thiazole to the piperazine/ortho-hydroxy-N-acylhydrazone portion of 
PAC-1, and substituents on each terminal arene were varied. In the second series (1.24a-g), the 
phenol ring was replaced with a hydantoin. The cytotoxicity of the 18 compounds was evaluated 
in A549 (human lung), HL-60 (human leukemia), and MDA-MB-231 (human breast) cancer cell 
lines in culture and compared to PAC-1 and sorafenib. In general, the compounds of series 1.23 
were much more potent than the compounds of series 1.24, confirming the essential nature of the 
ortho-hydroxy-N-acylhydrazone for activity of PAC-1 derivatives. Many of the 1.23 compounds 
were even more potent than PAC-1 or sorafenib, suggesting the potential for improved potency 
via dual pharmacophores. Compound 1.24g displayed comparable potency to the parent 
compounds, and because it lacks the hydroxyl group, it likely acts via a different mechanism 
than PAC-1. 
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Table 1.3. Structure and cytotoxicity of hybrid PAC-1/sorafenib derivatives. N.D. = not 
determined.
50
 
 
 In order to build upon these results, a second set of 18 diaryl urea/PAC-1 conjugates was 
synthesized (Table 1.4).
51
 Because the hydantoin derivatives were significantly less active, 
synthesis of derivatives was limited to those containing the ortho-hydroxy-N-acylhydrazone 
moiety. Nine additional derivatives of the 1.23 series (1.23l-t) were synthesized. In addition, nine 
derivatives (1.25a-i) were synthesized that contained an amide linkage instead of the thiazole. 
These compounds were also evaluated in A549, HL-60, and MDA-MB-231 cells in culture and 
compared to PAC-1 and sorafenib. Most of the compounds displayed comparable potency to 
both of the parent compounds in the cell lines tested. In general, the compounds of the 1.23 
14 
 
series were somewhat more potent than the compounds of the 1.25 series. The addition of a 
benzyloxy substituent to the benzylidene ring increased potency for compounds of the 1.23 
series. Three of the derivatives (1.23l, 1.23q, and 1.23s), as well as PAC-1 and sorafenib, were 
evaluated in a human embryonic lung fibroblast-derived cell line (WI-38) in culture. The 
compounds exhibited slightly reduced potency in this cell line compared to the cancer cell lines, 
suggesting a degree of selectivity for toxicity to cancer cells over normal cells.
51
 
 
 
Table 1.4. Structure and cytotoxicity of hybrid PAC-1/sorafenib derivatives. N.D. = not 
determined.
51
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 The final set of 26 diaryl urea/PAC-1 conjugates is shown in Table 1.5. This set of 
compounds included 23 phenol derivatives (1.23u-qq) and three hydantoin derivatives (1.24h-j), 
conjugated to the diaryl urea moiety via a thiazole linker.
52
 The compounds were evaluated in 
A549, HL-60, and MDA-MB-231 cells in a 72-hour cytotoxicity assay and compared to PAC-1 
and sorafenib. The compounds of the hydantoin series were again observed to be less potent than 
the compounds of the phenol series. Within the phenol series, the coumarin derivatives 
(1.23mm-qq) were less potent than the other derivatives. Many of the substituted phenol 
derivatives had sub-micromolar potency in the cell lines, improving upon the activity of either 
parent compound alone, and the benzyloxy derivatives were among the most potent compounds 
in this library. This provides additional validation that the conjugation of other cytotoxic agents 
to PAC-1 can help to increase the potency of either agent alone.
52
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Table 1.5. Structure and cytotoxicity of hybrid PAC-1/sorafenib derivatives. N.D. = not 
determined.
52
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1.4 Benzothiazole PAC-1 derivatives 
 Building on the promising results from the phenylthiazole-containing PAC-1 derivatives, 
two series of benzothiazole-conjugated semicarbazone PAC-1 derivatives were synthesized by 
Gong and coworkers.
55, 56
 The benzothiazole derivatives were substituted at the 6-position to 
block metabolism. Positively-charged substituents were chosen in order to mimic the piperazine 
nitrogen atoms present in PAC-1.
55, 56
 The first series (Table 1.6) contained 26 derivatives 
(1.26a-z).
55
 Cytotoxicity of the compounds was evaluated over 72 hours in HT-29 (human colon 
cancer), MDA-MB-231 (human breast cancer), MKN-45 (human gastric cancer), NCI-H226 
(human lung cancer), and SK-N-SH (human neuroblastoma) cell lines in culture. Many of the 
compounds were found to display equal or greater potency compared to PAC-1. As with the 
diaryl urea conjugates, the benzyloxy substituent increased potency, while the coumarin-derived 
compounds were less potent. Importantly, the semicarbazone proved to be an acceptable 
replacement for the hydrazone of PAC-1, as compounds retained potency in the cell lines 
tested.
55
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Table 1.6. Structure, procaspase-3 activity, and cytotoxicity of benzothiazole PAC-1 derivatives. 
Pip = piperidinyl; N.D. = not determined.
55
 
 
 Based on these results, a second set of benzothiazole PAC-1 derivatives was designed 
(Table 1.7).
56
 These 36 compounds (1.26aa-jjj) were also linked via the semicarbazone and 
contained basic substituents at the 6 position of the benzothiazole. Several of the compounds 
(1.26ii-fff) contained the benzyloxy group that helped to improve potency for the first series of 
benzothiazole derivatives. In four derivatives (1.26ggg-jjj) the phenyl of the benzyloxy was 
modified to a piperonylthiazole moiety, a motif present in the PAC-1 derivatives WF-210 and 
WF-208
48, 49
 (discussed in Section 1.10). The compounds were evaluated in a 72-hour cell 
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culture assay against the five cell lines previously discussed. All compounds were potent in the 
cytotoxicity assays, with many exhibiting sub-micromolar IC50 values. As previously, the 
compounds containing the benzyloxy substituents were among the most potent compounds in the 
library, and the piperonylthiazole derivatives were also potent in cell culture. Compounds 
containing the morpholino substituent were somewhat less potent than other derivatives. In 
addition, there was a general correlation between potency and intracellular procaspase-3 
concentration; NCI-H226 cells express procaspase-3 to a much greater degree than SK-N-SH 
cells, and the compounds were more potent in the NCI-H226 cells than the SK-N-SH cells. This 
provides further support to the proposed mechanism of action of PAC-1.
56
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Table 1.7. Structure and cytotoxicity of benzothiazole PAC-1 derivatives. Pip = piperidinyl; 
Morph = morpholino; N.D. = not determined.
56
 
 
1.5. Oxadiazole PAC-1 derivatives 
 In addition to the benzothiazole-containing compounds, several PAC-1 derivatives 
(1.27a-s) were synthesized by Gong, Wu, and coworkers, containing an oxadiazole with a 
21 
 
substituted (phenoxymethyl)phenyl linked to the piperazine ring (Table 1.8).
48, 49
 The ortho-
hydroxy-N-acylhydrazone remained intact, while substitution varied on the benzylidene ring. 
Four derivatives (1.27a-d) contained the 3-allyl substituent characteristic of PAC-1. An 
additional 12 derivatives (1.27e-p) contained a substituted benzyloxy group at the 4-position of 
the benzylidene ring. Finally, three derivatives (1.27q-s) contained a piperonyl substituent 
attached via a thiazole linker. The cytotoxicity of the compounds to HL-60 cells was evaluated in 
a 72-hour experiment. PAC-1 had an IC50 value of 2.10 µM under these conditions, and most of 
the derivatives were more potent than PAC-1 in the HL-60 cell line, although compound 1.27p 
was inactive in this experiment. In general, the compounds containing the allyl and the 
piperonylthiazole substituents were more potent than those containing the benzyloxy 
substituents. Compounds 1.27r-s showed high potency in cell culture, with 80 nM IC50 values, 
and further experiments were performed with these two derivatives.
48, 49
 These efforts will be 
discussed in Section 1.10. 
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Table 1.8. Structure and cytotoxicity of oxadiazole-containing PAC-1 derivatives.
48, 49
 
 
1.6. Replacement of benzylidene 
 PAC-1 chelates zinc with affinity in the low nanomolar range,
43, 44
 which is strong 
enough to remove the labile pool of zinc, but not strong enough to disrupt essential zinc ions.
25, 72
 
In contrast, TPEN (1.28, Figure 1.7), which binds zinc with 0.26 fM affinity,
82
 inhibits the 
activity of certain metalloenzymes via chelation of the essential metal ion.
83
 It is likely that the 
relatively modest affinity of PAC-1 for zinc is responsible for its selectivity for chelation of 
labile zinc over essential zinc ions. However, in an effort to slightly increase the affinity of PAC-
1 for zinc, two new PAC-1 derivatives were synthesized by Rongved and coworkers.
57
 For ZnA-
23 
 
DPA (1.29), the benzylidene was replaced by a dipicolylamine (DPA) moiety, which is present 
in TPEN. For ZnA-Pyr (1.30), the phenol was replaced by a 4-pyridoxyl group, which also 
contains the ortho-hydroxyl substituent necessary for PAC-1 activity.
57
 
 
 
Figure 1.7. Structures of TPEN (1.28) and PAC-1 derivatives ZnA-DPA (1.29) and ZnA-Pyr 
(1.30).
57
 
 
ZnA-Pyr was found to bind zinc in a dose-dependent manner, although a Kd value was 
not calculated. The binding of ZnA-DPA to zinc could not be assessed due to the lack of a 
chromophore. Dissociation constants for compounds analogous to ZnA-DPA and ZnA-Pyr were 
in the low nanomolar
84
 and high femtomolar
85
 ranges, respectively. PAC-1, TPEN, ZnA-DPA, 
and ZnA-Pyr were evaluated in PC-12 cells in a 24-hour experiment (Figure 1.8). TPEN (Fiugre 
1.8A) was the most potent compound in inducing cell death, followed by PAC-1 (Figure 1.8B). 
Neither ZnA-DPA (Figure 1.8C) nor ZnA-Pyr (Figure 1.8D) induced greater than 40% cell 
death at concentrations up to 200 µM. All four compounds induced activation of caspases-3/-7 in 
whole cells, as measured by cleavage of the fluorogenic substrate (DEVD)2-Rhodamine 110. The 
activity of PAC-1 and TPEN in this experiment was slightly higher than ZnA-DPA and ZnA-
Pyr. The addition of zinc or the caspase-3/-7 inhibitor Ac-DEVD-cmk reduced the amount of 
cell death induced by each agent, although zinc-mediated protection of cell death induced by 
ZnA-DPA was not statistically significant.
57
 While it remains possible that an alternative zinc-
binding motif could lead to an improved PAC-1 derivative, this study shows that the DPA and 
pyridoxyl substituents are most likely not appropriate for this purpose. 
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Figure 1.8. A. TPEN, B. PAC-1, C. ZnA-DPA, and D. ZnA-Pyr induce dose-dependent cell 
death. PC-12 cells were treated with compounds for 24 hours. E. The four derivatives induce 
activation of executioner caspases in PC-12 cells over a 24-hour treatment. Figures adapted with 
permission from literature.
57
 
 
1.7 Study of matrix metalloproteinase inhibition 
 In an effort to evaluate potential off-target effects of PAC-1, a series of derivatives 
(1.31a-f, Figure 1.9) was synthesized, and the ability of the compounds to inhibit zinc-dependent 
matrix metalloproteinases-9 and -14 was evaluated by Winberg and coworkers.
72
 The 
compounds do not inhibit the enzymes at 5 µM. Slight inhibition is observed at the high 
concentration of 100 µM, which is outside of physiologically relevant ranges. IC50 values for 
1.31a and 1.31b were calculated at >100 µM.
72
 This relatively weak level of inhibition of the 
metalloenzymes provides further support that PAC-1 and derivatives selectively chelate the 
labile pool of zinc over essential metal ions. 
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Figure 1.9. Structures of compounds (1.31a-f) used to study matrix metalloproteinase 
inhibition.
72
 
 
1.8. Modification of piperazine 
 An additional strategy to improve the potency of PAC-1 involved modification of the 
piperazine to acyclic 1,2-ethylenediamine and 1,3-propylenediamine linkers (Table 1.9), as 
performed by Jun-hai, Xiao-hong, and coworkers.
59
 These derivatives (1.32a-l, 1.33a-f) retained 
the benzyl substituent, and all but two (1.32d and 1.32h) of the 18 derivatives synthesized 
contained the ortho-hydroxy-N-acylhydrazone; substituents on both aromatic rings were varied 
to assess structure-activity relationships. The compounds were evaluated in HL-60 (human 
leukemia) and HLF (human embryonic lung fibroblast) cells over 72 hours and compared to 
PAC-1. Many of the compounds were highly potent against the HL-60 cells, with IC50 values 
below 1 µM, compared to PAC-1 at 1.90 ± 0.01 µM. Notably, the two derivatives lacking the 
ortho-hydroxyl group were significantly less potent, confirming the previously determined 
structure-activity relationships. Unfortunately, many of the compounds displayed comparable 
potency in the non-cancerous HLF cell line, suggesting that there may be a narrow therapeutic 
window for these compounds. 
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Table 1.9 Structure and cytotoxicity of ethylenediamine and propylenediamine PAC-1 
derivatives.
59
 
 
Compound 1.33b was ten-fold less potent in the HLF cell line than the HL-60 cell line. 
For this reason, compound 1.33b was selected for further study in a panel of 14 additional human 
cancer cell lines (Table 1.10). Compound 1.33b was more potent than PAC-1 in all of the 
cancerous cell lines evaluated, suggesting that modification of the piperazine may be a useful 
strategy for the development of improved PAC-1 derivatives. In this experiment, three cell lines 
(A-498, DU145, and MCF7) were insensitive to PAC-1, as IC50 values were higher than 300 
µM.
59
 The reason for this insensitivity is unclear; PAC-1 was cytotoxic to DU145 and MCF7 
cells in other reports
48, 49
 (this is the only reported evaluation of PAC-1 in A-498 cells). 
However, it is possible that slight differences in experimental design and execution led to this 
observed difference in cytotoxicity. 
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Table 1.10. Cytotoxicity of PAC-1 and derivative 1.33b against a panel of human cell lines.
59
 
 
1.9 S-PAC-1 
 
1.9.1 Discovery and initial evaluation 
 In addition to its procaspase-3 activating properties, PAC-1 can also induce significant 
neuroexcitation in vivo. Seizures are observed after administration of high doses via IV or IP 
injection in animals, and elevated doses are lethal.
45
 It was hypothesized that in order to induce 
this neuroexcitation, PAC-1 must cross the blood-brain barrier (BBB), although the specific 
interactions leading to this phenotype are not well understood. Therefore, in order to develop a 
compound with improved safety, the design of a PAC-1 derivative that would not cross the BBB 
was explored. Compounds that cross the BBB tend to be small, rigid, and lipophilic;
86
 therefore, 
the introduction of a polar substituent would help to prevent passage of the compound across the 
BBB. With the knowledge that substituents on the aromatic rings of PAC-1 could be modified 
while still maintaining anticancer activity,
44
 a derivative containing a highly polar sulfonamide 
group, S-PAC-1 (1.34, Figure 1.10), was designed and developed by researchers in the 
Hergenrother group.
45
 S-PAC-1 bound zinc with a Kd of 46 ± 5 nM, comparable to the value for 
PAC-1,
44
 and it was able to relieve zinc-mediated inhibition of procaspase-3 in vitro, although it 
was not as potent as PAC-1 in this assay.
45
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Figure 1.10. Structure of S-PAC-1 (1.34).
45
 
 
 After confirmation that S-PAC-1 was active in vitro, S-PAC-1 and PAC-1 were 
evaluated in cell culture against a panel of cell lines over 72 hours (Table 1.11). In preparation 
for an animal model of lymphoma, five lymphoma cell lines were evaluated, including U-937 
(human), EL4 (mouse), 17-71 (dog), GL-1 (dog), and OSW (dog). PAC-1 and S-PAC-1 both 
displayed IC50 values in the low micromolar range for all five cell lines evaluated. The 
compounds were also evaluated in four additional human cell lines, including Jurkat (leukemia), 
SK-MEL-5 (melanoma), HeLa (cervical), and MDA-MB-231 (breast), and comparable potency 
was observed across these cell lines as well. Investigation of the mode of cell death induced by 
S-PAC-1 was performed by treatment of U-937 cells with S-PAC-1 and staining with Annexin 
V-FITC/propidium iodide. Flow cytometry analysis indicated that S-PAC-1 induces cell death 
via apoptosis.
45
 
 
 
Table 1.11. Comparison of cytotoxicity of PAC-1 and S-PAC-1. Values shown are mean ± 
s.e.m. (n = 3).
45
 
 
 In order to determine an effective in vivo dosing regimen, the cytotoxicity of S-PAC-1 
was evaluated after varying treatment times (Table 1.12). U-937 cells were treated with S-PAC-
1 for times ranging from 1-72 hours. The compound was then washed out, and cells were 
allowed to grow until 72 hours after the initiation of treatment. The compound induces minimal 
cell death at time points up to 6 hours, and the first toxicity is observed at 9 hours. The potency 
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increases until 24 hours and does not change significantly between 24-72 hours. These results 
indicated that in order to observe anticancer efficacy in vivo, serum concentrations of 10 µM for 
at least 24 hours would be most effective.
45
 
 
 
Table 1.12. Time-dependence of cytotoxicity of S-PAC-1 in U-937 cells. Cells were treated with 
S-PAC-1 for the indicated time, compound was washed out, and cell death was assessed 72 
hours after initiation of treatment. Values shown are mean ± s.e.m. (n = 3).
45
 
 
1.9.2. Safety and pharmacokinetics 
 S-PAC-1 was advanced to in vivo experiments based on its promising activity in vitro 
and in cell culture. S-PAC-1 was administered to mice via IV injection, and no adverse effects 
were observed at doses up to 350 mg/kg. In contrast, PAC-1 induces mild neurological 
symptoms at doses as low as 20 mg/kg when administered via IV injection. The pharmacokinetic 
profiles of PAC-1 and S-PAC-1 were evaluated, and the peak plasma concentration was 
compared between S-PAC-1 at 350 mg/kg and PAC-1 at 20 mg/kg, the lowest dose to induce 
neurological symptoms, and 50 mg/kg, a dose at which neurotoxicity is severe. The maximum 
serum concentration of PAC-1 at 20 mg/kg was approximately 50 µM, and the maximum 
concentration at 50 mg/kg was approximately 100 µM. However, the 350 mg/kg dose of S-PAC-
1 resulted in serum concentration of approximately 3500 µM, a 70-fold increase over the 
threshold for induction of neurotoxicity for PAC-1.
45
 
 Despite the improved safety profile of S-PAC-1, evaluation in murine tumor models was 
not feasible due to the rapid clearance of the compound from circulation; the half-life was 
approximately 1 hour following IP administration of compound to mice (Figure 1.11A). 
Therefore, further in vivo evaluation of S-PAC-1 was performed in dogs. A 25 mg/kg 
intravenous dose of S-PAC-1 administered over 10 minutes (Figure 1.11B) was well tolerated 
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and gave a peak plasma concentration of approximately 150 µM. However, the compound was 
cleared rapidly from dogs as well, with an elimination half-life of 1.09 ± 0.02 hours. In order to 
achieve serum concentrations of 10 µM for 24 hours, a continuous-rate infusion strategy was 
investigated, with an initial loading dose administered over 10 minutes, followed by a 
maintenance dose over 24 hours (Figure 1.11C). Healthy research dogs tolerated the continuous 
administration of S-PAC-1 well, and a loading dose of 7 mg/kg followed by a constant-rate 
infusion of 3 mg/kg/h was chosen to achieve a serum concentration of 10 µM during the course 
of the treatment.
45
 
 
 
Figure 1.11. Pharmacokinetics of S-PAC-1 following A. 125 mg/kg i.p. injection in mice, B. 25 
mg/kg i.v. injection in dogs administered over 10 minutes, and C. initial loading dose followed 
by 24-hour continuous rate infusion in dogs administered by i.v. injection. Figures adapted with 
permission from literature.
45
 
 
1.9.3. Evaluation in canine lymphoma patients 
 With an initial understanding of the pharmacokinetics of S-PAC-1 upon continuous-rate 
infusion, a clinical trial of six canine lymphoma patients was initiated. Three patients received 
four doses via 24-hour continuous infusions once weekly, while three additional patients 
received two 72-hour continuous infusions two weeks apart. In general, the 7 mg/kg loading dose 
followed by the 3 mg/kg/h continuous infusion was successful in maintaining the desired 10 µM 
serum concentration during the administration. No hematologic or nonhematologic toxicity was 
observed in any of the six patients, and only minor adverse events were reported, including mild 
gastrointestinal symptoms and localized irritation at the site of injection. Encouragingly, one of 
the six patients showed a partial response to S-PAC-1 therapy (Figure 1.12). A 30% reduction in 
the tumor size was observed both by caliper RECIST score (Figure 1.12A) and CT scan of the 
A B C
31 
 
lymph nodes (Figure 1.12B). Three of the patients showed stable disease, while two showed 
disease progression. Flow cytometry analysis of lymph node aspirates from two patients 
demonstrated the presence of procaspase-3 prior to treatment, as well as an increase in cleaved 
caspase-3 seven days after initiation of treatment. A rapid increase in the tumor volume in all six 
patients was observed immediately after therapy ceased. These results provide the first validation 
for procaspase-3 activation as an anticancer strategy.
45
 
  
 
Figure 1.12. Partial response to S-PAC-1 therapy in canine patient. A. RECIST scores for 
patient administered S-PAC-1 on days 0, 7, 14, and 21. Tumor size decreased upon each dose 
and rapidly increased upon cessation of treatment. B. CT scans of lymph nodes on days 0 and 7 
show decreased tumor size after a single dose of S-PAC-1. Figures adapted with permission 
from literature.
45
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1.9.4. Comparison to PAC-1 
 Efforts were undertaken to further elucidate the mechanism of action of PAC-1 and S-
PAC-1 in order to further understand the significant difference in tolerability.
47
 An initial 
experiment involved treatment of HeLa cells containing the genetically encoded fluorescent zinc 
sensor ZapCY2. This sensor contains a zinc finger conjugated to cyan fluorescent protein (CFP) 
and yellow fluorescent protein (YFP). The sensor undergoes a conformational change upon 
binding to zinc, allowing for fluorescence resonance energy transfer (FRET) to occur between 
CFP and YFP, and the YFP fluorescence is observed. Release of zinc prevents FRET, and CFP 
fluorescence is observed. Therefore, the cellular zinc concentration is proportional to the FRET 
ratio (FRET/CFP).
87
 Both PAC-1 and S-PAC-1 reduced intracellular zinc concentrations within 
seconds after addition of compound, and the rate and amount of zinc sequestration were similar 
for both compounds (Figure 1.13).
47
 
 
 
Figure 1.13. Changes in intracellular zinc concentration upon treatment with A. PAC-1 or B. S-
PAC-1. C. Both PAC-1 and S-PAC-1 cause significant decreases in intracellular zinc 
concentration compared to untreated controls. Figures adapted with permission from literature.
47
 
 
 To confirm that the compounds act similarly in cells, a transcript profiling experiment 
was performed to assess differences in global gene expression upon treatment with compounds. 
A
B
C
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In this experiment, HL-60 cells were treated with either PAC-1 or S-PAC-1 at 25 µM, mRNA 
was collected after six hours, and the transcript levels were compared to a vehicle-treated 
control. In general, there was a high correlation between the two different treatment groups; 
many of the most upregulated transcripts for PAC-1 were also highly upregulated in S-PAC-1, 
while expression of many of the most downregulated transcripts for PAC-1 was also suppressed 
for S-PAC-1 treatment. The degree of similarity was measured by calculating the Spearman rank 
correlation value for the two treatment groups. The value was calculated at 0.928, very close to a 
perfect correlation of 1.0, demonstrating that PAC-1 and S-PAC-1 induce a similar 
transcriptional response and likely act similarly within cells at the 25 µM concentration.
47
 
 In order to further understand the difference in the observed neurological phenotypes for 
PAC-1 and S-PAC-1, experiments were performed to determine the ability of the compounds to 
penetrate relevant physiological barriers (Figure 1.14). It was proposed that PAC-1 enters the 
brain to induce the neuroexcitation by a mechanism that is not yet well understood, while the 
polar sulfonamide group prevents S-PAC-1 from crossing the BBB.
45
 An initial experiment 
demonstrated that equal concentrations of PAC-1 and S-PAC-1 enter Neuro-2a (murine 
neuroblastoma) cells after incubation with either compound at 50 µM for 30 minutes (Figure 
1.14A), suggesting that the difference in toxicity is not related to a difference in cell 
permeability. Following this, an experiment was performed to determine the BBB permeability 
of the compounds in vivo (Figure 1.14B-C). C57BL/6 mice were administered PAC-1 or S-
PAC-1 at 75 mg/kg via i.v. injection. Mice were sacrificed after five minutes, samples from 
blood and brains were collected, and concentrations were analyzed by HPLC. PAC-1 displayed 
approximately 30:70 distribution between brain and blood, consistent with the observed 
neurological phenotype. In contrast, less than 1% of S-PAC-1 entered the brain.
47
 This 
difference in BBB permeability is most likely sufficient to explain the difference in 
neurotoxicity, although further experiments on the mechanism of neuroexcitation are necessary 
to determine whether other factors may be partially responsible. 
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Figure 1.14. Penetration of physiological barriers by PAC-1 and S-PAC-1. A. Concentrations of 
PAC-1 and S-PAC-1 in Neuro-2a cells following treatment with 50 µM for 30 minutes. B. 
Concentrations of PAC-1 and S-PAC-1 in serum, and C. concentrations of PAC-1 and S-PAC-1 
in brains of mice. C57BL/6 mice received PAC-1 or S-PAC-1 at 75 mg/kg via lateral tail vein 
injection and sacrificed 5 minutes post-injection. Values shown are mean ± standard deviation (n 
= 4). Figures adapted with permission from literature.
47
 
 
 Finally, the effect of treatment time on cell death induced by PAC-1 and S-PAC-1 was 
assessed in order to determine effective dosing strategies for in vivo studies. U-937 cells were 
treated with compounds at 100 µM for 4, 8, 12, or 24 hours. The cells were then washed, and 
fresh growth medium was added. Cell death was assessed 24 hours after the initiation of 
treatment via Annexin V-FITC/propidium iodide staining. The results are shown in Figure 1.15. 
PAC-1 induced greater than 50% cell death after only 4 hours, and greater than 90% of cells 
were no longer viable after an 8-hour treatment. In contrast, S-PAC-1 induced apoptosis much 
more slowly; the 50% cell death threshold was reached between 8-12 hours of treatment.
47
 This 
is consistent with the previous study on the rate of apoptosis induced by S-PAC-1.
45
 Taken 
together, these results suggest that achieving a high serum concentration for a short time period 
may represent an effective dosing strategy for PAC-1, while serum concentrations of S-PAC-1 
should be higher for sustained periods of time in order to achieve efficacy. 
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Figure 1.15. High concentrations of PAC-1, but not S-PAC-1, induce apoptosis upon short 
treatment times. U-937 cells were treated with DMSO or compound (100 µM) for various 
exposure times, and cell viability was assessed by flow cytometry of the cells double stained 
with Annexin V-FITC/propidium iodide. Values shown are mean ± s.e.m. (n = 3). Figure 
adapted with permission from literature.
47
 
 
1.10 WF-210 and WF-208 
 
1.10.1 Discovery and initial evaluation 
 As discussed in Section 1.5, a series of oxadiazole-containing PAC-1 derivatives were 
synthesized and evaluated in HL-60 cells by Gong, Wu, and coworkers.
48, 49
 The two most potent 
compounds identified from this assay (Figure 1.16) were WF-208 (1.27r) and WF-210 (1.27s), 
each of which contains a piperonylthiazole attached to the benzylidene ring and a halogen-
substituted (phenoxymethyl)phenyl group attached to the oxadiazole. Each compound was 
highly potent against HL-60 cells in culture, with 72-hour IC50 values of 80 nM.
48, 49
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Figure 1.16. Structure of WF-208 (1.27r) and WF-210 (1.27s).
48, 49
 
 
 PAC-1 and the two new derivatives were then evaluated in a panel of 15 cancer cell lines 
in culture for their ability to induce cell death (Table 1.13). The cell lines represented a wide 
range of tumor types, including leukemia, lung cancer, liver cancer, gastric cancer, breast cancer, 
glioma, prostate cancer, colon cancer, and gallbladder cancer. In general, WF-208 and WF-210 
were highly potent in the cell lines evaluated, with 72-hour IC50 values in the mid-nanomolar to 
low micromolar range, and potency was greater than that of PAC-1 in all cell lines evaluated. In 
addition, all three compounds were evaluated in four non-cancerous cell lines. Less than 50% 
cell death was observed at concentrations up to 100 µM, suggesting the potential for selectivity 
of cancer cell death over healthy tissue toxicity in vivo.
48, 49
 
 
 
Table 1.13. Potency of PAC-1, WF-208, and WF-210 against a diverse array of cancer cell lines 
in culture.
48, 49
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1.10.2. Caspase-dependent cell death 
 The dependence of caspase activity on cell death induced by PAC-1, WF-208, and WF-
210 was evaluated in a series of assays. The first set of experiments demonstrated the ability of 
the compounds to activate caspase enzymes in cells. Treatment of HL-60 or U-937 cells with 
PAC-1, WF-208, or WF-210 for time periods between 0 and 24 hours, followed by 
immunofluorescence staining for cleaved caspase-3, indicated that each compound led to the 
activation of caspase-3 in a dose- and time-dependent manner. The cells were then treated with 
PAC-1 (50 µM), WF-208 (10 µM), or WF-210 (10 µM), and western blotting was used to 
analyze procaspases-3, -8, and -9, as well as poly (ADP-ribose) polymerase (PARP), a canonical 
caspase-3 substrate. Western blots from HL-60 cells are shown in Figure 1.17. For each 
compound in both cell lines, cleavage of procaspase-3 and PARP were the earliest events, 
followed by cleavage of procaspases-8 and -9. These results were further supported by analysis 
of fluorogenic substrates for each of these three caspase enzymes. In HL-60 cells treated with 
PAC-1 or WF-210, caspase-3 activity was detected as early as 1 hour after the initiation of 
treatment, followed by caspase-8 and -9 activities at 4 hours (boxes in Figure 1.17). In contrast, 
cells treated with the DNA topoisomerase II inhibitor etoposide, which induces apoptosis via the 
intrinsic pathway, showed caspase-3 and -9 activities simultaneously at 4 hours, followed by 
caspase-8 at 6 hours. These results suggest that PAC-1 and derivatives induce apoptosis via a 
different mechanism than the canonical intrinsic or extrinsic pathways.
48, 49
 
 
 
Figure 1.17. Activation of caspases in HL-60 cells by PAC-1, WF-210, and WF-208. Cells 
were treated with compounds for 24 hours. Cleavage of caspase-3 and PARP were detected first, 
followed by caspases-8 and -9 (boxes). Figures adapted with permission from literature.
48, 49
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Following this experiment, HL-60 and U-937 cells were treated with compound for 12 
hours (WF-208) or 24 hours (PAC-1 and WF-210). Flow cytometry analysis with Annexin V-
FITC/propidium iodide staining indicated significant portions of apoptotic cells. WF-210 was 
more potent than PAC-1 in this assay, while both compounds induced apoptosis to a greater 
degree after 24 hours than did WF-208 at 12 hours.
48, 49
 
 The ability of caspase inhibitors to protect against apoptosis induced by PAC-1 and 
derivatives was then evaluated. HL-60 and U-937 cells were treated for 24 hours with PAC-1 
(50 µM), WF-208 (10 µM), or WF-210 (10 µM) alone or in combination with a pan-caspase 
inhibitor (Z-VAD-fmk), a caspase-3/-7 inhibitor (Z-DEVD-fmk), a caspase-8 inhibitor (Z-IETD-
fmk), or a caspase-9 inhibitor (Z-LEHD-fmk). Cell death was assessed by Annexin V-
FITC/propidium iodide staining. Results for HL-60 cells are shown in Figure 1.18. Apoptosis 
induced by all three compounds was significantly reduced by either the pan-caspase inhibitor or 
the caspase-3/-7 inhibitor, but not by the inhibitors of the initiator caspases.
48, 49
 In addition, co-
treatment of WF-208 with zinc led to a decrease in cell death;
49
 although this experiment was not 
performed with WF-210, previous experiments have shown the protective effects of zinc on 
PAC-1-induced apoptosis.
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Figure 1.18. Pan-caspase and caspase-3/-7 inhibitors, but not inhibitors of caspases-8 and -9, 
protect against apoptosis induced by PAC-1, WF-210, and WF-208. HL-60 cells were treated 
with compound and caspase inhibitor for 24 hours, and cell death was assessed via Annexin V-
FITC/propidium iodide staining (p < 0.05). Figures adapted with permission from literature.
48, 49
 
 
 Finally, the dependence on procaspase-3 for the cytotoxic activity of PAC-1 and 
derivatives was studied using HL-60 cells, which overexpress procaspase-3, and MCF7 (human 
PAC-1
50 µM
WF-210
10 µM
WF-208
10 µM
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breast cancer) cells, which do not express procaspase-3. Knockdown of caspase-3 in HL-60 cells 
with siRNA resulted in a loss of potency for all three compounds compared to a control siRNA. 
Further, the addition of a plasmid encoding for procaspase-3 increased susceptibility of MCF7 
cells to the PAC-1 derivatives compared to the control plasmid. Western blots for caspase-3 and 
PARP demonstrated decreased procaspase-3 activation in knockdown HL-60 cells, as well as 
increased caspase-3 activity in transfected MCF7 cells. In contrast, knockdown or 
overexpression of procaspase-3 showed no effect on the cytotoxicity of the pan-kinase inhibitor 
staurosporine or etoposide. These results support the importance of caspase-3 activity for the 
cytotoxicity of PAC-1 and derivatives.
48, 49
 
 
1.10.3. Antitumor efficacy in vivo 
 Based on favorable results from cell culture experiments, PAC-1, WF-208, and WF-210 
were evaluated in a series of murine xenograft tumor models. PAC-1 and WF-210 were first 
evaluated in Hep 3B (human hepatocellular carcinoma) and MDA-MB-435S (human melanoma) 
models. Mice received PAC-1 (5 mg/kg) or WF-210 (2.5 mg/kg) daily for two weeks via i.v. 
injection. Both compounds reduced tumor volume significantly compared to control in both 
models, although WF-210 showed a greater effect than PAC-1, especially in the Hep 3B model 
(Figure 1.19A). These results correlate with the increased cell culture potency of WF-210 as 
compared with PAC-1. Western blots of samples derived from the tumors showed increased 
cleavage of caspase-3 and PARP in both treatment groups compared to control. In addition, WF-
210 was evaluated in a GBC-SD (human gallbladder carcinoma) xenograft and a second MDA-
MB-435S xenograft, with oral administration of compound (100 mg/kg). WF-210 significantly 
reduced tumor volume compared to control in these models as well. Finally, PAC-1 and WF-210 
were evaluated in an MCF7 xenograft model. Since this cell line lacks functional procaspase-3, 
any efficacy in this model would suggest that factors other than procaspase-3 activation are 
important in PAC-1 activity. Neither PAC-1 (5 mg/kg i.v.) nor WF-210 (2.5 mg/kg i.v.) 
demonstrated anticancer efficacy in the MCF7 model (Figure 1.19B), and western blots showed 
minimal PARP cleavage in all treatment groups, demonstrating the importance of procaspase-3 
for the mechanism of action of PAC-1 and derivatives.
48
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Figure 1.19. A. WF-210 slows tumor growth in Hep 3B xenograft model compared to PAC-1 
and untreated control (* p < 0.05 compared to control). B. Neither PAC-1 nor WF-210 slow 
tumor growth in MCF7 xenograft model. C. WF-208 slows tumor growth in PC-3 xenograft 
model compared to PAC-1 and untreated control (* p < 0.05 compared to control). Figures 
adapted with permission from literature.
48, 49
 
 
 PAC-1 and WF-208 were evaluated in a PC-3 (human prostate cancer) model (Figure 
1.19C). Both compounds were given at 2.5 mg/kg via i.v. injection daily for 15 days. WF-208 
showed significant tumor reduction compared to control, while PAC-1 showed no significant 
tumor reduction. Western blots of samples derived from the tumors demonstrated increased 
caspase-3 cleavage in samples from mice treated with WF-208 or PAC-1, as well as increased 
PARP cleavage in WF-208-treated animals, further demonstrating the importance of procaspase-
3 for PAC-1 and WF-208 activity.
49
 
 
1.11. B-PAC-1 
 
1.11.1. Discovery and cell death induction 
 In an effort to discover more potent derivatives of PAC-1, a combinatorial library of 837 
PAC-1 derivatives was synthesized and evaluated by members of the Hergenrother group. Six 
highly potent compounds were discovered to induce apoptosis in U-937 cells.
1
 These efforts will 
be discussed further in Chapter 3. One compound discovered from this library, named B-PAC-1 
(1.35, Figure 1.20) for the benzyloxy and butyl substituents, was evaluated by Gandhi and 
coworkers in patient-derived samples from chronic lymphocytic leukemia (CLL).
25
 
 
A B CHep 3B MCF7 PC-3
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Figure 1.20. Structure of B-PAC-1.
1, 25
 
 
 B-PAC-1 induced apoptosis in CLL cells in a dose-dependent manner. Apoptosis was 
rapid; at 10 µM B-PAC-1, cells began to die as early as 6 hours post-treatment, and cell death 
was significant at 10 hours. Treatment of CLL lymphocytes across 38 samples with 10 µM B-
PAC-1 led to a median of 60% cell death. This was significantly greater than cytotoxicity to 
noncancerous peripheral blood mononuclear cells (median 21%, n = 6) or normal B lymphocytes 
(median 31%, n = 6), demonstrating potential selectivity for apoptosis induction by B-PAC-1 in 
cancer cells over healthy cells.
25
 
 
1.11.2. Role of zinc in B-PAC-1 activity 
 Because the proposed mechanism of action of PAC-1 involves chelation of labile zinc,
43
 
experiments were performed to assess the role of zinc in B-PAC-1 cytotoxicity. CLL cells were 
treated for 24 hours with the Bcl-2 inhibitor ABT-199 (1 nM), staurosporine (100 nM), B-PAC-
1 (10 µM), or the negative control compound PAC-1a (10 µM), in the presence or absence of 
ZnSO4 (100 µM). ABT-199 and staurosporine induce apoptosis via the intrinsic pathway through 
mechanisms independent of zinc, while PAC-1a does not bind zinc. The addition of zinc fully 
inhibited cell death induced by B-PAC-1, consistent with the proposed mechanism of action, 
while having no effect on the cytotoxicity of ABT-199 or staurosporine. Treatment with PAC-1a 
or ZnSO4 alone did not induce apoptosis. Similar results were observed whether zinc was added 
at the same time as B-PAC-1 or five hours later, and zinc protected against B-PAC-1 
cytotoxicity in a dose-dependent manner.
25
 
 For the development of any therapeutic metal-chelating compound, it is important to 
ensure that chelation will be selective for the metal ion of interest, in order to minimize off-target 
effects. For this reason, B-PAC-1 was evaluated against carboxypeptidase A and histone 
deacetylace, two zinc-dependent enzymes, in vitro. B-PAC-1 showed no inhibition of either 
42 
 
enzyme, confirming the selectivity of PAC-1 derivatives for sequestration of labile zinc over 
essential metal ions.
25
 
 
1.11.3. Role of apoptotic proteins in B-PAC-1 activity 
 Several experiments were performed in order to assess the role of caspase activity in B-
PAC-1-mediated apoptosis. After 24 hours of treatment with B-PAC-1 (10 µM), increased 
cleavage of initiator caspases-8 and -9, as well as executioner caspases-3 and -7 was observed by 
western blot; executioner caspase-6 was not activated in response to B-PAC-1 treatment. In 
addition, the caspase-3 substrate PARP was cleaved in the treated samples, but not in untreated 
samples, demonstrating that B-PAC-1 induces caspase-3 activation in CLL cells.
25
 
 Following this experiment, the effect of genetic knockdown of key apoptotic proteins on 
B-PAC-1 activity was evaluated. The extent of apoptosis induced by B-PAC-1 (5 µM) or 
staurosporine (100 nM) in wild-type Jurkat cells was identical to the cell death in caspase-8 
double knockout Jurkat cells (Casp8 (-/-)) in a 24-hour treatment. In contrast, the Fas ligand (100 
ng/mL), which induces apoptosis via the extrinsic pathway, was cytotoxic in wild-type Jurkat 
cells but showed minimal cytotoxicity in Casp8 (-/-) cells. These results suggest that the extrinsic 
pathway is not important in B-PAC-1 cytotoxicity, and that caspase-8 is most likely cleaved 
after the activation of caspase-3 or -7.
25
 
 The role of caspases-3 and -7 in B-PAC-1 activity was then evaluated, using mouse 
embryonic fibroblasts (MEFs) with a single knockout of both genes (Casp3/7 (+/-)) or a double 
knockout of both genes (Casp3/7 (-/-)), and cells were treated with compounds for 24 hours. 
Both staurosporine (100 nM) and B-PAC-1 (5 µM) were equally potent in the wild-type and 
Casp3/7 (+/-) MEFs, but a significant decrease in cell death was observed for each compound in 
the Casp3/7 (-/-) MEFs. These results demonstrate the importance of the executioner caspases in 
B-PAC-1 activity.
25
 
 In addition, the role of proapoptotic Bcl-2 family proteins Bax and Bak in B-PAC-1-
mediated apoptosis was evaluated. Both proteins were doubly knocked down in MEFs (Bax/Bak 
(-/-)), and the cells were treated with staurosporine (100 nM) or B-PAC-1 (2 or 5 µM) for 24 
hours. B-PAC-1 was not cytotoxic at 2 µM, but approximately 50% cell death was observed in 
both the wild-type and Bax/Bak (-/-) MEFs. In contrast, staurosporine induced nearly 100% cell 
death in wild-type MEFs, but minimal cell death was observed in Bax/Bak (-/-) MEFs. These 
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results indicate that B-PAC-1 can induce apoptosis independent of certain upstream apoptotic 
effector proteins.
25
 
 Finally, the ability of pan-caspase inhibitors Z-VAD-fmk and Q-VD-OPh to inhibit B-
PAC-1-induced apoptosis was assessed. In a 24-hour experiment, Z-VAD-fmk and Q-VD-OPh 
(50 µM each) partially but significantly reduced the extent of apoptosis induced by B-PAC-1 (10 
µM); both fully inhibited apoptosis induced by staurosporine (100 nM). In addition, the effect of 
these inhibitors on PARP cleavage was assessed by western blot. Co-treatment of B-PAC-1 (10 
µM) or ABT-199 (5 nM) with Q-VD-OPh (50 µM) fully inhibited cleavage of PARP, while co-
treatment with Z-VAD-fmk (50 µM) partially reduced the amount of cleaved PARP detected.
25
 
 
1.11.4. Combination of B-PAC-1 with Smac mimetic 
Smac, a proapoptotic protein, binds to the antiapoptotic IAPs and inhibits their interaction 
with procaspase-3. This relief of inhibition allows for procaspase-3 to be cleaved to caspase-3, 
and cells undergo apoptosis.
3
 Many small-molecule mimics of Smac, including SM-164,
15
 LCL-
161,
16
  and Smac066,
88
 are currently under development as anticancer agents. Treatment of CLL 
cells with B-PAC-1 led to an elevation in Smac protein levels. Because this effect was observed, 
it was proposed that a small molecule with Smac-like activity could synergize with B-PAC-1 to 
induce apoptosis. Cells were treated with B-PAC-1, Smac066, or a combination at 5, 7.5, or 10 
µM. Combinations were synergistic for the majority of samples evaluated, as measured by 
combination indices of less than 1.0, demonstrating the potential for induction of apoptosis via 
combination therapy with B-PAC-1 and additional proapoptotic agents.
25
 
 
1.12. Summary and outlook 
 Previous work by the Hergenrother group and others has identified the activation of 
procaspase-3 by small molecules as a promising anticancer strategy. Because labile zinc pools 
exist throughout the body, induction of apoptosis via the removal of labile zinc has the potential 
to treat a diverse array of tumors. The efficacy of PAC-1 and related derivatives in cell culture 
and in vivo cancer models reinforce the hypotheses formed from in vitro data and has led to the 
initiation of a Phase 1 clinical trial in human cancer patients. As further studies are performed, 
the potential therapeutic effect of procaspase-3 activation will be fully elucidated. Described 
herein are chemical studies on PAC-1, efforts to further understand the structure-activity 
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relationships of PAC-1 and derivatives, and the development of novel PAC-1 derivatives with 
the goal of improving potency, metabolic stability, and safety.  
45 
 
1.13. References 
1. Hsu, D. C.; Roth, H. S.; West, D. C.; Botham, R. C.; Novotny, C. J.; Schmid, S. C.; 
Hergenrother, P. J. Parallel synthesis and biological evaluation of 837 analogues of Procaspase-
Activating Compound 1 (PAC-1). ACS Comb. Sci. 2012, 14, 44-50. 
2. Roth, H. S.; Botham, R. C.; Schmid, S. C.; Fan, T. M.; Dirikolu, L.; Hergenrother, P. J. 
Removal of metabolic liabilities enables development of derivatives of Procaspase-Activating 
Compound 1 (PAC-1) with improved pharmacokinetics. J. Med. Chem. 2015, 58, 4046-4065. 
3. Hengartner, M. O. The biochemistry of apoptosis. Nature 2000, 407, 770-776. 
4. Elmore, S. Apoptosis: A review of programmed cell death. Toxicol. Pathol. 2007, 35, 
495-516. 
5. Nicholson, D. W. Caspase structure, proteolytic substrates, and function during apoptotic 
cell death. Cell Death Differ. 1999, 6, 1028-1042. 
6. Earnshaw, W. C.; Martins, L. M.; Kaufmann, S. H. Mammalian caspases: Structure, 
activation, substrates, and functions during apoptosis. Annual Review of Biochemistry 1999, 68, 
383-424. 
7. Slee, E. A.; Adrain, C.; Martin, S. J. Executioner caspase-3, -6, and -7 perform distinct, 
non-redundant roles during the demolition phase of apoptosis. J. Biol. Chem. 2001, 276, 7320-
7326. 
8. Sakahira, H.; Enari, M.; Nagata, S. Cleavage of CAD inhibitor in CAD activation and 
DNA degradation during apoptosis. Nature 1998, 391, 96-99. 
9. Hanahan, D.; Weinberg, R. A. The hallmarks of cancer. Cell 2000, 100, 57-70. 
10. Hanahan, D.; Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 2011, 144, 
646-674. 
11. Vassilev, L. T.; Vu, B. T.; Graves, B.; Carvajal, D.; Podlaski, F.; Filipovic, Z.; Kong, N.; 
Kammlott, U.; Lukacs, C.; Klein, C.; Fotouhi, N.; Liu, E. A. In vivo activation of the p53 
pathway by small-molecule antagonists of MDM2. Science 2004, 303, 844-848. 
12. Vu, B.; Wovkulich, P.; Pizzolato, G.; Lovey, A.; Ding, Q.; Jiang, N.; Liu, J. J.; Zhao, C.; 
Glenn, K.; Wen, Y.; Tovar, C.; Packman, K.; Vassilev, L.; Graves, B. Discovery of RG7112: A 
small-molecule MDM2 inhibitor in clinical development. ACS Med. Chem. Lett. 2013, 4, 466-
469. 
13. Oltersdorf, T.; Elmore, S. W.; Shoemaker, A. R.; Armstrong, R. C.; Augeri, D. J.; Belli, 
B. A.; Bruncko, M.; Deckwerth, T. L.; Dinges, J.; Hajduk, P. J.; Joseph, M. K.; Kitada, S.; 
Korsmeyer, S. J.; Kunzer, A. R.; Letai, A.; Li, C.; Mitten, M. J.; Nettesheim, D. G.; Ng, S.; 
Nimmer, P. M.; O'Connor, J. M.; Oleksijew, A.; Petros, A. M.; Reed, J. C.; Shen, W.; Tahir, S. 
K.; Thompson, C. B.; Tomaselli, K. J.; Wang, B. L.; Wendt, M. D.; Zhang, H. C.; Fesik, S. W.; 
Rosenberg, S. H. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. 
Nature 2005, 435, 677-681. 
14. Souers, A. J.; Leverson, J. D.; Boghaert, E. R.; Ackler, S. L.; Catron, N. D.; Chen, J.; 
Dayton, B. D.; Ding, H.; Enschede, S. H.; Fairbrother, W. J.; Huang, D. C.; Hymowitz, S. G.; 
Jin, S.; Khaw, S. L.; Kovar, P. J.; Lam, L. T.; Lee, J.; Maecker, H. L.; Marsh, K. C.; Mason, K. 
D.; Mitten, M. J.; Nimmer, P. M.; Oleksijew, A.; Park, C. H.; Park, C. M.; Phillips, D. C.; 
Roberts, A. W.; Sampath, D.; Seymour, J. F.; Smith, M. L.; Sullivan, G. M.; Tahir, S. K.; Tse, 
C.; Wendt, M. D.; Xiao, Y.; Xue, J. C.; Zhang, H.; Humerickhouse, R. A.; Rosenberg, S. H.; 
Elmore, S. W. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity 
while sparing platelets. Nat. Med. 2013, 19, 202-208. 
46 
 
15. Lu, J.; Bai, L.; Sun, H.; Nikolovska-Coleska, Z.; McEachern, D.; Qiu, S.; Miller, R. S.; 
Yi, H.; Shangary, S.; Sun, Y.; Meagher, J. L.; Stuckey, J. A.; Wang, S. SM-164: a novel, bivalent 
Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the 
blockade of cIAP-1/2 and XIAP. Cancer Res. 2008, 68, 9384-9393. 
16. Houghton, P. J.; Kang, M. H.; Reynolds, C. P.; Morton, C. L.; Kolb, E. A.; Gorlick, R.; 
Keir, S. T.; Carol, H.; Lock, R.; Maris, J. M.; Billups, C. A.; Smith, M. A. Initial testing (stage 1) 
of LCL161, a SMAC mimetic, by the pediatric preclinical testing program. Pediatr. Blood 
Cancer 2012, 58, 636-639. 
17. Putt, K. S.; Chen, G. W.; Pearson, J. M.; Sandhorst, J. S.; Hoagland, M. S.; Kwon, J. T.; 
Hwang, S. K.; Jin, H.; Churchwell, M. I.; Cho, M. H.; Doerge, D. R.; Helferich, W. G.; 
Hergenrother, P. J. Small-molecule activation of procaspase-3 to caspase-3 as a personalized 
anticancer strategy. Nat. Chem. Biol. 2006, 2, 543-550. 
18. Wolan, D. W.; Zorn, J. A.; Gray, D. C.; Wells, J. A. Small-molecule activators of a 
proenzyme. Science 2009, 326, 853-858. 
19. Schipper, J. L.; MacKenzie, S. H.; Sharma, A.; Clark, A. C. A bifunctional allosteric site 
in the dimer interface of procaspase-3. Biophys. Chem. 2011, 159, 100-109. 
20. Vickers, C. J.; Gonzalez-Paez, G. E.; Umotoy, J. C.; Cayanan-Garrett, C.; Brown, S. J.; 
Wolan, D. W. Small-molecule procaspase activators identified using fluorescence polarization. 
ChemBioChem 2013, 14, 1419-1422. 
21. Ghavami, S.; Hashemi, M.; Ande, S. R.; Yeganeh, B.; Xiao, W.; Eshraghi, M.; Bus, C. J.; 
Kadkhoda, K.; Wiechec, E.; Halayko, A. J.; Los, M. Apoptosis and cancer: mutations within 
caspase genes. J. Med. Genet. 2009, 46, 497-510. 
22. Soini, Y.; Paakko, P. Apoptosis and expression of caspases 3, 6 and 8 in malignant non-
Hodgkin's lymphomas. APMIS 1999, 107, 1043-1050. 
23. Wrobel, G.; Maldyk, J.; Kazanowska, B.; Rapala, M.; Maciejka-Kapuscinska, L.; Chaber, 
R. Immunohistochemical expression of procaspase-3 and its clinical significance in childhood 
non-Hodgkin lymphomas. Pediatr. Dev. Pathol. 2011, 14, 173-179. 
24. Estrov, Z.; Thall, P. F.; Talpaz, M.; Estey, E. H.; Kantarjian, H. M.; Andreeff, M.; Harris, 
D.; Van, Q.; Walterscheid, M.; Kornblau, S. M. Caspase 2 and caspase 3 protein levels as 
predictors of survival in acute myelogenous leukemia. Blood 1998, 92, 3090-3097. 
25. Patel, V.; Balakrishnan, K.; Keating, M. J.; Wierda, W. G.; Gandhi, V. Expression of 
executioner procaspases and their activation by a procaspase activating compound in chronic 
lymphocytic leukemia cells. Blood 2015, 125, 1126-1136. 
26. Fink, D.; Schlagbauer-Wadl, H.; Selzer, E.; Lucas, T.; Wolff, K.; Pehamberger, H.; 
Eichler, H. G.; Jansen, B. Elevated procaspase levels in human melanoma. Melanoma Res. 2001, 
11, 385-393. 
27. Chen, N.; Gong, J.; Chen, X.; Meng, W.; Huang, Y.; Zhao, F.; Wang, L.; Zhou, Q. 
Caspases and inhibitor of apoptosis proteins in cutaneous and mucosal melanoma: expression 
profile and clinicopathologic significance. Hum. Pathol 2009, 40, 950-956. 
28. Gdynia, G.; Grund, K.; Eckert, A.; Bock, B. C.; Funke, B.; Macher-Goeppinger, S.; 
Sieber, S.; Herold-Mende, C.; Wiestler, B.; Wiestler, O. D.; Roth, W. Basal caspase activity 
promotes migration and invasiveness in glioblastoma cells. Mol. Cancer Res. 2007, 5, 1232-
1240. 
29. Murphy, A. C.; Weyhenmeyer, B.; Schmid, J.; Kilbride, S. M.; Rehm, M.; Huber, H. J.; 
Senft, C.; Weissenberger, J.; Seifert, V.; Dunst, M.; Mittelbronn, M.; Kogel, D.; Prehn, J. H.; 
47 
 
Murphy, B. M. Activation of executioner caspases is a predictor of progression-free survival in 
glioblastoma patients: a systems medicine approach. Cell Death Dis. 2013, 4, e629. 
30. Virkajarvi, N.; Paakko, P.; Soini, Y. Apoptotic index and apoptosis influencing proteins 
bcl-2, mcl-1, bax and caspases 3, 6 and 8 in pancreatic carcinoma. Histopathology 1998, 33, 432-
439. 
31. Persad, R.; Liu, C.; Wu, T. T.; Houlihan, P. S.; Hamilton, S. R.; Diehl, A. M.; Rashid, A. 
Overexpression of caspase-3 in hepatocellular carcinomas. Mod. Pathol. 2004, 17, 861-867. 
32. Tormanen-Napankangas, U.; Soini, Y.; Kahlos, K.; Kinnula, V.; Paakko, P. Expression 
of caspases-3, -6 and -8 and their relation to apoptosis in non-small cell lung carcinoma. Int. J. 
Cancer 2001, 93, 192-198. 
33. Krepela, E.; Prochazka, J.; Liul, X.; Fiala, P.; Kinkor, Z. Increased expression of Apaf-1 
and procaspase-3 and the functionality of intrinsic apoptosis apparatus in non-small cell lung 
carcinoma. Biol. Chem. 2004, 385, 153-168. 
34. Krepela, E.; Prochazka, J.; Fiala, P.; Zatloukal, P.; Selinger, P. Expression of apoptosome 
pathway-related transcripts in non-small cell lung cancer. J. Cancer Res. Clin. Oncol. 2006, 132, 
57-68. 
35. O'Donovan, N.; Crown, J.; Stunell, H.; Hill, A. D.; McDermott, E.; O'Higgins, N.; Duffy, 
M. J. Caspase 3 in breast cancer. Clin. Cancer Res. 2003, 9, 738-742. 
36. Zapata, J. M.; Krajewska, M.; Krajewski, S.; Huang, R. P.; Takayama, S.; Wang, H. G.; 
Adamson, E.; Reed, J. C. Expression of multiple apoptosis-regulatory genes in human breast 
cancer cell lines and primary tumors. Breast Cancer Res. Treat. 1998, 47, 129-140. 
37. Krajewski, S.; Krajewska, M.; Turner, B. C.; Pratt, C.; Howard, B.; Zapata, J. M.; 
Frenkel, V.; Robertson, S.; Ionov, Y.; Yamamoto, H.; Perucho, M.; Takayama, S.; Reed, J. C. 
Prognostic significance of apoptosis regulators in breast cancer. Endocr. Relat. Cancer 1999, 6, 
29-40. 
38. Nakopoulou, L.; Alexandrou, P.; Stefanaki, K.; Panayotopoulou, E.; Lazaris, A. C.; 
Davaris, P. S. Immunohistochemical expression of caspase-3 as an adverse indicator of the 
clinical outcome in human breast cancer. Pathobiology 2001, 69, 266-273. 
39. Jiang, H.; Gong, M.; Cui, Y.; Ma, K.; Chang, D.; Wang, T. Y. Upregulation of caspase-3 
expression in esophageal cancer correlates with favorable prognosis: an immunohistochemical 
study from a high incidence area in northern China. Dis. Esophagus 2010, 23, 487-492. 
40. Roy, S.; Bayly, C. I.; Gareau, Y.; Houtzager, V. M.; Kargman, S.; Keen, S. L.; Rowland, 
K.; Seiden, I. M.; Thornberry, N. A.; Nicholson, D. W. Maintenance of caspase-3 proenzyme 
dormancy by an intrinsic "safety catch" regulatory tripeptide. Proc. Natl. Acad. Sci. U.S.A. 2001, 
98, 6132-6137. 
41. Sadowska, A.; Car, H.; Pryczynicz, A.; Guzinska-Ustymowicz, K.; Kowal, K. W.; 
Cepowicz, D.; Kedra, B. Expression of apoptotic proteins in human colorectal cancer and 
metastatic lymph nodes. Pathol. Res. Pract. 2014, 210, 576-581. 
42. Hector, S.; Conlon, S.; Schmid, J.; Dicker, P.; Cummins, R. J.; Concannon, C. G.; 
Johnston, P. G.; Kay, E. W.; Prehn, J. H. Apoptosome-dependent caspase activation proteins as 
prognostic markers in Stage II and III colorectal cancer. Br. J. Cancer 2012, 106, 1499-1505. 
43. Peterson, Q. P.; Goode, D. R.; West, D. C.; Ramsey, K. N.; Lee, J. J. Y.; Hergenrother, P. 
J. PAC-1 activates procaspase-3 in vitro through relief of zinc-mediated inhibition. J. Mol. Biol. 
2009, 388, 144-158. 
44. Peterson, Q. P.; Hsu, D. C.; Goode, D. R.; Novotny, C. J.; Totten, R. K.; Hergenrother, P. 
J. Procaspase-3 activation as an anti-cancer strategy: structure-activity relationship of 
48 
 
Procaspase-Activating Compound 1 (PAC-1) and its cellular co-localization with caspase-3. J. 
Med. Chem. 2009, 52, 5721-5731. 
45. Peterson, Q. P.; Hsu, D. C.; Novotny, C. J.; West, D. C.; Kim, D.; Schmit, J. M.; 
Dirikolu, L.; Hergenrother, P. J.; Fan, T. M. Discovery and canine preclinical assessment of a 
nontoxic procaspase-3-activating compound. Cancer Res. 2010, 70, 7232-7241. 
46. Lucas, P. W.; Schmit, J. M.; Peterson, Q. P.; West, D. C.; Hsu, D. C.; Novotny, C. J.; 
Dirikolu, L.; Churchwell, M. I.; Doerge, D. R.; Garrett, L. D.; Hergenrother, P. J.; Fan, T. M. 
Pharmacokinetics and derivation of an anticancer dosing regimen for PAC-1, a preferential small 
molecule activator of procaspase-3, in healthy dogs. Invest. New Drugs 2011, 29, 901-911. 
47. West, D. C.; Qin, Y.; Peterson, Q. P.; Thomas, D. L.; Palchaudhuri, R.; Morrison, K. C.; 
Lucas, P. W.; Palmer, A. E.; Fan, T. M.; Hergenrother, P. J. Differential effects of procaspase-3 
activating compounds in the induction of cancer cell death. Mol. Pharmaceutics 2012, 9, 1425-
1434. 
48. Wang, F. Y.; Wang, L. H.; Zhao, Y. F.; Li, Y.; Ping, G. F.; Xiao, S.; Chen, K.; Zhu, W. 
F.; Gong, P.; Yang, J. Y.; Wu, C. F. A novel small-molecule activator of procaspase-3 induces 
apoptosis in cancer cells and reduces tumor growth in human breast, liver and gallbladder cancer 
xenografts. Mol. Oncol. 2014, 8, 1640-1652. 
49. Wang, F.; Liu, Y.; Wang, L.; Yang, J.; Zhao, Y.; Wang, N.; Cao, Q.; Gong, P.; Wu, C. 
Targeting procaspase-3 with WF-208, a novel PAC-1 derivative, causes selective cancer cell 
apoptosis. J. Cell. Mol. Med. [Online early access]. DOI: 10.1111/jcmm.12566. Published 
Online: March 8, 2015. 
50. Zhang, B.; Zhao, Y. F.; Zhai, X.; Fan, W. J.; Ren, J. L.; Wu, C. F.; Gong, P. Design, 
synthesis and antiproliferative activities of diaryl urea derivatives bearing N-acylhydrazone 
moiety. Chin. Chem. Lett. 2012, 23, 915-918. 
51. Zhang, B.; Zhao, Y. F.; Zhai, X.; Wang, L. H.; Yang, J. Y.; Tan, Z. H.; Gong, P. Design, 
synthesis and anticancer activities of diaryl urea derivatives bearing N-acylhydrazone moiety. 
Chem. Pharm. Bull. 2012, 60, 1046-1054. 
52. Zhai, X.; Huang, Q.; Jiang, N.; Wu, D.; Zhou, H. Y.; Gong, P. Discovery of hybrid dual 
N-acylhydrazone and diaryl urea derivatives as potent antitumor agents: design, synthesis and 
cytotoxicity evaluation. Molecules 2013, 18, 2904-2923. 
53. Huang, Q.; Fu, Q.; Liu, Y.; Bai, J.; Wang, Q.; Liao, H.; Gong, P. Design, synthesis and 
anticancer activity of novel 6-(aminophenyl)-2,4-bismorpholino-1,3,5-triazine derivatives 
bearing arylmethylene hydrazine moiety. Chem. Res. Chin. Univ. 2014, 30, 257-265. 
54. Botham, R. C.; Fan, T. M.; Im, I.; Borst, L. B.; Dirikolu, L.; Hergenrother, P. J. Dual 
small-molecule targeting of procaspase-3 dramatically enhances zymogen activation and 
anticancer activity. J. Am. Chem. Soc. 2014, 136, 1312-1319. 
55. Ma, J.; Zhang, G.; Han, X.; Bao, G.; Wang, L.; Zhai, X.; Gong, P. Synthesis and 
biological evaluation of benzothiazole derivatives bearing the ortho-hydroxy-N-acylhydrazone 
moiety as potent antitumor agents. Arch. Pharm. Chem. Life Sci. 2014, 347, 936-949. 
56. Ma, J. J.; Chen, D.; Lu, K.; Wang, L. H.; Han, X. Q.; Zhao, Y. F.; Gong, P. Design, 
synthesis, and structure-activity relationships of novel benzothiazole derivatives bearing the 
ortho-hydroxy N-carbamoylhydrazone moiety as potent antitumor agents. Eur. J. Med. Chem. 
2014, 86, 257-269. 
57. Astrand, O. A. H.; Aziz, G.; Ali, S. F.; Paulsen, R. E.; Hansen, T. V.; Rongved, P. 
Synthesis and initial in vitro biological evaluation of two new zinc-chelating compounds: 
comparison with TPEN and PAC-1. Bioorg. Med. Chem. 2013, 21, 5175-5181. 
49 
 
58. Qin, M. Z.; Liao, W. K.; Xu, C.; Fu, B. L.; Ren, J. G.; Gu, Y. C.; Gong, P. Synthesis and 
biological evaluation of novel 4-(2-fluorophenoxy)-2-(1H-tetrazol-1-yl)pyridines bearing 
semicarbazone moieties as potent antitumor agents. Arch. Pharm. Chem. Life Sci. 2013, 346, 
840-850. 
59. Hao-ming, L.; Chun-ling, Y.; Xiao-ying, Z.; Ming-ming, Z.; Dan, J.; Jun-hai, X.; Xiao-
hong, Y.; Song, L. Design, synthesis, and antitumor activity of a novel series of PAC-1 
analogues. Chem. Res. Chin. Univ. 2013, 29, 906-910. 
60. Razi, S. S.; Schwartz, G.; Boone, D.; Li, X.; Belsley, S.; Todd, G.; Connery, C. P.; 
Bhora, F. Y. Small molecule activation of procaspase-3 induces apoptosis in human lung 
adenocarcinoma: a tailored anti-cancer strategy. J. Surg. Res. 2010, 158, 402-403. 
61. Razi, S. S.; Rehmani, S.; Li, X.; Park, K.; Schwartz, G. S.; Latif, M. J.; Bhora, F. Y. 
Antitumor activity of paclitaxel is significantly enhanced by a novel proapoptotic agent in non–
small cell lung cancer. J. Surg. Res. 2015, 194, 622-630. 
62. Razi, S. S.; Schwartz, G.; Li, X. G.; Boone, D.; Belsley, S.; Todd, G.; Connery, C. P.; 
Bhora, F. Y. Direct activation of procaspase-3 inhibits human lung adenocarcinoma in a murine 
model. J. Am. Coll. Surgeons 2010, 211, S36-S36. 
63. Charkoudian, L. K.; Pham, D. M.; Franz, K. J. A pro-chelator triggered by hydrogen 
peroxide inhibits iron-promoted hydroxyl radical formation. J. Am. Chem. Soc. 2006, 128, 
12424-12425. 
64. Johnson, D. K.; Murphy, T. B.; Rose, N. J.; Goodwin, W. H.; Pickart, L. Cytotoxic 
chelators and chelates. 1. Inhibition of DNA synthesis in cultured rodent and human cells by 
aroylhydrazones and by a copper(II) complex of salicylaldehyde benzoyl hydrazone. Inorg. 
Chim. Acta 1982, 67, 159-165. 
65. Peng, X.; Tang, X.; Qin, W.; Dou, W.; Guo, Y.; Zheng, J.; Liu, W.; Wang, D. 
Aroylhydrazone derivative as fluorescent sensor for highly selective recognition of Zn
2+
 ions: 
syntheses, characterization, crystal structures and spectroscopic properties. Dalton Trans. 2011, 
40, 5271-5277. 
66. Muzio, M.; Salvesen, G. S.; Dixit, V. M. FLICE induced apoptosis in a cell-free system. 
Cleavage of caspase zymogens. J. Biol. Chem. 1997, 272, 2952-2956. 
67. Perry, D. K.; Smyth, M. J.; Stennicke, H. R.; Salvesen, G. S.; Duriez, P.; Poirier, G. G.; 
Hannun, Y. A. Zinc is a potent inhibitor of the apoptotic protease, caspase-3. A novel target for 
zinc in the inhibition of apoptosis. J. Biol. Chem. 1997, 272, 18530-18533. 
68. Huber, K. L.; Hardy, J. A. Mechanism of zinc-mediated inhibition of caspase-9. Protein 
Sci. 2012, 21, 1056-1065. 
69. Velazquez-Delgado, E. M.; Hardy, J. A. Zinc-mediated allosteric inhibition of caspase-6. 
J. Biol. Chem. 2012, 287, 36000-36011. 
70. Truong-Tran, A. Q.; Grosser, D.; Ruffin, R. E.; Murgia, C.; Zalewski, P. D. Apoptosis in 
the normal and inflamed airway epithelium: role of zinc in epithelial protection and procaspase-3 
regulation. Biochem. Pharmacol. 2003, 66, 1459-1468. 
71. Daniel, A. G.; Peterson, E. J.; Farrell, N. P. The bioinorganic chemistry of apoptosis: 
potential inhibitory zinc binding sites in caspase-3. Angew. Chem. Int. Ed. Engl. 2014, 53, 4098-
4101. 
72. Sjoli, S.; Solli, A. I.; Akselsen, O.; Jiang, Y.; Berg, E.; Hansen, T. V.; Sylte, I.; Winberg, 
J. O. PAC-1 and isatin derivatives are weak matrix metalloproteinase inhibitors. Biochim. 
Biophys. Acta 2014, 1840, 3162-3169. 
50 
 
73. Baell, J. B.; Holloway, G. A. New substructure filters for removal of pan assay 
interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J. 
Med. Chem. 2010, 53, 2719-2740. 
74. Song, Z.; Chen, X. H.; Zhang, D.; Ren, L.; Fang, L. N.; Cheng, W. M.; Gong, P.; Bi, K. 
S. Kinetic study of the degradation of PAC-1 and identification of a degradation product in 
alkaline condition. Chromatographia 2009, 70, 1575-1580. 
75. Goode, D. R.; Totten, R. K.; Heeres, J. T.; Hergenrother, P. J. Identification of 
promiscuous small molecule activators in high-throughput enzyme activation screens. J. Med. 
Chem. 2008, 51, 2346-2349. 
76. Putinski, C.; Abdul-Ghani, M.; Stiles, R.; Brunette, S.; Dick, S. A.; Fernando, P.; 
Megeney, L. A. Intrinsic-mediated caspase activation is essential for cardiomyocyte hypertrophy. 
Proc. Natl. Acad. Sci. U.S.A. 2013, 110, E4079-E4087. 
77. Franz, K. J. Clawing back: broadening the notion of metal chelators in medicine. Curr. 
Opin. Chem. Biol. 2013, 17, 143-149. 
78. Richon, V. M. Cancer biology: mechanism of antitumour action of vorinostat 
(suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor. Br. J. Cancer 2006, 95, 
S2-S6. 
79. Russell, R. G.; Watts, N. B.; Ebetino, F. H.; Rogers, M. J. Mechanisms of action of 
bisphosphonates: similarities and differences and their potential influence on clinical efficacy. 
Osteoporosis Int. 2008, 19, 733-759. 
80. Huesca, M.; Lock, L. S.; Khine, A. A.; Viau, S.; Peralta, R.; Cukier, I. H.; Jin, H.; Al-
Qawasmeh, R. A.; Lee, Y.; Wright, J.; Young, A. A novel small molecule with potent anticancer 
activity inhibits cell growth by modulating intracellular labile zinc homeostasis. Mol. Cancer 
Ther. 2009, 8, 2586-2596. 
81. Yu, Y.; Wong, J.; Lovejoy, D. B.; Kalinowski, D. S.; Richardson, D. R. Chelators at the 
cancer coalface: desferrioxamine to triapine and beyond. Clin. Cancer Res. 2006, 12, 6876-6883. 
82. Makhov, P.; Golovine, K.; Uzzo, R. G.; Rothman, J.; Crispen, P. L.; Shaw, T.; Scoll, B. 
J.; Kolenko, V. M. Zinc chelation induces rapid depletion of the X-linked inhibitor of apoptosis 
and sensitizes prostate cancer cells to TRAIL-mediated apoptosis. Cell Death Differ. 2008, 15, 
1745-1751. 
83. Hepowit, N. L.; Uthandi, S.; Miranda, H. V.; Toniutti, M.; Prunetti, L.; Olivarez, O.; De 
Vera, I. M.; Fanucci, G. E.; Chen, S.; Maupin-Furlow, J. A. Archaeal JAB1/MPN/MOV34 
metalloenzyme (HvJAMM1) cleaves ubiquitin-like small archaeal modifier proteins (SAMPs) 
from protein-conjugates. Mol. Microbiol. 2012, 86, 971-987. 
84. Lee, H. G.; Lee, J. H.; Jang, S. P.; Park, H. M.; Kim, S. J.; Kim, Y.; Kim, C.; Harrison, R. 
G. Zinc selective chemosensor based on pyridyl-amide fluorescence. Tetrahedron 2011, 67, 
8073-8078. 
85. Richardson, D. R.; Hefter, G. T.; May, P. M.; Webb, J.; Baker, E. Iron chelators of the 
pyridoxal isonicotinoyl hydrazone class. III. Formation constants with calcium(II), 
magnesium(II) and zinc(II). Biol. Metals 1989, 2, 161-167. 
86. Cecchelli, R.; Berezowski, V.; Lundquist, S.; Culot, M.; Renftel, M.; Dehouck, M. P.; 
Fenart, L. Modelling of the blood-brain barrier in drug discovery and development. Nat. Rev. 
Drug Discov. 2007, 6, 650-661. 
87. Qin, Y.; Dittmer, P. J.; Park, J. G.; Jansen, K. B.; Palmer, A. E. Measuring steady-state 
and dynamic endoplasmic reticulum and Golgi Zn
2+
 with genetically encoded sensors. Proc. 
Natl. Acad. Sci. U.S.A. 2011, 108, 7351-7356. 
51 
 
88. Cossu, F.; Malvezzi, F.; Canevari, G.; Mastrangelo, E.; Lecis, D.; Delia, D.; Seneci, P.; 
Scolastico, C.; Bolognesi, M.; Milani, M. Recognition of Smac-mimetic compounds by the BIR 
domain of cIAP1. Protein Sci. 2010, 19, 2418-2429. 
 
 
52 
 
Chapter 2. Synthetic and Spectroscopic Studies of PAC-1, and Synthesis of S-PAC-1 
 
2.1. Introduction 
 As discussed in Chapter 1, PAC-1 (1.1) was discovered as a small molecule capable of 
enhancing the enzymatic activity of procaspase-3 in vitro.
1
 Based on promising results from 
murine anticancer efficacy experiments, clinical trials in canine and human cancer patients were 
planned. In order to facilitate these studies, it became necessary to develop an improved gram-
scale synthetic route to PAC-1, as well as to improve upon the synthetic route toward S-PAC-1. 
In addition, it was necessary to determine the identity of two species in the 
1
H- and 
13
C-NMR 
spectra of PAC-1. If these were truly two distinct species, the final product would need to be 
purified more rigorously, but if these were two interconverting isomers of PAC-1, then the purity 
would be acceptable. 
 
2.2. Improved large-scale synthesis of PAC-1 
 
2.2.1. First-generation synthesis of PAC-1 
The synthesis of PAC-1 involves the late-stage condensation of a hydrazide (1.6) and an 
aldehyde (2.1) to form the essential ortho-hydroxy-N-acylhydrazone (Scheme 2.1). The original 
synthetic route toward PAC-1 is shown in Scheme 2.1. The synthesis of PAC-1 begins by the 
reaction of benzyl chloride (2.2) with 6 equivalents of piperazine (2.3) to form 1-
benzylpiperazine (1.10) in 91% yield, while also forming 1,4-dibenzylpiperazine (1.9) in <10% 
yield. The slow addition of benzyl chloride into a solution of excess piperazine is essential to 
favor the formation of 1.10 over 1.9. A second alkylation of 1.10 with a slight excess of ethyl 
chloroacetate (2.3) gives disubstituted piperazine 1.7 in 84% yield, and subsequent reaction of 
the ethyl ester with 3 equivalents of anhydrous hydrazine gives hydrazide 1.6 in 76% yield.
1
 
Synthesis of the aldehyde fragment begins by the alkylation of salicylaldehyde (2.4) with allyl 
bromide (2.5) to give 2-allyloxybenzaldehyde (2.6) in high yield. Compound 2.6 is subjected to a 
Claisen rearrangement by heating with or without microwave irradiation to form 3-
allylsalicylaldehyde (2.1) in 70% yield.
2, 3
 Finally, aldehyde 2.1 is condensed with a slight excess 
of hydrazide 1.6 with catalytic hydrochloric acid, and recrystallization from 15:1 hexane:ethanol 
gives PAC-1 (1.1) in 85% yield. The synthesis of PAC-1 proceeded in an overall yield of 49% 
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over the longest linear sequence of four steps. This strategy was successful for the generation of 
20-25 gram batches of PAC-1.
1
 
 
 
Scheme 2.1. First-generation synthesis of PAC-1.
1
 
 
2.2.2. Second-generation synthesis of PAC-1 
 The first-generation synthesis of PAC-1 generated sufficient material to support initial 
experiments in vitro, in cell culture, and in mice.
1
 However, studies in dogs required larger 
quantities of compound, and any clinical trials in human cancer patients would require even 
larger quantities. Therefore, it became necessary to modify the synthesis so that larger batches of 
PAC-1 could be produced. The most significant challenges to increasing scale are highlighted in 
blue in Scheme 2.1: intermediates 1.10, 1.7, and 2.1 were purified by chromatography, which is 
challenging and expensive on large scale, and synthesis of hydrazide 1.6 involved the use of 
anhydrous hydrazine, which is expensive, dangerous, and unstable upon storage. In particular, 
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the highly polar intermediate 1.10 has a very high affinity for silica, requiring large amounts of 
polar eluent to elute the product, and intermediate 2.1 is difficult to separate from the major side 
product, 2-allylphenol (2.7). In addition, while recrystallization of hydrazide 1.6 was not a 
significant limitation of the first-generation synthesis, there was significant material that could 
not be recovered from the mother liquor. 
Fortunately, neither these challenging purifications nor reaction with anhydrous 
hydrazine proved necessary for the synthesis of PAC-1. The improved synthetic route is shown 
in Scheme 2.2, with modifications highlighted in red. After full consumption of benzyl chloride, 
excess piperazine was removed quantitatively by filtration and extraction to give intermediate 
1.10 in high yield and high purity, with <5% 1.9. Intermediate 1.10 was alkylated with 1 
equivalent of ethyl chloroacetate to give intermediate 1.7 after filtration of inorganic solids. 
Instead of using anhydrous hydrazine, formation of hydrazide 1.6 was accomplished by reaction 
of 1.7 with hydrazine monohydrate, which is safer, less expensive, and more shelf-stable. In 
addition, the stoichiometry of the reaction was increased to 4 equivalents of hydrazine to ensure 
full conversion. Product of high purity was isolated after extraction, with no recrystallization 
necessary. Formation of intermediate 2.6 was already optimized, but synthesis of intermediate 
2.1 remained the most significant challenge of the route. After the reaction was complete, 
distillation of the crude material provided a distillate consisting of 2.1 and 2.7 in a 6:1 ratio. 
Since 2.7 would not react with the hydrazide, crude 2.1 was condensed with 1.6 to yield PAC-1. 
In order to avoid wasting valuable intermediates 1.6 and 2.1, the condensation was performed 
using a 1:1 ratio of hydrazide and aldehyde. It was also discovered that using heptane instead of 
hexane in the final recrystallization allowed for a slightly greater recovery of product, and 
heptane is less toxic in vivo than hexane. This route proceeded in 46% overall yield over the 
longest linear sequence of four steps and facilitated the synthesis of 155-gram batches on 
laboratory scale. The important advances included the elimination of all chromatographic 
purifications and one recrystallization, the removal of anhydrous hydrazine, and the ability to 
scale up six-fold on the laboratory scale. 
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Scheme 2.2. Second-generation synthesis of PAC-1. 
 
 In the optimized route toward PAC-1, piperazine was first alkylated with benzyl chloride, 
followed by ethyl chloroacetate, but the reverse order was also attempted (Scheme 2.3A). In this 
alternate route, piperazine was first alkylated with ethyl chloroacetate to form monosubstituted 
piperazine 2.8. A second alkylation with benzyl chloride gave 1.7, with a small amount of 
unreacted benzyl chloride. Reaction of the crude mixture of 1.7 and benzyl chloride with 
hydrazine gave hydrazide 1.6, while the remaining benzyl chloride was converted to 
benzylhydrazine (2.9), which could not be removed via extraction or recrystallization. Removal 
of benzyl chloride from crude 1.7 was accomplished by acid-base extraction, but this procedure 
led to a significant loss of yield due to ester hydrolysis. However, alkylation with benzyl chloride 
first (Scheme 2.3B) solved this problem. In this route, 1.10 was formed first, followed by 
reaction with ethyl chloroacetate to form 1.7 with a small amount of unreacted ethyl 
56 
 
chloroacetate. Reaction with hydrazine then gave hydrazide 1.6, along with a side product that is 
most likely 2.10, but this material was never observed in the isolated material, and it is likely 
removed during aqueous extraction. 
 
 
Scheme 2.3. A. Alkylation of piperazine with ethyl chloroacetate first gives a side product that 
cannot be easily removed. B. Alkylation of piperazine with benzyl chloride first leads to the 
isolation of pure 1.6. 
 
The optimized synthetic route toward PAC-1 was adapted by Regis Technologies to 
produce a batch greater than 10 kilograms with only two modifications. The presence of 2-
allylphenol in the final reaction makes recrystallization challenging due to trace 2-allylphenol in 
the final product, so intermediate 2.1 was purified by chromatography, although use of hexane 
and dichloromethane as the eluent allowed for a more facile separation than the original eluent of 
hexane and ethyl acetate. In addition, the relatively small increase in recovery when using 
A
B
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heptane in the final recrystallization did not overcome the increase in cost compared to hexane, 
so hexane was used instead. 
 
2.3. Determination of N-acylhydrazone isomers by NMR spectroscopy 
 
2.3.1. Assignment of NMR spectral resonances 
 In addition to the development of an improved large-scale synthesis of PAC-1, it was 
necessary to characterize the identity of the purified PAC-1. 
1
H-NMR and 
13
C-NMR spectra of 
the purified PAC-1 suggested that two species were present in solution, despite other analytical 
techniques suggesting a pure product. Since the active pharmaceutical ingredient needs to be of 
the highest possible purity for in vivo studies, it was necessary to determine whether the minor 
species was an impurity or a second conformer of PAC-1, although HPLC analysis of PAC-1 
showed a single peak, suggesting two interconverting species. 
 
2.3.1.1. 
1
H-NMR and 
13
C-NMR spectroscopy 
 In order to determine the identity of these species, it was necessary to assign all 
resonances in the 
1
H- and 
13
C-NMR spectra. The numbering scheme for all atoms is shown in 
Figure 2.1A; Figure 2.1B shows the 
1
H-NMR spectrum, acquired at 500 MHz in chloroform-d. 
Because the minor species is not present in a high enough concentration for all peaks to be easily 
visible, only the major isomer is considered in this analysis. Many peaks in the 
1
H-NMR 
spectrum can be assigned based upon the analogous positions of these resonances in synthetic 
intermediates. The OH and NH resonances appear at 11.34 and 10.12 ppm, although it was not 
immediately clear which resonance corresponded to each atom. Hydrogen 10, corresponding to 
the hydrazone CH, appears at 8.34 ppm. Resonances corresponding to aromatic hydrogens 
appear between 6.5-7.5 ppm; the four hydrogens at positions 2 and 3 appear as a multiplet 
centered around 7.33 ppm, while hydrogen 1 appears as a multiplet centered at 7.27. The triplet 
at 6.84 ppm corresponds to hydrogen 13, while hydrogens 12 and 14 appear at 7.19 and 7.07 
ppm, although it was not apparent which resonance corresponded to each atom. The single 
hydrogen atom 18 appears as a complex multiplet at 6.04 ppm, while the two hydrogen atoms on 
carbon 19 appear as a multiplet centered at 5.08 ppm. The doublet at 3.46 ppm corresponds to 
the two hydrogens on carbon 17. The remaining four resonances correspond to methylene groups 
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adjacent to the nitrogen atoms: the sharp singlets at 3.54 and 3.19 correspond to hydrogens at 5 
and 8, while the broad singlets correspond to the hydrogens in the piperazine ring (6 and 7), 
although two-dimensional NMR analysis was necessary to unambiguously assign these 
resonances. Also visible are several resonances corresponding to hydrogen atoms in the minor 
isomer, denoted with the prime symbol: the phenol (OH’) and hydrazone (10’), methylene 17’, a 
second methylene correlating to either 5’ or 8’, and a broad peak corresponding to the piperazine 
hydrogens (6’ or 7’). It is difficult to assign resonances in the 13C-NMR spectrum (Figure 2.1C; 
acquired at 125 MHz in chloroform-d) via similar analysis, in part due to the proximity of many 
resonances, including five resonances within the range of 127-130 ppm (Figure 2.1C inset). 
 
 
Figure 2.1. A. Atom numbering scheme, B. 
1
H-NMR spectrum, and C. 
13
C-NMR spectrum of 
PAC-1, with inset showing five peaks between 127-130 ppm in 
13
C-NMR spectrum. 
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2.3.1.2. Two-dimensional heteronuclear spectroscopy 
 In order to unambiguously assign all resonances in the 
1
H- and 
13
C-NMR spectra, it was 
necessary to analyze PAC-1 via two-dimensional NMR spectroscopy. Because most non-singlets 
in the 
1
H-NMR spectrum had been assigned, 
1
H/
1
H-COSY analysis was not necessary. However, 
analysis via 
1
H/
13
C-heteronuclear correlation spectroscopy was useful for assigning all 
resonances. The full HSQC spectrum of PAC-1 is shown in Figure 2.2. Based on these one-bond 
correlations, resonances for carbons 10 (151.1 ppm), 13 (119.1 ppm), 17 (33.9 ppm), 18 (136.6 
ppm), and 19 (115.8 ppm) can be assigned. In addition, one-bond heteronuclear correlations 
were observed for resonances corresponding to atoms 5, 6, 7, and 8. Interestingly, the farther 
upfield hydrogen resonance in the piperazine ring correlates to the farther downfield carbon 
resonance. An expansion of the aromatic region is shown in Figure 2.2B. This spectrum indicates 
the assignment of carbon 1 at 127.3 ppm, while also indicating resonances corresponding to 
carbons 2, 3, 12, and 13. 
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Figure 2.2. HSQC spectrum of PAC-1. A. Full spectrum. B. Expanded view of aromatic region. 
 
 The remaining resonances were assigned via HMBC spectroscopy (Figure 2.3; full 
spectrum in Figure 2.3A). An expansion around 3.1-3.7 ppm is shown in Figure 2.3B. The 
hydrogen at 3.54 ppm shows correlations with carbons at 53.1 ppm, 129.20 ppm, and 137.9 ppm, 
while the hydrogen at 3.19 ppm shows correlations with carbons at 53.8 ppm and 166.0 ppm. 
Because hydrogen resonance 5 is expected to correlate with three carbon resonances, while 
hydrogen resonance 8 is expected to correlate with two carbon resonances, hydrogen resonances 
at 3.54 ppm and 3.19 ppm can be assigned as hydrogens 5 and 8, respectively. The carbon 
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resonances at 53.8 ppm and 166.0 ppm can be assigned as carbons 7 and 9, respectively, due to 
their correlations to hydrogen resonance 8. Further, the carbon resonances at 53.1 ppm, 129.20 
ppm, and 137.9 ppm can be assigned as carbons 6, 3, and 4, respectively, based upon their 
correlations to hydrogen 5 and relative chemical shifts, and assignment of 3 also gives definitive 
assignment of carbon 2 at 128.4 ppm. Hydrogen resonances 6 and 7 can be assigned via the 
HSQC results previously discussed. 
 
 
 
Figure 2.3. HMBC spectrum of PAC-1. A. Full spectrum. B-D. Expanded views. 
 
 Figure 2.3C shows an expansion of the HMBC spectrum around hydrogen 10. This 
hydrogen resonance correlates to carbon resonances at 117.0 ppm, 129.24 ppm, and 156.4 ppm; 
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hydrogen 10 is expected to correlate to carbons 11, 12, and 16. Carbon 16, bearing a hydroxyl 
group, is the most upfield of these, at 117.0 ppm, while carbon 11, bearing the electron-
withdrawing hydrazone, is the most downfield, at 156.4 ppm. The remaining resonance, at 
129.24 ppm, belongs to carbon 12, and assignment of carbon 12 also allows for the assignment 
of carbon 14 at 132.3 ppm; hydrogens 12 and 14 can be assigned based upon HSQC results. The 
last remaining carbon resonance, at 128.2 ppm, belongs to carbon 15. 
 Figure 2.3D shows the expansion of the HMBC spectrum between 9.8-11.7 ppm. The 
hydrogen resonance at 11.34 ppm exhibits correlations to carbons 11, 15, and 16, as would be 
expected for the OH, while the hydrogen resonance at 10.12 ppm, corresponding to the NH, 
correlates to no carbon resonances. The assignments are summarized in Table 2.1. 
 
 
Table 2.1. Assignment of resonances in 
1
H- and 
13
C-NMR spectra of PAC-1. 
 
2.3.2. Interconversion of species by exchange spectroscopy 
 Assignment of resonances in the 
1
H-NMR spectrum facilitated further NMR study of the 
two species present in the spectrum. Exchange spectroscopy (EXSY) was used to determine 
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whether the two species underwent chemical exchange. EXSY is a dynamic NMR technique 
used to identify resonances corresponding to two or more nuclei undergoing chemical exchange 
on the NMR timescale. The pulse sequence is identical to the NOESY experiment; however, in 
contrast to observed NOE interactions, resonances corresponding to nuclei undergoing chemical 
exchange will appear in phase with each other. For the EXSY experiment with PAC-1, the 
hydrazone CH (hydrogen atom 10) was chosen because of the large difference in chemical shift 
for resonances corresponding to the major species (8.34 ppm) and minor species (7.91 ppm) and 
the isolation of these resonances from other resonances in the spectrum. The EXSY spectra are 
shown in Figure 2.4. Irradiation of the peaks at both 8.39 ppm (Figure 2.4A) and 7.95 ppm 
(Figure 2.4B) results in the in-phase appearance of the non-irradiated peak. This result confirms 
that the two species present correspond to interconverting isomers of PAC-1. 
 
 
Figure 2.4. EXSY spectrum of PAC-1 following irradiation at A. 8.39 ppm and B. 7.95 ppm. 
Irradiated peaks are indicated with a black arrow. 
 
2.3.3. Assignment of isomers by chemical shifts 
 The interconverting species most likely correspond to two isomers of the N-
acylhydrazone. It is known that two isomers (E and Z) can exist at the hydrazone C-N double 
bond, while two isomers can also exist at the amide C-N single bond (syn and antiperiplanar; 
relating to the configuration of the carbonyl oxygen and the amide hydrogen), for a total of four 
possible isomers (general N-acylhydrazone isomers in Figure 2.5A; isomers of PAC-1 in figure 
2.5B). It is known that interconversion between syn and anti isomers is rapid, while 
A
B
10 10’
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interconversion between E and Z isomers is slow; in fact, E-Z isomerization is slow enough that 
the isomers are separable by HPLC.
4
 The interconversion of the two PAC-1 isomers on the 
NMR timescale strongly suggests a syn/anti relationship between the two isomers. 
 
 
Figure 2.5. Four possible configurational isomers of N-acylhydrazones, for A. general structure 
and B. PAC-1. 
 
The E isomers are favored for N-acylhydrazones derived from aromatic aldehydes due to 
minimization of steric interactions, with the (E, anti) conformation favored over the (E, syn) 
conformation.
4-7
 In addition, the E isomers are favored over the Z isomers for ortho-hydroxy-N-
acylhydrazones due to the presence of an intramolecular hydrogen bond between the hydrazone 
nitrogen atom and the hydroxyl hydrogen atom not possible in the Z isomer. This intramolecular 
hydrogen bond results in a sharper, more downfield resonance for the hydroxyl hydrogen atom in 
the NMR spectrum, as compared to a non-hydrogen bonded phenol, which would be broader and 
farther upfield. The resonances corresponding to the phenolic hydrogens for the major and minor 
isomer of PAC-1 appear at 11.34 and 10.50 ppm, respectively, while analogous resonances in 
spectra for PAC-1 derivatives that lack the hydrazone, and thus lack the ability to hydrogen 
bond, appear between 9.0-9.5 ppm.
8
 This provides strong evidence to suggest that PAC-1 exists 
as a mixture of (E, anti) and (E, syn) isomers. 
The carbonyl carbon (carbon 9) and hydrogens adjacent to the carbonyl (hydrogens 8) are 
also diagnostic for the syn and anti isomers. Resonances for both carbonyl carbons and adjacent 
hydrogens for syn isomers of N-acylhydrazones are shifted downfield relative to corresponding 
resonances for anti isomers, because the N
+
=C-O
-
 resonance form contributes less to the syn 
isomers than to the anti isomers.
4, 5, 7, 9
 Hydrogen resonance 8 appears at 3.19 ppm, while 
A B
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hydrogen resonance 8’ appears at 3.52 ppm. Similarly, carbon resonance 9 appears at 166.0 ppm, 
while carbon resonance 9’ appears at 170.7 ppm. Since the resonances for the minor isomer for 
both of these diagnostic signals appear downfield relative to the resonances for the major isomer, 
it is most likely that the major isomer has the (E, anti) configuration, while the minor isomer has 
the (E, syn) configuration. 
The hydrogen and carbon chemical shifts for the hydrazone (carbon and hydrogen 10) are 
also important in assigning the isomers. The differences in chemical shifts between syn and anti 
isomers are expected to be less than 0.5 ppm for hydrogens and less than 5 ppm for carbons, 
while the differences between E and Z isomers are expected to be closer to 1 ppm for hydrogens 
and 10 ppm for carbons. The chemical shifts appear in the order (E, anti) > (E, syn) > (Z, anti) > 
(Z, syn) for both hydrogens and carbons.
7
 The distance between hydrogen 10 and hydrogen 10’ 
for PAC-1 is approximately 0.4 ppm, while the distance between carbon 10 and carbon 10’ is 
approximately 4 ppm, both of which strongly suggest a syn/anti relationship between the two 
isomers. Further, hydrogen 10 of PAC-1 appears at 8.39 ppm, and only the hydrogen for the (E, 
anti) isomer is expected to appear this far downfield.
7
 Taken together, these results strongly 
suggest that the major isomer of PAC-1 exists in the (E, anti) configuration, while the minor 
isomer exists in the (E, syn) configuration. 
 
2.3.4. Diphenylmethylene hydrazone 
 In order to support the assignment of the isomers, compound 2.8, a diphenylmethylene 
hydrazone, was synthesized via the condensation of hydrazide 1.6 and benzophenone (2.9, 
Scheme 2.3). The reaction proceeded in only 10% yield; it is likely that the steric interactions 
between the added phenyl ring and the NH that disfavor formation of Z-hydrazones made 
formation of this product more difficult or made hydrolysis to the starting materials more facile. 
Because both substituents at the hydrazone carbon are identical, compound 2.8 does not exhibit 
different E and Z isomers. Therefore, the existence of two isomers of compound 2.8 would 
strongly suggest that PAC-1 exists as a mixture of syn and anti isomers. 
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Scheme 2.4. Synthesis of 2.11. 
 
 The 
1
H-NMR spectrum of 2.8 is shown in Figure 2.6A. While the major isomer of 2.8 is 
present in a much higher proportion, the presence of a minor isomer is clear; four singlets, 
corresponding to two methylene groups on each of the two isomers, are observed between 3.0-
4.0 ppm. An EXSY experiment irradiating either the major isomer (Figure 2.6B) or the minor 
isomer (Figure 2.6C) indicates that the two isomers exchange on the NMR timescale. 
 
 
Figure 2.6. A. 
1
H-NMR spectrum of 2.11. B.-C. EXSY spectra of 2.11 with irradiation at B. 
3.07 ppm and C. 3.78 ppm. Irradiated peaks are indicated with black arrows. 
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2.4. Improved large-scale synthesis of S-PAC-1 
 
2.4.1. First-generation synthesis of S-PAC-1 
 In order to support clinical studies of S-PAC-1 in canine cancer patients, it was necessary 
to improve upon the synthesis of this compound as well. The initial synthetic route toward S-
PAC-1 is shown in Scheme 2.5.
2
 The synthesis begins with the alkylation of piperazine (2.2) 
with ethyl chloroacetate (2.3) to form monosubstituted piperazine 2.8 in 43% yield. Sulfonyl 
chloride 2.13 is converted to sulfonamide 2.14 in high yield by reaction with aqueous ammonia, 
and alkylation of 2.8 with 2.14 gives disubstituted piperazine 2.15. Reaction of the ester with 
anhydrous hydrazine gives hydrazide 2.16, and condensation of the hydrazide with aldehyde 2.1 
gives S-PAC-1. The route was used to prepare the compound in batches of 40-45 grams in an 
11% overall yield over the longest linear sequence of four steps beginning with ethyl 
chloroacetate.
2
 
 
 
Scheme 2.5. First-generation synthesis of S-PAC-1.
2
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2.4.2. Second-generation synthesis of S-PAC-1 
 Sufficient quantities of S-PAC-1 were produced via the above synthetic route to supply 
the initial canine clinical trial. However, a larger trial was planned, and it became necessary to 
produce larger batches of compound to supply these efforts. The major challenges in scalability 
are highlighted in blue in Scheme 2.4. The most significant loss in yield occurs in the formation 
of monosubstituted piperazine 2.8. While the formation of 2.8 is highly efficient, it is necessary 
to purify by acid-base extraction to remove disubstituted piperazine 2.17 (Scheme 2.6), which 
results in significant hydrolysis of the ester. In addition, the use of anhydrous hydrazine for 
formation of hydrazide 2.16 is not optimal for the reasons discussed in the PAC-1 synthesis. 
Finally, the use of excess hydrazide 2.16 in the final condensation reaction to form S-PAC-1 
makes production of large quantities of compound challenging, since it is difficult to recover the 
excess unreacted starting material, and nearly half of the hydrazide is discarded. The excess 
hydrazide makes it necessary to purify the final product by chromatography, which also limits 
the scalability. 
 
 
Scheme 2.6. Second-generation synthesis of S-PAC-1. 
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 The improved synthesis of S-PAC-1 is shown in Scheme 2.6. As with the formation of 
monosubstituted piperazine 1.10 in the synthesis of PAC-1, compound 2.8 could be isolated at 
greater than 95% purity after initial extraction, with less than 5% 2.17. Use of this material in the 
next reaction, along with a slight increase to 1.5 equivalents of 2.8, led to an isolated yield of 
82% of 2.15, an increase from the 60% isolated yield in the initial synthesis. Finally, reacting 
hydrazide 2.14 with aldehyde 2.1 in a 1:1 molar ratio eliminated the need for chromatography 
and reduced the amount of unreacted 2.14 that was discarded. Overall, the batch size was 
increased to a maximum of 65 grams, with a 36% overall yield over the longest linear sequence 
of four steps from ethyl chloroacetate. It is possible that further optimizations could be made, 
including the use of hydrazine monohydrate rather than anhydrous hydrazine, as well as efforts 
toward a higher recovery of S-PAC-1 during the final recrystallization. 
 
2.5. Materials and methods 
 
2.5.1. Chemical information 
General All reactions requiring anhydrous conditions were conducted under a positive 
atmosphere of nitrogen or argon in oven-dried glassware. Standard syringe techniques were used 
for anhydrous addition of liquids. Unless otherwise noted, all starting materials, solvents, and 
reagents were acquired from commercial suppliers and used without further purification. Flash 
chromatography was performed using 230-400 mesh silica gel. 
Compound Analysis All NMR experiments were recorded in CDCl3 (Sigma or Cambridge), 
(CD3)2CO (Sigma or Cambridge), or CD3OD (Cambridge) on a Varian Unity 500 MHz 
spectrometer with residual undeuterated solvent as the internal reference for 
1
H-NMR (CDCl3 – 
7.26 ppm; (CD3)2CO – 2.04 ppm; CD3OD – 3.30 ppm) and 
13
C-NMR (CDCl3 – 77.23 ppm 
(CD3)2CO – 29.80 ppm; CD3OD – 49.00 ppm). Chemical shift, δ (ppm); coupling constants, J 
(Hz); multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, quint = quintet, sext = sextet, 
m = multiplet, br = broad); and integration are reported. High-resolution mass spectral data was 
recorded on a Micromass Q-Tof Ultima hybrid quadrupole/time-of-flight ESI mass spectrometer 
or a Micromass 70-VSE at the University of Illinois Mass Spectrometry Laboratory. 
 
 
70 
 
 
1-benzylpiperazine (1.10) 
 
To a 5L three-necked round-bottom flask with a mechanical stirrer and condenser were added 
piperazine (2.2, 517 g, 6000 mmol, 6.0 equiv.) and THF (2.5 L, 0.4 M). The third neck was 
sealed with a septum, and the mixture was stirred at reflux until all piperazine dissolved. Benzyl 
chloride (2.1, 127 g, 116 mL, 1000 mmol, 1.0 equiv.) was added dropwise with stirring via 
addition funnel over 30 minutes. The reaction mixture was stirred at reflux for an additional hour 
after addition was complete. The reaction mixture was cooled to room temperature. The solid 
was filtered and washed with THF. The filtrate was filtered a second time. The second filtrate 
was concentrated and partitioned between CH2Cl2 (400 mL) and saturated Na2CO3 (400 mL). 
H2O (400 mL) was added to dissolve all remaining solid. The layers were separated, and the 
aqueous layer was extracted with CH2Cl2 (3 x 300 mL). The combined organic layers were 
washed with brine (3 x 300 mL), dried over MgSO4, filtered, and concentrated to yield 1.10 
(135.92 g, 77.2%) as a pale yellow oil at >95% purity (as assessed by 
1
H-NMR; remainder was 
1.9), which was used without further purification. 
1
H-NMR (500 MHz, CDCl3): δ 7.33-7.29 (m, 
4H), 7.26-7.23 (m, 1H), 3.49 (s, 2H), 2.88 (br t, 4H, J = 4.5 Hz), 2.41 (br s, 4H), 1.63 (br s, 1H). 
13
C-NMR (125 MHz, CDCl3): δ 138.3, 129.4, 128.4, 127.2, 63.9, 54.7, 46.3. HRMS (ESI): 
177.1379 (M+H)
+
; calcd. for C11H17N2: 177.1386. 
Ethyl 2-(4-benzylpiperazin-1-yl)acetate (1.7) 
 
To a 3L three-necked round-bottom flask with a mechanical stirrer and condenser were added 
1.10 (79.25 g, 448 mmol, 1.0 equiv.), NaHCO3 (56.5 g, 673 mmol, 1.5 equiv.), and acetone (900 
mL, 0.5 M). The mixture was stirred, and ethyl chloroacetate (2.3, 54.7 g, 47.6 mL, 448 mmol, 
1.0 equiv.) was added dropwise via addition funnel over 10 minutes. The reaction mixture was 
stirred at reflux overnight. The reaction mixture was cooled to room temperature. The solid was 
vacuum filtered and washed with acetone. The filtrate was concentrated to yield 1.7 (113.3 g, 
96.4%) as a dark yellow-orange liquid at >90% purity (as assessed by 
1
H-NMR; remainder was 
1.9 and excess unreacted 2.3), which was used without further purification. 
1
H-NMR (500 MHz, 
CDCl3): δ 7.32-7.29 (m, 4H), 7.26-7.23 (m, 1H), 4.20 (q, 2H, J = 7.0 Hz), 3.53 (s, 2H), 3.20 (s, 
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2H), 2.61 (br s, 4H), 2.54 (br s, 4H), 1.26 (t, 3H, J = 7.0 Hz). 
13
C-NMR (125 MHz, CDCl3): δ 
170.5, 138.2, 129.4, 128.4, 127.3, 63.2, 60.8, 59.8, 53.3, 53.0, 14.5. HRMS (ESI): 263.1752 
(M+H)
+
; calcd. for C15H23N2O2: 263.1754. 
2-(4-benzylpiperazin-1-yl)acetohydrazide (1.6) 
 
To a 3L three-necked round-bottom flask with a mechanical stirrer and condenser were added 
1.7 (140 g, 534 mmol, 1.0 equiv.) and EtOH (1068 mL, 0.5 M). The solution was stirred, and 
hydrazine monohydrate (107 g, 104 mL, 2136 mmol, 4.0 equiv.) was added dropwise via 
addition funnel over 30 minutes. The reaction mixture was stirred at reflux overnight. The 
reaction mixture was cooled to room temperature and concentrated. The resulting solid was 
partitioned between CH2Cl2 (250 mL) and 1:1 brine:0.1 M KOH (200 mL). The layers were 
separated, and the aqueous layer was extracted with CH2Cl2 (2 x 200 mL). The combined 
organic layers were dried over MgSO4, filtered, and concentrated to yield 1.6 (122.78 g, 92.3%) 
as a white solid, which was used without further purification. 
1
H-NMR (500 MHz, CDCl3): δ 
8.12 (br s, 1H), 7.34-7.31 (m, 4H), 7.29-7.25 (m, 1H), 3.84 (br s, 2H), 3.53 (s, 2H), 3.08 (s, 2H), 
2.56 (br s, 4H), 2.50 (br s, 4H). 
13
C-NMR (125 MHz, CDCl3): δ 170.7, 138.0, 129.3, 128.4, 
127.3, 63.0, 60.8, 53.8, 53.2. HRMS (ESI): 249.1708 (M+H)
+
; calcd. for C13H21N4O: 249.1710. 
2-(allyloxy)benzaldehyde (2.6) 
 
To a 2L three-necked round-bottom flask with a mechanical stirrer and condenser were added 
K2CO3 (173 g, 1250 mmol, 1.25 equiv.), DMF (250 mL), and salicylaldehyde (2.4, 122 g, 106 
mL, 1000 mmol, 1.0 equiv.). The mixture was stirred, and allyl bromide (2.5, 145 g, 104 mL, 
1200 mmol, 1.2 equiv.) was added dropwise via addition funnel over 2 hours. The reaction 
mixture was stirred at room temperature overnight. The reaction mixture was diluted with H2O 
(1L) and extracted with EtOAc (4 x 250 mL). The combined organic layers were washed with 
H2O (2 x 200 mL), 0.1 M KOH (2 x 200 mL), H2O (2 x 200 mL), and brine (2 x 200 mL), dried 
over MgSO4, filtered, and concentrated to yield 2.6 (154.87 g, 95.6%) as a dark brown liquid, 
which was used without further purification. 
1
H-NMR (500 MHz, CDCl3): δ 10.54 (s, 1H), 7.84 
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(dd, 1H, J = 1.5, 7.5 Hz), 7.53 (dt, 1H, J = 1.5, 7.0 Hz), 7.03 (t, 1H, J = 7.5 Hz), 6.98 (d, 1H, J = 
8.0 Hz), 6.08 (tdd, 1H, J = 5.0, 10.5, 17.5 Hz), 5.45 (qd, 1H, J = 1.5, 17.0 Hz), 5.34 (qd, 1H, J = 
1.5, 10.5 Hz), 4.66 (td, 2H, J = 1.5, 5.0 Hz). 
13
C-NMR (125 MHz, CDCl3): δ 190.0, 161.1, 136.0, 
132.6, 128.6, 125.3, 121.1, 118.3, 113.0, 69.4. HRMS (EI): 162.0679 (M)
+
; calcd. for C10H10O2: 
162.0681. 
3-allylsalicylaldehyde (2.1) 
 
2.6 (154 g, 950 mmol, 1.0 equiv.) was stirred at 200°C overnight. The reaction mixture was 
cooled to room temperature. Purification by vacuum distillation (b.p. = 95-105°C at 1 torr) 
yielded 2.1 (127.80 g, 83.0%) as a yellow liquid at 85% purity (remainder was 2.7), which was 
used without further purification. 
1
H-NMR (500 MHz, CDCl3): δ 11.31 (s, 1H), 9.89 (s, 1H), 
7.44 (dd, 1H, J = 1.5, 7.5 Hz), 7.41 (dd, 1H, J = 1.0, 7.5 Hz), 6.97 (t, 1H, J = 7.5 Hz), 6.00 (tdd, 
1H, J = 6.5, 10.0, 16.5 Hz), 5.12-5.10 (m, 1H), 5.09-5.08 (m, 1H), 3.44 (d, 2H, J = 7.0 Hz). 
13
C-
NMR (125 MHz, CDCl3): δ 196.9, 159.7, 137.4, 136.0, 132.1, 129.0, 120.5, 119.8, 116.5, 33.3. 
HRMS (ESI): 163.0765 (M+H)
+
; calcd. for C10H11O2: 163.0754. 
N'-(3-allyl-2-hydroxybenzylidene)-2-(4-benzylpiperazin-1-yl)acetohydrazide (PAC-1, 1.1) 
 
To a 3L three-necked round-bottom flask with a mechanical stirrer and condenser were added 
1.6 (72.8 g, 293 mmol, 1.0 equiv.), 2.1 (47.5 g, 293 mmol, 1.0 equiv.), and EtOH (1200 mL, 0.15 
M). The solution was stirred, and 1 M HCl (20.5 mL, 20.5 mmol, 0.070 equiv.) was added 
dropwise. The reaction mixture was stirred at reflux overnight. The reaction mixture was cooled 
to room temperature and concentrated. Recrystallization from 15:1 heptane:EtOH yielded PAC-
1 (1.1, 78.5 g, 68.3%) as a white solid, which was an interconverting mixture of two isomers. 
Spectral data for major isomer: 
1
H-NMR (500 MHz, CDCl3): δ 11.27 (s, 1H), 10.04 (br s, 1H), 
8.40 (s, 1H), 7.35-7.32 (m, 4H), 7.29-7.26 (m, 1H), 7.19 (dd, 1H, J = 1.0, 7.5 Hz), 7.08 (dd, 1H, 
J = 1.5, 8.0 Hz), 6.85 (t, 1H, J = 7.5 Hz), 6.04 (tdd, 1H, J = 6.5, 10.0, 16.5 Hz), 5.12-5.05 (m, 
2H), 3.55 (s, 2H), 3.46 (d, 2H, J = 6.5 Hz), 3.19 (s, 2H), 2.63 (br s, 4H), 2.54 (br s, 4H).
 13
C-
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NMR (125 MHz, CDCl3): δ 166.0, 156.6, 151.5, 137.9, 136.7, 132.5, 129.3, 129.3, 128.5, 128.4, 
127.4, 119.2, 117.1, 115.8, 63.1, 61.2, 53.9, 53.2, 34.0. HRMS (ESI): 393.2291 (M+H)
+
; calcd. 
for C23H29N4O2: 393.2291. 
2-(4-benzylpiperazin-1-yl)-N'-(diphenylmethylene)acetohydrazide (2.11) 
 
To a round-bottom flask were added 1.6 (124 mg, 0.50 mmol, 1.0 equiv.), EtOH (3 mL, 0.15 M), 
benzophenone (2.12, 91 mg, 0.50 mmol, 1.0 equiv.), and 1.2 M HCl (29 μL, 0.035 mmol, 0.070 
equiv.). The reaction mixture was stirred at reflux for 3 days. The reaction mixture was then 
concentrated. Purification by silica gel column chromatography (0-10% MeOH/EtOAc) yielded 
2.11 (21 mg, 10.3%) as a white solid.  
1
H-NMR (500 MHz, CDCl3) δ 10.18 (s, 1H), 7.68-7.64 
(m, 2H), 7.60-7.50 (m, 3H), 7.38-7.30 (m, 5H), 7.30-7.25 (m, 5H), 3.40 (s, 2H), 3.07 (s, 2H), 
2.39 (br s, 4H), 2.07 (br s, 2H). 
13
C-NMR (125 MHz, CDCl3) δ 166.4, 155.0, 137.9, 136.8, 
133.0, 130.14, 130.06, 129.9, 129.3, 128.5, 128.38, 128.37, 128.2, 127.4, 63.0, 60.9, 53.5, 52.8. 
HRMS (ESI): 413.2343 (M+1); calcd. for C26H29N4O: 413.2336. 
Ethyl 2-(piperazin-1-yl)acetate (2.8) 
 
To a 5L three-necked round-bottom flask with a mechanical stirrer and condenser were added 
piperazine (2.2, 362 g, 4200 mmol, 6.0 equiv.) and THF (2100 mL). The third neck was sealed 
with a septum, and the mixture was stirred at reflux until all piperazine dissolved (approx. 1 
hour). The heat source was removed, and ethyl chloroacetate (2.3, 74.4 mL, 700 mmol, 1.0 
equiv.) was added dropwise with stirring via addition funnel (approx. 30 minutes). A white solid 
formed immediately upon addition of ethyl chloroacetate. 
1
H-NMR showed complete 
consumption of ethyl chloroacetate after addition was complete. The reaction mixture was 
cooled to room temperature. The solid was filtered and washed with THF. The filtrate was 
concentrated and partitioned between CH2Cl2 (300 mL) and sat. Na2CO3 (300 mL), and H2O 
(500 mL) was added to dissolve the remaining solid. The layers were separated, and the aqueous 
layer was extracted with CH2Cl2 (3 x 250 mL). The combined organic layers were washed with 
brine (3 x 150 mL), dried over MgSO4, filtered, and concentrated to yield 2.8 (99.14 g, 82.2%) as 
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a pale yellow oil at >95% purity, which was used without further purification. 
1
H-NMR (500 
MHz, CDCl3) δ 4.17 (q, 2H, J = 7.0 Hz), 3.18 (s, 2H), 2.94 (t, 4H, J = 5.0 Hz), 2.55 (br s, 4H), 
2.18 (br s, 1H), 1.26 (t, 3H, J = 7.5 Hz). 
13
C-NMR (125 MHz, CDCl3) δ 170.5, 60.8, 60.2, 54.2, 
46.0, 14.4. 
4-(bromomethyl)benzenesulfonamide (2.14) 
 
To a round-bottom flask were added 4-(bromomethyl)benzenesulfonyl chloride (2.13, 100 g, 371 
mmol) and THF (1340 mL). The solution was stirred at 0°C, and 28% aqueous ammonia (94 mL, 
1.48 mol, 4.0 equiv.) was added dropwise, during which time a white solid formed in the flask. 
The reaction mixture was stirred at 0°C for 1 hour. The reaction was quenched by the addition of 
water (300 mL). The mixture was extracted with EtOAc (2 x 100 mL). The combined organic 
layers were washed with water (100 mL) and brine (2 x 100 mL), dried over MgSO4, filtered, 
and concentrated to afford 2.14 (76.56 g, 82.5%) as a white solid. 
1
H-NMR (500 MHz, 
(CD3)2CO) δ 7.87 (d, 2H, J = 8.5 Hz), 7.64 (d, 2H, J = 8.5 Hz), 6.65 (br s, 2H), 4.70 (s, 2H). 
13
C-
NMR (125 MHz, (CD3)2CO) δ 144.7, 143.2, 130.4, 127.3, 32.8. 
Ethyl 2-(4-(4-sulfamoylbenzyl)piperazin-1-yl)acetate (2.15) 
 
To a 3L three-necked round-bottom flask with a mechanical stirrer and condenser were added 
2.14 (78.3 g, 313 mmol, 1.0 equiv.), K2CO3 (103.7 g, 751 mmol, 3.0 equiv.), 3:2 THF:acetone 
(1565 mL, 0.2 M), and 2.8 (80.9 g, 470 mmol, 1.5 equiv.). The reaction mixture was stirred at 
reflux overnight. The reaction mixture was cooled to rt. The solid was filtered and washed with 
acetone, and the filtrate was concentrated. Recrystallization from EtOH afforded 2.15 (88 g, 
82%) as an off-white solid. 
1
H-NMR (500 MHz, CD3OD) δ 7.85 (d, 2H, J = 8.5 Hz), 7.51 (d, 
2H, J = 8.5 Hz), 4.16 (q, 2H, J = 7.0 Hz), 3.60 (s, 2H), 3.22 (s, 2H), 2.62 (br s, 4H), 2.52 (br s, 
4H), 1.25 (t, 3H, J = 7.0 Hz). 
13
C-NMR (125 MHz, CD3OD) δ 171.5, 144.0, 143.5, 130.9, 127.2, 
63.0, 61.2, 59.7, 53.7, 53.5, 14.5. 
4-((4-(2-hydrazinyl-2-oxoethyl)piperazin-1-yl)methyl)benzenesulfonamide (2.16) 
 
75 
 
To a 2L three-necked round-bottom flask with a mechanical stirrer and condenser were added 
2.15 (88 g, 258 mmol, 1.0 equiv.) and 2:1 EtOH:MeOH (520 mL, 0.5 M). The solution was 
stirred, and anhydrous hydrazine (33 mL, 1031 mmol, 4.0 equiv.) was added dropwise via 
addition funnel. The reaction mixture was stirred at reflux overnight. The reaction mixture was 
cooled to rt and concentrated. Recrystallization from MeOH afforded 2.16 (77.15 g, 91.4%) as a 
white solid. 
1
H-NMR (500 MHz, CD3OD) δ 7.85 (d, 2H, J = 8.5 Hz), 7.51 (d, 2H, J = 8.5 Hz), 
3.60 (s, 2H), 3.03 (s, 2H), 2.53 (br s, 8H). 
13
C-NMR (125 MHz, CD3OD) δ 171.4, 144.0, 143.5, 
130.9, 127.2, 63.0, 61.0, 54.1, 53.8. 
4-((4-(2-(2-(3-allyl-2-hydroxybenzylidene)hydrazinyl)-2-oxoethyl)piperazin-1-
yl)methyl)benzenesulfonamide (S-PAC-1, 1.34) 
 
To a round-bottom flask were added 2.16 (77.15 g, 236.7 mmol, 1.0 equiv.), 2.1 (38.39 g, 236.7 
mmol, 1.0 equiv.), 2:1 MeOH:MeCN (1580 mL, 0.15 M), and 1.2 M HCl (16.6 mL, 16.6 mmol, 
0.070 equiv.). The reaction mixture was stirred at reflux overnight. The reaction mixture was 
cooled to rt and concentrated. Purification by recrystallization from MeOH yielded S-PAC-1 
(65.56 g, 58.7%) as a white solid. 
1
H-NMR (500 MHz, (CD3)2CO) δ 11.84 (s, 1H), 10.78 (br s, 
1H), 8.49 (s, 1H), 7.84 (d, 2H, J = 8.0 Hz), 7.51 (d, 2H, J = 8.0 Hz), 7.17 (d, 2H, J = 7.5 Hz), 
6.85 (t, 1H, J = 7.5 Hz), 6.55 (br s, 2H), 6.01 (tdd, 1H, J = 6.5, 10.0, 16.5 Hz), 5.09-5.05 (m, 
1H), 5.01-4.98 (m, 1H), 3.59 (s, 2H), 3.41 (d, 2H, J = 7.0 Hz), 3.17 (s, 2H), 2.61 (br s, 4H), 2.51 
(br s, 4H). 
13
C-NMR (125 MHz, (CD3)2CO) δ 166.4, 157.0, 150.7, 144.0, 143.8, 137.6, 132.4, 
129.9, 129.9, 128.5, 126.8, 119.8, 118.4, 115.7, 62.6, 61.7, 54.3, 53.6, 34.4. HRMS (ESI): 
472.2014 (M+1); calcd. for C23H30N5O4S: 472.2019. 
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2.5.2. Spectra 
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Chapter 3. Parallel Synthesis and Biological Evaluation of 837 Analogues of PAC-1 
 
Portions of this chapter are reproduced with permission from literature (Hsu, D. C.; Roth, H. S.; 
West, D. C.; Botham, R. C.; Novotny, C. J.; Schmid, S. C.; Hergenrother, P. J. Parallel synthesis 
and biological evaluation of 837 analogues of Procaspase-Activating Compound 1 (PAC-1). ACS 
Comb. Sci. 2012, 14, 44-50.).1 Library synthesis was performed in collaboration with Dr. Danny 
C. Hsu, Dr. Diana C. West, Chris J. Novotny, and Steven C. Schmid. Biological evaluation was 
performed by Dr. Danny C. Hsu, Dr. Diana C. West, and Rachel C. Botham. Animal 
experiments were performed by Prof. Timothy M. Fan. 
 
3.1. Combinatorial library design and synthesis 
 
3.1.1. Library design 
Given initial promising results with PAC-1 and S-PAC-1, efforts were undertaken to 
develop PAC-1 derivatives with improved properties, including potency, metabolic stability, and 
tolerability. In order to expand upon previously determined structure-activity relationships2 and 
identify a highly potent derivative, a library of diverse PAC-1 analogues was designed. As the 
maximal cytotoxicity of S-PAC-1 is not reached until at least 24 hours,3 and both PAC-1 and S-
PAC-1 exhibit short half-lives of 1-2 hours in vivo,3, 4 a secondary goal of this study was to 
identify PAC-1 analogues that could induce apoptosis more rapidly. Reported synthetic routes to 
PAC-1 and S-PAC-1, as well as other PAC-1 analogues, utilize the condensation of a hydrazide 
and an aldehyde as the final step in the synthetic scheme.1-3, 5-15 The modular nature of the PAC-
1 synthesis allows for a diverse array of functional groups to be conveniently incorporated into 
the PAC-1 scaffold without altering the core ortho-hydroxy N-acylhydrazone motif essential for 
procaspase-3 activation and induction of apoptosis.2 As shown in Figure 3.1, 31 hydrazides 
(3.1{1-31}) and 27 aldehydes (3.2{1-27}) were selected for building the library of 837 PAC-1 
analogues. 
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Figure 3.1. Hydrazides and aldehydes used to construct 837-membered combinatorial library of 
PAC-1 analogues.1 
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3.1.2. Synthesis of library building blocks 
The hydrazide building blocks were constructed from commercially available benzyl 
halide starting materials. The syntheses of hydrazides 3.1{1-6} have been reported previously.2, 3, 
5 Hydrazides 3.1{7-27} were synthesized according to Scheme 3.1. Substituted benzyl halides 
3.4{7-27} first reacted with piperazine to form substituted benzylpiperazines 3.5{7-27}. A 
second alkylation of the piperazine ring with ethyl chloroacetate gave disubstituted piperazines 
6{7-27}, and the esters were then converted to hydrazides 3.1{7-27} by reaction with hydrazine. 
The synthetic routes toward hydrazides 3.1{28-31} are detailed in Scheme 3.2. Synthesis of 
hydrazide 3.1{28} began by the alkylation of piperazine with 4-vinylbenzyl chloride (7) to form 
monosubstituted piperazine 3.8 (Scheme 3.2A). A second alkylation with ethyl chloroacetate 
formed ester 3.9, and reaction with hydrazine formed the hydrazide and reduced the olefin, 
giving hydrazide 3.1{28}. The reduction of olefins with hydrazine typically involves the addition 
of an oxidizing agent,16 but the presence of atmospheric oxygen was sufficient to achieve this 
transformation. Synthesis of hydrazide 3.1{29} (Scheme 3.2B) began with the reaction of 
monosubstituted piperazine 2.8 with benzyl bromide 3.4{29} to form intermediate 3.6{29}. 
Reaction of 3.6{29} with hydrazine then formed hydrazide 3.1{29}. Hydrazide 3.1{30} (Scheme 
3.2C) was synthesized beginning with the reaction of 1-phenylpiperazine (3.5{30}) with ethyl 
chloroacetate to give disubstituted piperazine 3.6{30}, and reaction with hydrazine formed 
hydrazide 3.1{30}. Hydrazide 3.1{31}, was synthesized by first protecting 4-
methylbenzophenone (3.10) as the ethylene acetal (3.11), as shown in Scheme 3.2D. This 
compound was brominated under radical conditions to give benzyl bromide 3.12. Reaction with 
monosubstituted piperazine 2.8 gave intermediate 3.13, and reaction with hydrazine gave 
hydrazide 3.14. Deprotection of the acetal with aqueous acid gave hydrazide 3.1{31}. 
 
 
Scheme 3.1. Synthesis of hydrazides 3.1{7-27}.1 
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Scheme 3.2. Synthesis of hydrazides A. 3.1{28}, B. 3.1{29}, C. 3.1{30}, and D. 3.1{31}.1 
 
The structure-activity relationships of PAC-1 derived from the synthesis and evaluation 
of ~30 compounds demonstrated the necessity of the ortho-hydroxyl group,2 so 27 
salicylaldehyde building blocks were selected for library construction. Aldehydes 3.2{1-23} 
were obtained from commercial sources, and the syntheses of aldehydes 3.2{24-26} have been 
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reported previously.2, 3, 17 Aldehyde 3.2{27} was synthesized via copper-catalyzed cycloaddition 
of aldehyde 3.2{26} with benzyl azide, as shown in Scheme 3.3. 
 
 
Scheme 3.3. Synthesis of aldehyde 3.2{27}.1 
 
3.1.3. Synthesis of library members 
 Using a Büchi Syncore parallel synthesizer, each hydrazide was condensed with each 
aldehyde, with over 80 reactions performed simultaneously. Each aldehyde (5-15 mg) was 
allowed to react with excess hydrazide (1.7 equiv.), and mass spectrometry was used to monitor 
the disappearance of the aldehyde from the reaction mixture. When the aldehyde had reacted 
completely, polystyrene-bound benzaldehyde was added as a scavenger resin to react with and 
remove the excess hydrazide. When mass spectrometry showed no hydrazide remaining, the 
beads were removed by filtration, and the solutions were dried under high vacuum. Each of the 
837 compounds was assessed by HPLC/MS. The purity of each compound is listed in Table 3.1, 
and the expected and observed molecular ions are listed in Tables 3.2 and 3.3, respectively. The 
library members had an average purity of 91%. 
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Table 3.1. Percent purity of PAC-1 analogues (determined by LC/MS).1 
 
3.2{1} 3.2{2} 3.2{3} 3.2{4} 3.2{5} 3.2{6} 3.2{7} 3.2{8} 3.2{9} 3.2{10} 3.2{11} 3.2{12} 3.2{13} 3.2{14} 3.2{15} 3.2{16} 3.2{17} 3.2{18} 3.2{19} 3.2{20} 3.2{21} 3.2{22} 3.2{23} 3.2{24} 3.2{25} 3.2{26} 3.2{27}
3.1{1} 91 93 90 85 91 92 98 96 92 95 99 96 95 96 98 86 95 98 93 97 95 95 95 97 99 90 100
3.1{2} 92 91 90 91 93 95 99 96 95 92 96 94 99 93 91 86 90 93 93 90 91 95 93 93 71 96 96
3.1{3} 91 94 91 95 79 88 97 89 91 91 97 83 99 99 85 90 87 86 80 90 87 87 87 92 86 88 91
3.1{4} 93 98 96 99 96 98 99 96 90 99 100 91 94 92 93 90 95 91 88 95 89 90 88 96 86 93 98
3.1{5} 94 96 97 93 90 97 100 98 90 98 97 93 61 96 98 90 96 97 91 97 97 88 88 88 89 90 89
3.1{6} 98 98 97 72 95 100 97 90 94 95 98 96 95 96 92 100 100 95 92 92 97 95 92 90 80 83 89
3.1{7} 93 98 93 98 93 96 98 98 96 98 100 97 100 94 98 83 96 97 86 92 100 93 99 93 97 89 96
3.1{8} 89 93 91 90 90 94 96 95 90 95 93 92 97 93 94 81 90 94 85 98 97 96 96 93 96 85 84
3.1{9} 92 90 88 92 82 91 96 92 94 92 92 93 92 90 92 92 90 90 96 93 89 82 90 88 90 82 87
3.1{10} 92 88 84 90 93 90 93 91 89 84 90 93 91 83 91 77 85 83 88 85 87 89 92 97 90 91 90
3.1{11} 91 92 86 90 89 91 96 92 90 89 93 96 96 92 91 90 88 94 89 90 91 95 91 92 88 90 88
3.1{12} 84 86 83 87 95 85 90 86 87 87 83 96 89 85 81 86 86 94 86 100 90 87 90 90 82 88 83
3.1{13} 95 86 86 92 89 91 96 95 90 86 93 91 90 89 94 91 85 84 90 100 86 90 90 90 91 83 98
3.1{14} 99 90 95 93 92 97 93 94 98 96 92 95 99 89 87 95 85 90 87 86 92 95 99 95 94 82 88
3.1{15} 98 87 85 99 94 86 92 93 82 88 93 99 95 82 87 84 90 88 92 100 91 91 90 93 96 93 98
3.1{16} 95 95 88 85 87 91 92 95 85 93 90 87 94 74 87 59 82 88 88 91 83 85 86 93 80 93 93
3.1{17} 86 95 89 73 84 92 95 92 86 82 89 97 93 80 84 86 86 90 87 100 81 86 88 89 89 80 97
3.1{18} 82 100 85 85 100 100 100 100 85 94 100 94 100 100 100 52 100 100 85 100 94 88 100 100 83 91 95
3.1{19} 93 99 100 70 100 92 94 94 87 99 93 98 100 93 92 83 88 97 66 100 92 75 99 98 90 87 98
3.1{20} 99 98 93 86 84 96 90 85 92 90 91 89 100 98 90 86 89 99 86 99 95 86 99 98 92 90 87
3.1{21} 88 83 89 85 93 85 88 90 100 86 99 100 92 92 100 85 100 96 67 95 92 84 93 93 92 92 86
3.1{22} 88 96 85 86 89 90 86 90 86 87 91 95 90 86 90 72 84 85 87 92 87 86 86 89 88 95 85
3.1{23} 88 86 84 87 91 85 98 92 93 98 87 88 96 81 88 90 86 96 90 100 97 83 84 98 85 81 90
3.1{24} 89 91 98 96 97 94 99 92 96 97 95 95 89 86 94 81 89 84 86 96 81 97 97 96 93 96 95
3.1{25} 100 96 96 93 95 96 98 91 91 95 97 95 92 92 95 82 90 90 87 94 90 93 94 94 86 92 88
3.1{26} 90 93 88 87 83 88 96 86 93 90 94 91 97 90 83 89 87 85 91 97 89 88 91 94 91 89 92
3.1{27} 93 92 92 87 80 94 95 91 89 90 92 92 91 88 94 89 90 90 91 94 90 88 89 90 95 82 95
3.1{28} 86 83 98 82 86 97 86 94 87 84 66 88 86 86 93 85 96 91 85 100 86 55 85 81 94 88 90
3.1{29} 86 91 93 88 86 94 98 90 94 89 91 93 83 91 90 90 87 86 89 98 87 95 95 89 87 84 88
3.1{30} 87 92 85 86 90 90 95 90 93 83 91 92 86 85 93 82 97 91 80 88 88 82 93 89 90 81 98
3.1{31} 82 83 83 90 82 86 96 83 86 90 92 94 84 91 79 84 89 80 84 95 89 91 87 91 99 93 90
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Table 3.2. Expected m/z for mass spectrometry of PAC-1 analogues. All masses are [M+H]+ 
except as noted: *=[M+Na]+ and **=[M+H2O+H]
+.1 
 
3.2{1} 3.2{2} 3.2{3} 3.2{4} 3.2{5} 3.2{6} 3.2{7} 3.2{8} 3.2{9} 3.2{10} 3.2{11} 3.2{12} 3.2{13} 3.2{14} 3.2{15} 3.2{16} 3.2{17} 3.2{18} 3.2{19} 3.2{20} 3.2{21} 3.2{22} 3.2{23} 3.2{24} 3.2{25} 3.2{26} 3.2{27}
3.1{1} 353.2 383.2 431.1 424.3 437.2 387.2 465.4 389.2 605.0 459.2 397.2 369.2 401.2 541.0 398.2 413.2 461.1 421.1 383.2 443.2 511.0 403.2 403.2 393.2 433.3 *400.2 510.3
3.1{2} 383.2 413.2 461.1 454.3 467.2 417.2 495.3 419.2 635.0 489.2 427.2 399.2 431.2 571.0 428.2 443.2 491.1 451.1 413.2 *496.2 541.0 433.2 433.2 423.2 463.3 **425.2 540.3
3.1{3} 398.2 428.2 476.1 469.3 482.2 432.1 510.3 434.2 650.0 504.2 442.2 414.2 446.2 586.0 443.2 458.2 506.1 466.1 428.2 488.2 556.0 448.2 448.2 438.2 478.2 **440.2 555.2
3.1{4} 413.2 443.2 491.1 484.3 497.2 447.2 525.3 449.2 665.0 519.3 457.2 429.2 461.2 601.0 458.2 473.2 521.1 481.1 443.2 503.2 571.0 463.2 463.2 453.2 493.3 **455.2 570.3
3.1{5} 432.2 462.2 510.1 503.2 516.2 466.1 544.3 468.1 684.0 538.2 476.2 448.2 480.1 620.0 477.2 492.2 540.1 500.1 462.2 522.1 590.0 482.2 482.2 472.2 512.2 **474.2 589.2
3.1{6} 408.2 438.2 486.1 479.3 492.2 442.2 520.3 444.2 660.0 514.3 452.2 424.2 456.2 596.0 453.2 468.2 516.1 476.1 438.2 498.2 566.0 458.2 458.2 448.2 488.3 **450.2 565.3
3.1{7} 405.1 435.2 485.1 476.2 489.1 439.1 517.3 441.1 656.9 511.2 449.2 421.1 453.1 593.0 450.1 465.2 515.1 473.1 435.2 495.1 563.0 455.2 455.2 445.2 485.2 **447.1 562.2
3.1{8} 387.2 417.2 467.1 458.2 471.1 421.1 499.3 423.1 638.9 493.3 431.2 403.2 435.1 575.0 432.1 447.2 497.1 455.1 417.2 477.1 545.0 437.2 437.2 427.2 467.2 **429.2 544.2
3.1{9} 431.1 461.1 511.0 502.2 515.1 467.1 543.3 467.1 682.9 537.1 475.1 447.1 481.0 618.9 476.1 491.1 541.0 501.0 461.1 521.1 588.9 481.1 481.1 471.1 511.1 **473.1 588.2
3.1{10} 565.3 595.3 643.2 636.4 649.3 599.2 677.4 601.3 817.1 671.3 609.3 581.3 613.3 753.1 610.3 625.3 673.2 633.2 595.3 655.2 723.1 615.3 615.3 605.3 645.3 **607.3 722.3
3.1{11} 445.2 475.2 523.1 515.3 529.2 479.2 557.3 481.2 697.0 551.3 489.2 461.2 493.2 633.1 490.2 505.2 553.1 513.1 475.2 535.2 603.0 495.2 495.2 485.3 525.3 **487.2 602.3
3.1{12} 429.2 459.2 507.1 500.3 513.2 463.2 541.4 465.2 681.0 535.3 473.3 445.2 477.2 617.1 474.2 489.2 537.1 497.1 459.2 519.2 587.0 479.2 479.2 469.3 509.3 453.2 586.3
3.1{13} 367.2 397.2 445.1 438.3 451.2 401.2 479.3 403.2 619.0 473.3 411.2 383.2 415.2 555.0 412.2 427.2 475.1 435.1 397.2 457.2 525.0 417.2 417.2 407.2 447.3 **409.2 524.3
3.1{14} 423.3 453.3 501.2 494.3 507.3 457.2 535.4 459.3 675.1 529.3 467.3 439.3 471.2 611.1 468.3 483.3 531.2 491.2 453.3 513.2 581.1 473.3 473.3 463.3 503.3 **465.3 580.3
3.1{15} 421.2 451.2 499.1 492.3 505.2 455.1 533.3 457.2 673.0 527.2 465.2 437.2 469.2 609.0 466.2 481.2 529.1 489.1 451.2 511.2 579.0 471.2 471.2 461.2 501.2 **463.2 578.2
3.1{16} 443.2 473.2 521.1 514.3 527.2 477.2 555.4 479.2 695.0 549.3 487.3 459.2 491.2 631.1 488.2 503.2 551.1 511.1 473.2 533.2 601.0 493.2 493.2 483.3 523.3 **484.2 600.3
3.1{17} 437.2 467.2 515.1 508.3 521.2 471.1 549.3 473.2 689.0 543.2 481.2 453.2 485.2 625.0 482.2 497.2 545.1 505.1 467.2 527.1 595.0 487.2 487.2 477.2 517.2 **479.2 594.2
3.1{18} 459.2 489.2 537.1 530.3 543.2 493.2 571.4 495.2 711.0 565.3 503.3 475.2 507.2 647.1 504.2 519.3 567.2 527.2 489.2 549.2 617.1 509.3 509.3 499.3 539.3 **501.2 616.3
3.1{19} 395.2 425.3 473.2 466.3 479.2 429.2 507.4 431.2 647.0 501.3 439.3 411.2 443.2 583.1 440.2 455.3 503.2 463.2 425.3 485.2 553.1 445.3 445.3 435.2 475.3 **437.2 552.3
3.1{20} 409.3 439.3 487.2 480.3 493.2 443.2 521.4 445.2 661.1 515.3 453.3 425.3 457.2 597.1 454.3 469.3 517.2 477.2 439.3 499.2 567.1 459.3 459.3 449.3 489.3 **451.3 566.3
3.1{21} 453.2 483.2 531.1 524.3 537.2 487.2 565.4 489.2 705.0 559.3 497.3 469.2 501.2 641.1 498.2 513.2 561.1 521.1 483.2 543.2 611.0 503.2 503.2 493.3 533.3 **495.2 610.3
3.1{22} 465.3 495.3 543.2 536.4 549.3 499.3 577.4 501.3 717.1 571.4 509.3 481.3 513.3 653.1 510.3 525.3 573.2 533.2 495.3 555.3 623.1 515.3 515.3 505.4 545.4 **507.3 622.4
3.1{23} 429.2 459.2 507.1 500.3 513.2 463.2 541.4 465.2 681.0 535.3 473.3 445.2 477.2 617.1 474.2 489.2 537.1 497.1 459.2 519.2 587.0 479.2 479.2 469.3 509.3 **471.2 586.3
3.1{24} 403.2 433.2 481.1 474.3 487.2 437.2 515.3 439.2 655.0 509.3 447.2 419.2 451.2 591.0 448.2 463.2 511.1 471.1 433.2 493.2 561.0 453.2 453.2 443.2 483.3 **445.2 560.3
3.1{25} 403.2 433.2 481.1 474.3 487.2 437.2 515.3 439.2 655.0 509.3 447.2 419.2 451.2 591.0 448.2 463.2 511.1 471.1 433.2 493.2 561.0 453.2 453.2 443.2 483.3 **445.2 560.3
3.1{26} 463.2 493.2 543.1 534.3 547.2 497.1 575.3 499.2 715.0 569.2 507.2 479.2 511.2 651.0 508.2 523.2 573.1 531.1 493.2 553.2 621.0 513.2 513.2 503.2 543.2 **505.2 620.3
3.1{27} 479.1 509.1 557.0 550.2 563.1 513.1 591.2 515.1 730.9 585.1 523.1 495.1 527.1 667.0 524.1 539.1 587.0 547.0 509.1 569.1 636.9 529.1 529.1 519.1 559.2 **521.1 636.2
3.1{28} 381.2 411.2 459.1 452.3 425.2 415.2 493.4 417.2 633.0 487.3 425.3 397.2 429.2 569.1 426.2 441.2 489.1 449.1 411.2 471.2 539.0 431.2 431.2 421.3 461.3 405.2 538.3
3.1{29} 507.2 537.2 585.1 578.3 591.2 541.2 619.3 543.2 759.0 613.2 551.2 523.2 555.2 695.0 552.2 567.2 615.1 575.1 537.2 597.2 665.0 557.2 557.2 547.2 587.3 **549.2 664.3
3.1{30} 339.2 369.2 417.1 410.3 423.2 373.1 451.3 375.2 591.0 445.2 383.2 355.2 387.2 527.0 384.2 399.2 447.1 407.1 369.2 429.1 497.0 389.2 389.2 379.2 419.2 **381.2 496.2
3.1{31} 457.2 487.2 535.1 528.3 541.2 491.2 569.3 493.2 709.0 563.3 501.2 473.2 505.2 645.1 502.2 517.2 565.1 525.1 487.2 547.2 615.0 507.2 507.2 497.3 537.3 **499.2 614.3
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Table 3.3. Observed m/z for mass spectrometry of PAC-1 analogues. All masses are [M+H]+ 
except as noted: *=[M+Na]+ and **=[M+H2O+H]
+. ***The correct m/z was not observed for 
these compounds.1 
 
3.2. Cell culture evaluation of library 
 With 837 PAC-1 analogues in hand, compounds were evaluated for their ability to induce 
apoptosis in cell culture. U-937 human lymphoma cells were exposed to the compounds for 24 
hours at a concentration of 20 μM. Both PAC-1 and S-PAC-1 display moderate potency (~50% 
cell death) versus this cell line under these conditions. Apoptotic cell death was assessed by flow 
cytometry, using Annexin V-FITC/propidium iodide staining. The full set of results is available 
in Table 3.4. Through this screening process, 61 compounds were identified that induced >80% 
cell death under these conditions, and re-screening the hits (Table 3.5) confirmed six potent 
PAC-1 derivatives (3.3{2,7}, 3.3{4,7}, 3.3{18,7}, 3.3{20,24}, 3.3{25,7}, and 3.3{28,7}). 
 
3.2{1} 3.2{2} 3.2{3} 3.2{4} 3.2{5} 3.2{6} 3.2{7} 3.2{8} 3.2{9} 3.2{10} 3.2{11} 3.2{12} 3.2{13} 3.2{14} 3.2{15} 3.2{16} 3.2{17} 3.2{18} 3.2{19} 3.2{20} 3.2{21} 3.2{22} 3.2{23} 3.2{24} 3.2{25} 3.2{26} 3.2{27}
3.1{1} 353.3 383.3 431.2 424.3 437.3 387.3 465.4 389.2 605.2 459.4 397.3 369.3 401.3 541.2 398.3 413.3 461.2 421.2 383.3 443.3 511.1 403.3 403.3 393.3 433.3 *395.1 510.2
3.1{2} 383.1 413.1 461.2 454.2 467.1 417.1 495.3 419.1 635.0 489.2 427.2 399.1 431.1 571.0 428.1 443.2 491.2 451.1 413.1 *495.1 542.0 433.2 433.2 423.2 463.1 **425.1 540.1
3.1{3} 398.3 428.3 476.3 469.3 482.3 432.2 510.4 434.3 650.0 504.3 442.3 414.2 446.3 586.1 443.3 458.3 506.2 466.2 428.3 488.3 556.1 448.3 448.3 438.3 478.1 **440.1 555.2
3.1{4} 413.3 443.3 491.3 484.4 497.3 447.3 525.4 449.2 665.1 519.3 457.3 429.3 461.3 601.2 458.2 473.3 521.3 481.1 443.1 503.1 570.9 463.2 463.2 453.3 493.2 **455.1 570.2
3.1{5} 432.1 462.1 510.0 503.2 516.1 466.1 544.2 468.1 683.9 538.2 476.1 448.1 480.1 620.0 477.1 492.1 540.0 500.1 462.1 522.1 590.0 482.1 482.1 472.1 512.2 **474.1 589.1
3.1{6} 408.1 438.1 486.0 479.2 492.1 442.1 520.2 444.1 659.9 514.1 452.1 424.1 456.1 595.9 453.1 468.1 516.0 476.1 438.1 498.1 566.0 458.1 458.1 448.1 488.2 **450.1 565.2
3.1{7} 405.2 435.2 485.2 476.3 489.3 439.2 517.4 441.3 657.1 511.3 449.3 421.2 453.2 593.1 450.3 465.3 515.1 473.2 435.2 495.2 563.0 455.2 455.2 445.3 485.2 **447.1 562.2
3.1{8} 387.2 417.2 467.1 458.2 471.2 421.1 499.3 423.2 639.0 493.2 431.2 403.2 435.2 575.0 432.2 447.2 497.1 455.2 417.2 477.2 545.0 437.2 437.2 427.2 467.2 **429.1 544.1
3.1{9} 431.1 461.1 511.0 502.2 515.1 467.1 543.3 467.1 683.0 537.2 475.1 447.1 481.0 619.0 476.2 491.1 541.0 501.0 461.1 521.2 589.0 481.2 481.2 471.1 511.1 **473.1 588.1
3.1{10} 565.1 595.1 643.0 636.2 649.1 599.1 677.2 601.1 817.0 671.2 609.1 581.1 613.1 753.0 610.0 625.1 673.1 633.0 595.1 655.0 723.0 615.1 615.1 605.1 645.1 **607.1 722.2
3.1{11} 445.2 475.2 523.2 516.2 529.2 479.2 557.4 481.2 697.0 551.2 489.2 461.2 493.2 633.1 490.2 505.2 553.2 513.3 475.1 ***539.8 603.1 495.1 495.3 485.3 525.2 **487.2 602.3
3.1{12} 429.2 459.3 507.2 500.3 513.2 463.2 541.4 465.2 681.0 535.3 473.3 445.2 477.2 617.1 474.2 489.3 537.2 497.2 459.3 519.2 587.1 479.3 479.3 469.3 509.2 453.1 586.3
3.1{13} 367.2 397.2 445.2 438.3 451.2 401.2 479.4 403.2 619.0 473.3 411.2 383.2 415.2 555.1 412.2 427.2 475.2 435.2 397.2 457.2 525.1 417.3 417.3 407.2 447.2 **409.1 524.2
3.1{14} 423.2 453.2 501.2 494.2 507.1 457.3 535.3 459.1 675.0 529.2 467.2 439.2 471.2 611.1 468.2 483.2 531.2 491.2 453.2 513.1 581.2 473.2 473.2 463.3 503.3 **465.1 580.2
3.1{15} 421.2 451.2 499.2 492.2 505.2 455.2 533.3 457.2 673.0 527.2 465.2 437.2 469.2 609.1 466.3 481.2 529.2 489.2 451.2 511.2 579.1 471.3 471.3 461.2 501.2 **463.1 578.2
3.1{16} 443.2 473.2 521.2 514.3 527.1 477.1 555.3 479.1 695.0 549.2 487.2 459.2 491.2 631.0 488.1 503.2 551.2 511.1 473.2 ***493.1 601.0 493.2 493.2 483.2 523.1 **485.1 600.2
3.1{17} 437.2 467.3 515.2 508.3 521.2 471.2 549.4 473.2 689.0 543.3 481.3 453.2 485.2 625.1 482.2 497.2 545.2 505.3 467.2 527.2 595.1 487.3 487.3 477.3 517.2 **479.1 594.2
3.1{18} 459.2 489.3 537.1 530.4 543.2 493.2 571.4 495.2 711.0 565.3 503.3 475.2 507.2 647.1 504.2 519.2 567.2 527.2 489.2 549.2 617.0 509.3 509.3 499.3 539.1 **501.1 616.2
3.1{19} 395.3 425.3 473.3 466.3 479.3 429.3 507.4 431.3 641.1 501.3 439.3 411.3 443.3 583.2 440.3 455.3 503.3 463.3 425.3 485.3 553.2 445.3 445.3 435.3 475.2 **437.2 552.2
3.1{20} 409.3 439.4 487.4 480.4 493.3 443.3 521.5 445.3 661.2 515.4 453.4 425.3 457.3 597.2 454.3 469.3 517.3 477.3 439.3 499.2 567.2 459.3 459.3 449.3 489.2 **451.2 566.3
3.1{21} 453.1 483.2 531.2 524.2 537.2 487.2 565.3 489.1 705.0 559.2 497.2 469.1 501.2 641.1 498.1 513.2 561.2 521.2 483.1 543.1 611.1 503.2 503.2 493.2 533.1 **495.0 610.1
3.1{22} 465.4 495.4 543.4 536.4 549.4 499.5 577.5 501.4 717.2 571.5 509.4 481.4 513.5 653.3 510.4 525.4 573.5 533.4 495.4 555.3 623.3 515.4 515.4 505.5 545.3 **507.3 622.3
3.1{23} 429.2 459.2 507.2 500.3 513.2 463.2 541.4 465.2 681.0 535.3 473.3 445.2 477.2 617.3 474.2 489.2 537.2 497.2 459.2 519.1 587.1 479.2 479.2 469.3 509.1 **471.0 586.1
3.1{24} 403.3 443.3 481.4 474.3 487.3 437.3 515.4 439.3 655.1 509.4 447.3 419.3 451.3 591.2 448.2 463.3 511.4 471.3 433.3 493.3 561.2 453.3 453.3 443.3 483.2 **445.2 560.2
3.1{25} 403.3 433.3 481.3 474.3 487.3 437.3 515.4 439.3 655.1 509.4 447.3 419.3 451.3 591.2 448.2 463.3 511.0 471.3 433.3 493.3 561.2 453.3 453.3 443.3 483.2 **445.2 560.2
3.1{26} 463.1 493.2 543.1 534.2 547.1 497.1 575.3 499.1 714.9 569.2 507.2 479.1 511.1 651.0 508.1 523.2 573.1 531.1 493.1 553.1 621.0 513.2 513.2 503.1 543.0 **505.0 620.1
3.1{27} 479.2 509.2 557.2 550.2 563.2 513.2 591.3 515.2 731.0 585.2 523.2 495.2 527.2 667.1 524.2 539.2 587.3 547.2 509.2 569.0 637.1 529.2 529.2 519.2 559.1 **521.0 636.1
3.1{28} 381.3 411.3 459.3 452.3 425.2 415.3 493.4 417.3 633.1 487.4 425.2 397.2 429.3 569.2 426.2 441.2 489.1 449.3 411.3 471.3 539.2 431.2 431.3 421.3 461.2 405.2 538.2
3.1{29} 507.3 537.3 585.4 578.4 591.3 541.4 619.5 543.3 759.2 613.4 551.3 523.3 555.4 695.3 552.3 567.3 615.4 575.4 537.3 597.3 665.2 557.4 557.4 547.4 587.2 **549.2 664.2
3.1{30} 339.1 369.1 417.1 410.1 423.1 373.1 451.2 375.1 590.9 445.1 383.1 355.1 387.1 527.0 384.1 399.1 447.0 407.0 369.1 429.1 497.0 389.1 389.1 379.1 419.2 **381.1 496.2
3.1{31} 457.2 487.2 535.0 528.2 541.2 491.1 569.3 493.2 709.0 563.2 501.2 473.2 505.1 645.0 502.2 517.2 565.1 525.1 487.2 547.2 615.0 507.2 507.2 497.2 537.2 **499.2 614.3
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Table 3.4. Percent cell death induced by PAC-1 analogues. U-937 cells were treated with 
compounds (20 µM) for 24 hours, and cell viability was determined by Annexin V-
FITC/propidium iodide staining.1 
 
3.2{1} 3.2{2} 3.2{3} 3.2{4} 3.2{5} 3.2{6} 3.2{7} 3.2{8} 3.2{9} 3.2{10} 3.2{11} 3.2{12} 3.2{13} 3.2{14} 3.2{15} 3.2{16} 3.2{17} 3.2{18} 3.2{19} 3.2{20} 3.2{21} 3.2{22} 3.2{23} 3.2{24} 3.2{25} 3.2{26} 3.2{27}
3.1{1} 5 5 32 68 42 10 92 9 11 43 7 14 26 37 11 10 15 35 17 7 47 39 36 34 84 3 33
3.1{2} 9 8 39 70 71 14 92 27 80 85 31 35 81 42 8 18 20 62 38 10 58 67 70 42 57 9 37
3.1{3} 7 5 57 87 50 5 30 20 40 70 15 46 26 26 4 3 35 68 22 7 82 76 81 30 9 7 40
3.1{4} 9 4 75 84 62 7 99 30 61 66 7 50 42 51 5 6 20 46 25 6 41 84 67 26 35 4 28
3.1{5} 3 3 5 51 3 3 65 3 4 57 5 4 3 3 3 4 3 3 4 3 3 21 40 5 4 6 3
3.1{6} 7 4 35 66 58 5 78 26 45 58 11 55 48 25 6 37 9 43 40 2 46 73 51 24 4 3 46
3.1{7} 31 13 74 55 67 11 31 41 59 91 93 55 69 74 25 48 39 90 72 34 76 71 71 33 72 14 54
3.1{8} 39 37 73 46 48 30 75 28 60 71 52 53 56 50 23 32 41 63 47 6 60 80 69 31 69 71 53
3.1{9} 62 41 64 92 66 27 92 49 60 41 7 60 67 47 38 68 26 13 74 3 42 42 66 54 55 67 65
3.1{10} 54 61 70 79 71 67 76 70 56 69 58 79 92 67 55 58 57 54 59 3 63 57 79 70 64 71 60
3.1{11} 24 11 69 76 74 21 74 57 65 46 47 73 70 42 22 63 26 43 36 6 36 65 69 22 59 42 66
3.1{12} 8 8 20 83 13 7 8 45 57 47 33 31 16 42 6 27 9 10 14 6 8 9 15 11 5 11 70
3.1{13} 10 7 35 69 61 7 89 11 56 62 8 13 28 23 4 16 13 25 26 4 40 7 10 42 63 6 58
3.1{14} 23 38 44 59 20 29 3 62 49 59 20 62 19 56 41 44 33 6 7 3 3 33 5 12 45 30 49
3.1{15} 30 42 51 46 57 37 74 38 55 55 67 14 62 82 13 48 34 36 56 3 46 68 60 74 63 66 51
3.1{16} 2 3 25 69 9 4 88 10 35 47 3 13 11 5 3 4 5 6 4 3 5 4 8 12 44 4 3
3.1{17} 26 40 64 60 69 53 68 52 53 40 38 65 57 35 21 44 26 43 32 3 47 30 27 73 71 79 48
3.1{18} 18 43 37 60 71 30 97 37 71 13 47 47 58 68 26 23 53 48 22 7 66 78 84 77 67 53 64
3.1{19} 72 54 80 86 58 55 77 38 81 69 62 55 79 42 26 31 50 52 45 6 65 60 68 89 80 80 64
3.1{20} 75 45 90 94 76 74 90 63 84 63 81 62 93 83 45 55 22 78 75 5 81 69 71 98 78 73 59
3.1{21} 3 44 52 79 31 42 5 43 51 32 59 56 19 39 69 44 35 43 4 6 37 81 46 8 5 9 12
3.1{22} 83 78 76 65 72 72 16 74 74 74 74 72 63 59 59 65 62 20 56 3 64 61 83 69 11 43 64
3.1{23} 55 62 63 74 64 58 6 53 38 48 59 61 43 66 58 80 62 69 37 6 86 70 84 17 5 13 23
3.1{24} 38 45 64 77 64 34 13 52 55 50 59 54 39 41 38 47 44 54 56 6 61 51 73 50 5 6 55
3.1{25} 40 60 61 52 77 41 87 36 83 50 59 45 77 58 31 59 47 68 66 7 60 75 85 72 48 51 69
3.1{26} 78 64 81 80 75 64 3 58 63 62 63 68 29 67 69 36 64 63 55 4 27 46 74 97 6 8 33
3.1{27} 20 29 54 76 38 35 7 46 43 81 54 53 32 63 20 61 54 57 60 6 56 58 51 7 7 71 53
3.1{28} 4 4 50 53 2 5 96 16 62 52 4 27 34 21 2 3 3 51 6 4 46 7 67 76 3 75 74
3.1{29} 11 14 19 80 62 10 11 20 99 28 53 88 33 38 10 46 21 14 51 4 11 77 68 40 45 16 14
3.1{30} 2 3 20 67 9 4 31 3 33 55 5 39 5 45 10 34 27 42 10 3 19 70 31 4 4 5 5
3.1{31} 65 57 81 82 70 47 81 69 71 75 71 70 62 68 14 79 42 75 68 4 97 77 73 75 31 7 55
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Table 3.5. Results of re-screen of hit compounds identified from combinatorial library. U-937 
cells were treated with compounds (20 µM) for 24 hours, and cell viability was determined by 
Annexin V-FITC/propidium iodide staining. Confirmed hits are highlighted in red.1 
 
3.3. Cell culture, in vitro, and in silico evaluation of hit compounds 
After re-synthesis of the hits, analytically pure samples of the compounds were evaluated 
in further biological assays. These structures and the biological results are shown in Table 3.6. 
The compounds were evaluated, at a range of concentrations, for their ability to induce cell death 
in U-937 cells. All six of these hits were found to be two- to four-fold more potent in cell culture 
than PAC-1 and S-PAC-1 in a 72-hour treatment. 
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Table 3.6. Six library compounds induce potent cell death of U-937 cells (human lymphoma) in 
both 24-ha and 72-hb experiments and enhance enzymatic activity of procaspase-3 in vitro.c 
Results adapted from literature.1 Predicted BBB permeability was also calculated for all 
compounds.d 
(a) Cell viability determined by Annexin V-FITC/propidium iodide staining. 
(b) Biomass quantified using the sulforhodamine B assay. 
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(c) Compounds were tested at a concentration of 50 μM with 1 µM procaspase-3 (wild-type) and 
3.5 μM ZnSO4. Cleavage of the Ac-DEVD-pNA substrate was monitored at 405 nm and 
normalized to a DMSO-treated control (0%) and a zinc-free control (100%).1 
(d) Calculated using equation 3.2:18  
predicted logBB = (-0.0148 x PSA) + (0.152 x ClogP) + 0.139. 
 
In a second experiment, flow cytometry analysis with Annexin V-FITC/propidium iodide 
was performed on U-937 cells that were exposed to the compounds at a single concentration (7.5 
M) for 24 hours (Table 3.6 and Figure 3.2).  As demonstrated by the histograms in Figure 3.2, 
the majority of the compound-treated cells were undergoing apoptosis within 24 hours (cells in 
the lower right quadrant of the histogram – Annexin V positive, propidium iodide negative), or 
were in a late apoptotic/necrotic stage (upper right quadrant – Annexin V positive, propidium 
iodide positive).  The novel analogues were found to be more potent than PAC-1 under these 24 
hour conditions. 
 
 
Figure 3.2. Annexin V-FITC/propidium iodide staining of U-937 cells treated with 7.5 μM of 
each compound for 24 hours.1 
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The six confirmed hits were then evaluated in vitro for their ability to relieve zinc-
mediated inhibition of procaspase-3 (Table 3.6 and Figure 3.3).  In this experiment, procaspase-3 
was incubated with ZnSO4, conditions under which procaspase-3 has >95% reduction in 
enzymatic activity.2, 19 All compounds were able to restore procaspase-3 enzymatic activity 
under these conditions (as assessed by the cleavage of the colorimetric caspase-3 substrate Ac-
DEVD-pNA, synthesized as previously reported20), and five of the six hit compounds showed 
greater activity than PAC-1 in this assay. These data indicate that the compounds enhance the 
activity of procaspase-3 in vitro through chelation of inhibitory zinc, and suggest that in the cell 
the compounds chelate zinc from the labile pool, allowing procaspase-3 to be processed to active 
caspase-3, leading to apoptotic cell death. 
 
 
Figure 3.3. Relief of zinc-mediated inhibition of 1 μM procaspase-3 (wild-type) by PAC-1 and 
hit compounds, as measured by the processing of the Ac-DEVD-pNA substrate. Compounds 
were tested at a concentration of 50 μM with 3.5 μM ZnSO4 and normalized to a DMSO-treated 
control (0%) and a zinc-free control (100%), and substrate cleavage was monitored at 405 nm.1 
 
Finally, because PAC-1 and derivatives are under investigation both for tumors of the 
central nervous system and for the remainder of the body, it is important to determine whether 
any PAC-1 derivative will enter the brain. The ability of a small molecule to penetrate the blood-
brain barrier (BBB) is commonly represented as logBB (Equation 3.1): 
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logBB = log10([compound]brain/[compound]blood)   (Equation 3.1) 
 
where [compound]brain and [compound]blood represent concentrations of the analyte in the brain 
and the blood, respectively. A negative logBB value indicates that the concentration is higher in 
the blood, while a positive value indicates higher concentration in the brain, and equal 
concentrations in brain and blood result in a logBB of 0.21 The prediction algorithm used herein 
(Equation 3.2) involves polar surface area (PSA) and the calculated logarithm of the 
octanol/water partition coefficient (AlogP):18 
 
predicted logBB = (-0.0148 x PSA) + (0.152 x AlogP) + 0.139  (Equation 3.2) 
 
 The PSA and AlogP values for PAC-1 and derivatives were calculated using the 
Schrodinger software, and insertion of these values into Equation 3.2 gave the predicted logBB 
values (Table 3.6). PAC-1 has a predicted logBB value of -0.37, which is very close to the 
experimentally determined value of -0.36.22 In general, the six hits contain relatively 
hydrophobic substituents, and five of them have predicted logBB values substantially higher than 
that of PAC-1. Compound 3.3{4,7} contains two relatively polar methoxy substituents, which 
offset the highly hydrophobic tert-butyl substituents, and the predicted logBB value is identical 
to that of PAC-1. 
 
3.4. Evaluation of B-PAC-1 
 Because it was potent in cell culture, stable in rat liver microsomes, and well tolerated in 
mice following a single 100 mg/kg i.p. dose, compound 3.3{18,7} was selected for further 
evaluation and given the name B-PAC-1 (referring to the benzyloxy and butyl substituents). The 
pharmacokinetics of B-PAC-1 were evaluated following i.v. and oral administration, and 
compared to equivalent doses of PAC-1 (Figure 3.4A). Pharmacokinetic curves for PAC-1 show 
an initial increase in concentration, followed by a rapid decrease, and the compound is not 
detectable in serum later than four hours post-administration following i.v. or oral 
administration. In contrast, B-PAC-1 achieves a lower maximum concentration upon i.v. or oral 
administration as compared to PAC-1, but the serum concentrations remain relatively constant 
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between two and eight hours post-administration. These flat concentration-time curves are 
unusual, and further studies are necessary to fully understand the pharmacokinetics of B-PAC-1. 
 
 
Figure 3.4. In vivo evaluation of PAC-1 and B-PAC-1. A. Comparison of pharmacokinetics. 
Mice received PAC-1 or B-PAC-1 at 50 mg/kg (dissolved in HPβCD) at 50 mg/kg via lateral tail 
vein injection or oral gavage. B. Comparison of BBB permeability. Mice received PAC-1 or B-
PAC-1 at 75 mg/kg (dissolved in HPβCD) via lateral tail vein injection. Concentrations of 
compounds within serum and brain tissue 5 minutes post-injection. Results for PAC-1 BBB 
permeability from literature.22 Error bars indicate standard deviation (n ≥ 3). 
 
 In addition, the BBB permeability of B-PAC-1 was determined and compared to the 
previously determined results for PAC-1 (Figure 3.4B).22 Mice were administered compound at 
75 mg/kg, and then sacrificed after 5 minutes. Brain and blood samples were collected, and 
concentrations were determined by HPLC. PAC-1 shows a 30:70 distribution between brain and 
blood,22 while B-PAC-1 shows a distribution of 5:95 between brain and blood. The experimental 
results for B-PAC-1 strongly contrast the calculation derived from the prediction algorithm, 
which predicts approximately 50:50 distribution between brain and blood. This discrepancy may 
be due to the relatively large size of B-PAC-1, which the algorithm does not consider. It has 
been suggested that compounds that cross the BBB should have molecular weights below 450.21 
PAC-1, with a molecular weight of 392, is small enough to enter the brain, but B-PAC-1 has a 
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molecular weight of 570, well above the cutoff, and it is excluded despite its increased 
hydrophobicity. The decreased BBB permeability is consistent with the lack of observed 
neuroexcitation in response to the compound and provides support for the evaluation of B-PAC-
1 in diverse tumor types not in the central nervous system. Evaluation in primary leukemic 
lymphocytes has shown promise,23 and further experiments are underway. 
 
3.5. Discussion 
The modular nature of the PAC-1 synthesis allows for the assembly of PAC-1 
derivatives via the late-stage condensation of a hydrazide with an aldehyde to form the essential 
ortho-hydroxy-N-acylhydrazone, which has been utilized for the construction of many PAC-1 
derivatives.1-3, 5-15 This allows for the creation of a large number of diverse molecules from a 
relatively small number of building blocks, as the diversification occurs during the final synthetic 
step. In this report, a total of 58 building blocks (31 hydrazides and 27 aldehydes) were used to 
produce 837 PAC-1 derivatives.1 
For compound libraries of this size, traditional methods of synthesis and purification are 
impractical; reaction flasks would require a large amount of space, and chromatographic 
purification of all of the library members would be costly and would likely require months to 
complete. Therefore, a strategy was developed that allowed for the rapid and efficient generation 
of PAC-1 derivatives. Each aldehyde was reacted with an excess of each hydrazide, and when 
consumption of the aldehyde was complete, resin-bound aldehyde was added to scavenge the 
remaining hydrazide, forming solid-phase hydrazones that could be removed by filtration. Using 
a parallel synthesizer, it was possible to perform 80 reactions simultaneously. The entire process 
was complete in approximately one week, which represents a significantly shorter time than 
would be required for the synthesis of 80 PAC-1 analogues using chromatographic purification. 
While this report described the creation of PAC-1 derivatives, the strategy represents a general 
method for the synthesis of combinatorial libraries of diverse compounds. In theory, this strategy 
could be adopted for other reactions of two compatible building blocks, including alkylations, 
acylations, reductive aminations, or dipolar cycloadditions, and a scavenger resin could remove 
excess unreacted starting materials. However, one main reason the strategy was successful for 
this application is because of the efficiency of hydrazone formation, and it may be more 
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challenging to apply this strategy to less robust reactions, such as metal-catalyzed cross-
couplings or alkene metathesis reactions. 
The resin purification strategy generated compounds of relatively high purity, and 
compounds of the highest possible purity were not necessary for the initial cell death screen. 
Secondary assays required compounds of higher purity, so the six hit compounds were 
resynthesized and purified more rigorously. If the goal in a drug discovery campaign is the rapid 
generation of large numbers of derivatives in order to identify a smaller number of active 
compounds, then the strategy described herein is a useful method. However, if a more thorough 
understanding of structure-activity relationships for a given compound series through complex 
biochemical assays is required, compounds generated via this method may not be pure enough, 
and traditional methods for purification may be more appropriate. An application of the 
traditional synthetic approach for PAC-1 derivatives is presented in Chapter 4. 
The six compounds shown in Table 3.6 emerged from the combinatorial library; these 
compounds are two- to four-fold more potent than PAC-1 at induction of cancer cell death in 
both 24-hour and 72-hour assays. Of note, five of the six hit compounds contain two tert-butyl 
substituents on the benzylidene ring, while the sixth contains a tert-butyl substituent on the 
benzyl ring. There are several marketed drugs containing aryl tert-butyl groups, including the 
antihistamine buclizine, the CFTR potentiator ivacaftor for the treatment of cystic fibrosis, and 
the mutant B-Raf kinase inhibitor dabrafenib for the treatment of metastatic melanoma. 
However, introduction of the tert-butyl substituent is often accompanied by a substantial increase 
in logD and logP, which can lead to decreased aqueous solubility and increased rate of 
metabolism. Several bioisosteric replacements for the tert-butyl group have been proposed, many 
of which rely on fluorine substitution to reduce hydrophobicity and block undesired 
metabolism.24 It is possible that these isosteric replacements could be beneficial for further 
development of the PAC-1 derivatives described herein, although at least one compound, B-
PAC-1, is not cleared rapidly from circulation. 
Given the general hydrophobicity of the hit compounds relative to PAC-1, it is possible 
that the enhanced potency and rate of cell death are driven by enhanced cell permeability. These 
qualities are likely to be advantageous as the compounds are moved forward in vivo. In addition, 
it is possible that other members of this library will emerge as viable in vivo candidates as 
alternate properties (such as propensity to cross the blood-brain barrier, improved metabolic 
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stability, improved solubility/formulation for in vivo studies, etc.) are examined. Thus, this 
library of 837 compounds represents a rich source from which to develop next-generation 
procaspase-3 activating compounds. 
 
3.6. Materials and methods 
 
3.6.1. Chemical information 
General All reactions requiring anhydrous conditions were conducted under a positive 
atmosphere of nitrogen or argon in oven-dried glassware. Standard syringe techniques were used 
for anhydrous addition of liquids. Unless otherwise noted, all starting materials, solvents, and 
reagents were acquired from commercial suppliers and used without further purification. Flash 
chromatography was performed using 230-400 mesh silica gel. A full set of experimental details 
is available in the literature.1 
Compound Analysis All NMR experiments were recorded in CDCl3 (Sigma or Cambridge) on 
a Varian Unity 500 MHz spectrometer with residual undeuterated solvent as the internal 
reference for 1H-NMR (7.26 ppm) and 13C-NMR (77.23 ppm). Chemical shift, δ (ppm); coupling 
constants, J (Hz); multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, quint = quintet, 
sext = sextet, m = multiplet, br = broad); and integration are reported. High-resolution mass 
spectral data was recorded on a Micromass Q-Tof Ultima hybrid quadrupole/time-of-flight ESI 
mass spectrometer or a Micromass 70-VSE at the University of Illinois Mass Spectrometry 
Laboratory. 
General Procedure A: Synthesis of PAC-1 analogue library. 
To a 16 × 150 mm test tube were added hydrazide (1.7 equiv.), aldehyde (1.0 equiv.), 2-
ethoxyethanol (1 mL), and 1.2 M HCl (10 mol %). The tubes were shaken on a Büchi Syncore 
parallel synthesizer at 110 °C until all aldehyde had reacted (monitoring by ESI-MS). The 
reaction mixture was cooled to room temperature, and polystyrene-benzaldehyde (3.5 equiv.) 
was added. The reaction mixture was shaken at 25−80°C until no hydrazide remained 
(monitoring by ESI-MS). The reaction mixture was cooled to room temperature, and the resin 
was filtered and washed with 2-ethoxyethanol. The filtrate was dried under high vacuum to 
afford the PAC-1 analogue. 
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General Procedure B: Synthesis of hit compounds. 
To a stirred solution of hydrazide (1.0 equiv.) and aldehyde (1.0 equiv.) in EtOH (0.15 M) was 
added 1.2 M HCl (7 mol%). The reaction mixture was stirred at reflux overnight. The reaction 
mixture was cooled to room temperature and concentrated. The crude product was purified by 
silica gel column chromatography to yield pure PAC-1 analogue. 
N'-(3,5-di-tert-butyl-2-hydroxybenzylidene)-2-(4-(4-methoxybenzyl)piperazin-1-
yl)acetohydrazide (3.3{2,7}) 
 
Synthesized according to General Procedure B: hydrazide (3.1{2}, 112 mg, 0.40 mmol, 1.0 
equiv.), aldehyde (3.2{7}, 94 mg, 0.40 mmol, 1.0 equiv.), EtOH (3 mL, 0.15 M), 1.2 M HCl (7 
mol%). A white crystalline solid formed upon cooling. The crystals were filtered and washed 
with cold EtOH to yield 3.3{2,7} (118 mg, 59.0%) as a white solid without further purification. 
1H-NMR (500 MHz, CDCl3): δ 11.32 (br s, 1H), 9.98 (br s, 1H), 8.44 (s, 1H), 7.38 (d, 1H, J = 
2.0 Hz), 7.23 (d, 2H, J = 9.0 Hz), 7.05 (d, 1H, J = 2.5 Hz), 6.87 (d, 2H, J = 8.5 Hz), 3.81 (s, 3H), 
3.49 (s, 2H), 3.19 (s, 2H), 2.62 (br s, 4H), 2.51 (br s, 4H), 1.44 (s, 9H), 1.30 (s, 9H). 13C-NMR 
(125 MHz, CDCl3): δ 165.6, 158.7, 155.5, 152.4, 140.7, 136.8, 130.2, 129.6, 126.8, 125.6, 116.3, 
113.6, 62.2, 60.9, 55.2, 53.6, 52.8, 35.0, 34.1, 31.4, 29.3. HRMS (ESI): 495.3340 (M+H)+; calcd. 
for C29H43N4O3: 495.3335. 
N'-(3,5-di-tert-butyl-2-hydroxybenzylidene)-2-(4-(2,5-dimethoxybenzyl)piperazin-1-
yl)acetohydrazide (3.3{4,7}) 
 
Synthesized according to General Procedure B: hydrazide (3.1{4}, 100 mg, 0.32 mmol, 1.0 
equiv.), aldehyde (3.2{7}, 75 mg, 0.32 mmol, 1.0 equiv.), EtOH (2.2 mL, 0.15 M), 1.2 M HCl (7 
mol%). Purification by silica gel column chromatography (gradient, 0-10% MeOH/EtOAc) 
yielded 3.3{4,7} (106 mg, 63.2%) as a white solid. 1H-NMR (500 MHz, CDCl3): δ 11.34 (br s, 
1H), 10.02 (br s, 1H), 8.43 (s, 1H), 7.38 (d, 1H, J = 2.5 Hz), 7.05 (d, 1H, J = 2.0 Hz), 6.97 (d, 
1H, J = 3.0 Hz), 6.82 (d, 1H, J = 8.0 Hz), 6.77 (dd, 1H, J = 3.0, 8.0 Hz), 3.79 (s, 3H), 3.78 (s, 
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3H), 3.59 (s, 2H), 3.19 (s, 2H), 2.64 (br s, 4H), 2.59 (br s, 4H), 1.44 (s, 9H), 1.30 (s, 9H). 13C-
NMR (125 MHz, CDCl3): δ 165.7, 155.5, 153.5, 152.5, 152.0, 140.7, 136.8, 127.1, 126.8, 125.6, 
116.5, 116.3, 112.2, 111.6, 60.9, 56.1, 55.8, 55.7, 53.7, 52.9, 35.1, 34.1, 31.4, 29.4. HRMS 
(ESI): 525.3449 (M+H)+; calcd. for C30H45N4O4: 525.3441. 
2-(4-(4-(benzyloxy)benzyl)piperazin-1-yl)-N'-(3,5-di-tert-butyl-2-
hydroxybenzylidene)acetohydrazide (3.3{18,7}) 
 
Synthesized according to General Procedure B: hydrazide (3.1{18} 100 mg, 0.29 mmol, 1.0 
equiv.), aldehyde (3.2{7}, 68 mg, 0.29 mmol, 1.0 equiv.), EtOH (2 mL, 0.15 M), 1.2 M HCl (7 
mol%). Purification by silica gel column chromatography (gradient, 0-10% MeOH/EtOAc) 
yielded 3.3{18,7} (97 mg, 58.7%) as a white solid. 1H-NMR (500 MHz, CDCl3): δ 11.38 (br s, 
1H), 10.03 (br s, 1H), 8.43 (s, 1H), 7.45 (d, 2H, J = 7.0 Hz), 7.42-7.39 (m, 3H), 7.34 (t, 1H, J = 
7.0 Hz), 7.24 (d, 2H, J = 8.5 Hz), 7.07 (d, 1H, J = 2.0 Hz), 6.96 (d, 2H, J = 8.5 Hz), 5.07 (s, 2H), 
3.50 (s, 2H), 3.20 (s, 2H), 2.63 (br s, 4H), 2.53 (br s, 4H), 1.46 (s, 9H), 1.32 (s, 9H). 13C-NMR 
(125 MHz, CDCl3): δ 165.7, 158.0, 155.5, 152.5, 140.7, 137.0, 136.8, 130.2, 130.0, 128.5, 127.9, 
127.4, 126.8, 125.6, 116.3, 114.5, 70.0, 62.2, 60.9, 53.6, 52.8, 35.1, 34.1, 31.4, 29.4. HRMS 
(ESI): 571.3652 (M+H)+; calcd. for C35H47N4O3: 571.3648. 
N'-(3-allyl-2-hydroxybenzylidene)-2-(4-(4-(tert-butyl)benzyl)piperazin-1-yl)acetohydrazide 
(3.3{20,24}) 
 
Synthesized according to General Procedure B: hydrazide (3.1{20}, 100 mg, 0.33 mmol, 1.0 
equiv.), aldehyde (3.2{24}, 53.5 mg, 0.33 mmol, 1.0 equiv.), EtOH (2.2 mL, 0.15 M), 1.2 M HCl 
(7 mol%). Purification by silica gel column chromatography (gradient, 0-10% MeOH/EtOAc) 
yielded 3.3{20,24} (102 mg, 68.9%) as a light brown solid. 1H-NMR (500 MHz, CDCl3): δ 
11.31 (br s, 1H), 10.09 (br s, 1H), 8.38 (s, 1H), 7.36 (d, 2H, J = 8.5 Hz), 7.25 (d, 2H, J = 8.5 Hz), 
7.19 (d, 1H, J = 7.5 Hz), 7.08 (dd, 1H, J = 1.5, 7.5 Hz), 6.85 (t, 1H, J = 7.5 Hz), 6.04 (tdd, 1H, J 
= 6.5, 10.0, 16.5 Hz), 5.12-5.06 (m, 2H), 3.52 (s, 2H), 3.47 (d, 2H, J = 6.5 Hz), 3.20 (s, 2H), 2.63 
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(br s, 4H), 2.54 (br s, 4H), 1.33 (s, 9H). 13C-NMR (125 MHz, CDCl3): δ 165.8, 156.3, 151.1, 
150.0, 136.4, 134.6, 132.2, 129.1, 128.7, 128.1, 125.1, 118.9, 116.8, 115.6, 62.5, 60.9, 53.6, 53.0, 
34.4, 33.8, 31.3. HRMS (ESI): 449.2915 (M+H)+; calcd. for C27H37N4O2: 449.2917. 
N'-(3,5-di-tert-butyl-2-hydroxybenzylidene)-2-(4-(naphthalen-2-ylmethyl)piperazin-1-
yl)acetohydrazide (3.3{25,7}) 
 
Synthesized according to General Procedure B: hydrazide (3.1{25}, 100 mg, 0.34 mmol, 1.0 
equiv.), aldehyde (3.2{7}, 80 mg, 0.34 mmol, 1.0 equiv.), EtOH (2.3 mL, 0.15 M), 1.2 M HCl (7 
mol%). Purification by silica gel column chromatography (gradient, 0-10% MeOH/EtOAc) 
yielded 3.3{25,7} (142 mg, 81.3%) as a white solid. 1H-NMR (500 MHz, CDCl3): δ 11.40 (br s, 
1H), 10.05 (br s, 1H), 8.43 (s, 1H), 7.86-7.83 (m, 3H), 7.75 (s, 1H), 7.53-7.43 (m, 3H), 7.41 (d, 
1H, J = 2.5 Hz), 7.07 (d, 1H, J = 2.5 Hz), 3.72 (s, 2H), 3.21 (s, 2H), 2.65 (br s, 4H), 2.59 (br s, 
4H), 1.47 (s, 9H), 1.33 (s, 9H). 13C-NMR (125 MHz, CDCl3): δ 165.6, 155.5, 152.4, 140.7, 
136.8, 135.3, 133.2, 132.7, 127.9, 127.6, 127.6, 127.6, 127.3, 126.8, 126.0, 125.6, 125.6, 116.3, 
62.9, 60.9, 53.6, 53.0, 35.0, 34.1, 31.4, 29.4. HRMS (ESI): 515.3389 (M+H)+; calcd. for 
C32H43N4O2: 515.3386. 
N'-(3,5-di-tert-butyl-2-hydroxybenzylidene)-2-(4-(4-ethylbenzyl)piperazin-1-
yl)acetohydrazide (3.3{28,7}) 
 
Synthesized according to General Procedure B: hydrazide (3.1{28}, 26 mg, 0.094 mmol, 1.0 
equiv.), aldehyde (3.2{7}, 22 mg, 0.094 mmol, 1.0 equiv.), EtOH (1 mL), 1.2 M HCl (7 mol%). 
Purification by silica gel column chromatography (gradient, 0-10% MeOH/EtOAc) yielded 
3.3{28,7} (34.6 mg, 75%) as a white solid. 1H-NMR (500 MHz, CDCl3): δ 11.33 (br s, 1H), 
10.00 (br s, 1H), 8.43 (s, 1H), 7.38 (d, 1H, J = 2.0 Hz), 7.23 (d, 2H, J = 8.0 Hz), 7.17 (d, 2H, J = 
8.0 Hz), 7.05 (d, 1H, J = 2.5 Hz), 3.52 (s, 2H), 3.19 (s, 2H), 2.65 (q, 2H, J = 7.5 Hz), 2.63 (br s, 
4H), 2.53 (br s, 4H), 1.44 (s, 9H), 1.30 (s, 9H), 1.24 (t, 3H, J = 7.5 Hz). 13C-NMR (125 MHz, 
CDCl3): δ 165.7, 155.6, 152.6, 143.2, 140.7, 136.9, 134.9, 129.1, 127.8, 126.9, 125.6, 116.3, 
109 
 
62.6, 61.0, 53.7, 53.0, 35.1, 34.1, 31.5, 29.4, 28.5, 15.6. HRMS (ESI): 493.3550 (M+H)+; calcd. 
for C30H45N4O2: 493.3543. 
 
3.6.2. Biological evaluation 
Materials All reagents were obtained from Fisher unless otherwise indicated. All buffers 
were made with MilliQ purified water. Ac-DEVD-pNA was synthesized as previously 
described.20 Luria broth (LB) was obtained from EMD. Doxorubicin was obtained from Sigma. 
Caspase Activity Buffer contains 50 mM HEPES, 300 mM NaCl, 1.5mM TCEP, 0.01% TritonX-
100 and is Chelex® treated. Ni NTA Binding Buffer contains 50 mM Tris (pH 8.0), 300 mM 
NaCl, and 10mM imidazole. Ni NTA Wash Buffer contains 50 mM Tris (pH 8.0), 300 mM 
NaCl, and 50 mM imidazole. Ni NTA Elution Buffer contains 50 mM Tris (pH 8.0), 300 mM 
NaCl, and 500 mM imidazole. Annexin V Binding Buffer contains 10 mM HEPES pH 7.4, 140 
mM NaCl, 2.5 mM CaCl2, 0.1% BSA. The C-terminal 6xHis-tagged procaspase-3 proteins were 
expressed as described below. 
Cell Culture U-937 cells were obtained from the American Type Culture Collection and 
maintained at low passage number. Cultures were maintained in RPMI 1640 supplemented with 
10% fetal bovine serum and 1% penicillin-streptomycin and grown at 37°C and 5% CO2. 
Cell Death Assay for Initial Screen Compound (2 µL of a 10 mM DMSO solution) was added 
in singlet by direct addition to a well containing 998 µL U-937 cells (1x106) in RPMI 1640 
media (10% FBS) at a final compound concentration of 20 µM. After incubation at 37°C for 24 
h, the cells were transferred to flow cytometry tubes, washed, and resuspended in Annexin V 
binding buffer. The cells were double stained with FITC-Annexin V and propidium iodide and a 
cell population of at least 10,000 events was collected by the LSR II flow cytometer. Percent 
viable cells (Annexin V- negative, propidium iodide - negative) were determined using FCS 
Express software. 
72hr IC50 Cell Death Assay U-937 human lymphoma cells were plated into the wells of 96 well 
plate at a density of 15,000 cells per well in 99 µL of RPMI 1640 growth media with 10% FBS 
and 1% pen-strep. To each well was added 1 µL of compound stock solutions in DMSO at 
varying concentrations such that the cells were treated with concentrations between 0 µM and 
100 µM compound. Each concentration was tested in quintuplicate per plate. In each plate 5 
wells received 20 µM doxorubicin as a positive death control and 5 wells received 1 µL of 
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DMSO as a negative control. The plates were then incubated at 37°C and 5% CO2 for 72 hours.  
After the 72 hour incubation period, the plates were analyzed using a Sulforhodamine B assay.25 
Specifically, to each well of the plate 25 µL of a 50% (w/v) solution of trichloroacetic acid in 
H2O was added and the plates were incubated for 4 hours at 4°C. The plates were then washed 
gently with H2O five times. The plates were allowed to air dry after which 100 µL of a 0.057% 
(w/v) Sulforhodamine B in a 1% (v/v) acetic acid solution was added to each well for 30 minutes 
at room temperature. The plates were gently washed 5 times with 1% (v/v) acetic acid and air 
dried. 200 µL of 10 mM Tris base (pH 10.4) was added to each well and the plates were placed 
on an orbital shaker for thirty minutes. The level of SRB was quantified fluorometrically at 
excitation and emission wavelengths 488 and 585nm, respectively, on a Molecular Devices plate 
reader and the percent cell death calculated and normalized to the positive control (100% cell 
death) and the negative control (0% cell death). The percent cell death was averaged for each 
compound concentration and plotted as a function of compound concentration. The data were fit 
to a logistical dose response curve using Table curve 2D and the IC50 value was calculated. The 
experiment was repeated three times and the average of the calculated IC50 values was reported. 
The standard error of the mean (SEM) was determined and reported for the triplicate 
experiments.   
Induction of Apoptosis by Hit Compounds U-937 Cells (1 mL of 6 x 105 cells/mL) were treated 
with 10 µL of 750µM DMSO solutions of the compounds to achieve a final concentration of 7.5 
µM. The cells were incubated at 37 ºC for 24 hours. The cells were harvested via centrifugation 
(200g for 5 min), washed with PBS (2 mL), and resuspended in 450 µL Annexin V Binding 
Buffer. To each sample was added 3.5 µL of FITC conjugated Annexin V stain (Southern 
Biotech) and 3.5 µL of propidium iodide (Sigma) to a final concentration of 50 µg/mL. Cell 
populations were analyzed on a Benton Dickinson LSR II cell flow cytometer. 
Recombinant Expression and Purification of Procaspase-3  Adapted from reference.5 A 
20 mL volume of an overnight culture of Rosetta E. coli containing the procaspase-3 (wild-type) 
expression plasmid was seeded into 2 L of LB media containing ampicillin. The culture was 
grown to an OD600 = 1.0, at which point protein expression was induced via addition of IPTG 
(to 1 mM); the culture was allowed to grow for 30 additional minutes. Cells were then harvested 
(10 minute spins at 10,000xg and re-suspended in NTA binding buffer (300 mM NaCl, 50 mM 
Tris, 10 mM imidazole, pH 8.0). The cells were lysed on ice via sonication. The cell lysate was 
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then spun at 35,000xg for 35 min. The supernatant was decanted and 1 mL of nickel-NTA resin 
was added.  The cell lysate was incubated for 45 minutes at 4°C. The resin was loaded on a 
column, washed with 10 mL NTA binding buffer followed by 10 mL NTA wash buffer (300 mM 
NaCl, 50 mM Tris, 50 mM imidazole, pH 8.0). The proteins were eluted in 0.5 mL fractions with 
10 mL of NTA elution buffer (300 mM NaCl, 50 mM Tris, 500 mM imidazole, pH 8.0). 
Fractions containing protein were pooled and further purified to remove any contaminating zinc 
by applying the protein to a PD-10 column (GE Healthcare) charged with Caspase Activity 
Buffer that had been treated with Chelex ® resin. The resulting concentration was determined 
using the Edelhoch method and the molar absorptivity of procaspase-3 of 26150 M−1 cm−1. 
Protein stocks were flash-frozen in liquid nitrogen and stored at -80°C 
Procaspase-3 Activity Assay  In a 384-well plate recombinantly expressed, zinc-free 
procaspase-3 (wild type, at 1 µM) in Caspase Activity Buffer (50mM HEPES, 300mM NaCl, 
1.5mM TCEP, 0.01% TritonX-100) was incubated at 37 °C in the presence of 3.5 µM ZnSO4 
and the basal activity was assessed via the addition of Ac-DEVD-pNA (final concentration in 
well of 200 µM). The absorbance at 405nm was monitored with a SpectraMax plate reader 
(Molecular Devices). After the basal activity was determined, DMSO, PAC-1 and analogues 
were added to each sample to a final concentration of 25 µM. Activity of each treatment was 
assessed at 5, 20, 40 and 60 minutes via 5-minute kinetic reads. The slope of each data set was 
used to determine the activity of the protein. Activity was normalized to a percent activity at 
each time point using a zinc-free sample and a zinc-inhibited sample treated with DMSO.  
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3.6.3. Spectra 
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Chapter 4. Removal of metabolic liabilities enables development of PAC-1 derivatives with 
improved pharmacokinetics 
 
Portions of this chapter are reproduced with permission from literature (Roth, H. S.; Botham, R. 
C.; Schmid, S. C.; Fan, T. M.; Dirikolu, L.; Hergenrother, P. J. Removal of metabolic liabilities 
enables development of derivatives of Procaspase-Activating Compound 1 (PAC-1) with 
improved pharmacokinetics. J. Med. Chem. 2015, 58(9), 4046-4065.)
1
 Cytotoxicity screen for 
first library was performed by Rachel C. Botham. Animal experiments were performed by 
Rachel C. Botham and Prof. Timothy M. Fan. Pharmacokinetic analysis was performed by Prof. 
Levent Dirikolu. 
 
4.1. Introduction 
 While studies with PAC-1 and S-PAC-1 have been encouraging, a challenge in using 
these compounds in animals is the relatively short in vivo half-lives of both PAC-1 (2.1 ± 0.3 h 
in dogs)
2
 and S-PAC-1 (1.09 ± 0.02 h in dogs)
3
 following IV administration. A study in rats 
identified three main pathways of metabolism for PAC-1, including oxidative N-dealkylation, 
olefin oxidation, and arene oxidation (Figure 4.1).
4
 While many of these metabolites may be 
active based on the predicted structure-activity relationships, the alcohols and secondary amines 
resulting from these metabolites provide sites for conjugation, including sulfation and 
glucuronidation; these conjugates are then cleared from circulation. The metabolic liabilities 
present in PAC-1 likely contribute to its pharmacokinetic profile, necessitating relatively large 
doses to achieve therapeutic levels in vivo. A PAC-1 analogue lacking some of these liabilities 
may allow for lower or less frequent dosing, which could potentially reduce toxicity. 
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Figure 4.1. PAC-1 is susceptible to enzymatic oxidation in vitro and in vivo, giving metabolites 
that result from N-dealkylation, olefin oxidation, and arene oxidation.
1, 4
 
 
4.2. First-generation library for enhancement of metabolic stability 
 
4.2.1. Compound design and synthesis 
 The structure-activity relationships of PAC-1 indicate that modifications to the aryl rings 
can be tolerated, as long as the core ortho-hydroxy-N-acylhydrazone remains intact.
3, 5-7
 The 
synthetic strategy that has been adopted to access these active compounds involves the late-stage 
condensation of a hydrazide and an aldehyde to form the key ortho-hydroxy-N-acylhydrazone.
3, 
5, 6, 8-16
 This strategy was useful for the generation of a large combinatorial library of 837 diverse 
PAC-1 analogues, as discussed in Chapter 3.
8
 For the study described in this chapter, the library 
design was focused on the creation of derivatives with systematic removal of the metabolic 
liabilities. The initial library of PAC-1 analogues (Figure 4.2) was constructed from six 
hydrazides (1.6, 2.16, 4.1a-d) and five aldehydes (2.1, 4.2a-d). In order to avoid oxidative N-
dealkylation, the benzyl moiety was modified to a benzoyl (as in 4.1a, and 4.1c), hypothesized to 
be more resistant to oxidation,
17
 or substituted with ortho-chlorine substituents (as in 4.1d), 
hypothesized to block oxidation due to steric effects. In order to avoid olefin oxidation, the allyl 
group was reduced to a propyl group (as in 4.2a) or removed entirely (as in 4.2b and 4.2c). 
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Finally, in order to block arene oxidation, building blocks were introduced containing nitrile 
substituents (4.1b-c, 4.2b), which have been shown to resist metabolic oxidation.
18
 A secondary 
goal of this library was to identify derivatives with improved aqueous solubility, so building 
blocks containing polar substituents (including 2.16, 4.1b-c, and 4.2b-d) were employed. 
Multiple derivatives were synthesized containing only one modification to the PAC-1 core, so 
that the effect of individual changes could be systematically evaluated. 
 
 
Figure 4.2. Design of first-generation library of PAC-1 derivatives designed to display enhanced 
metabolic stability.
1
 
 
 The hydrazides were synthesized according to Scheme 4.1. Alkylation of 
monosubstituted piperazine 2.8 with substituted benzyl bromides 4.3b and 4.3d gave dialkylated 
piperazines 4.4b and 4.4d. Acylation of 2.8 with benzoyl chlorides 4.3a and 4.3c gave amides 
4.4a and 4.4c. Finally, reaction of ethyl esters 4.4a-d with anhydrous hydrazine gave hydrazides 
4.1a-d. 
 
123 
 
 
Scheme 4.1. Synthesis of hydrazide building blocks.
1
  
 
 Synthesis of the aldehyde building blocks is shown in Scheme 4.2. Hydrogenation of 2.1 
with diphenyl sulfide as a catalyst poison allowed for chemoselective reduction of the olefin,
19
 
giving aldehyde 4.2a in high yield. Synthesis of aldehyde 4.2b began with the Negishi-like 
coupling of bromide 4.5 with zinc cyanide to give nitrile 4.6, and demethylation with lithium 
chloride gave 4.2b. Manganese(IV) oxide-mediated oxidation of alcohol 4.7 gave aldehyde 4.2c, 
and dihydroxylation of 2.1 with osmium tetroxide gave 4.2d. 
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Scheme 4.2. Synthesis of aldehyde building blocks.
1
 
 
 The PAC-1 derivatives (4.8-4.31) were synthesized by condensation of each hydrazide 
with one molar equivalent of each aldehyde in the presence of catalytic HCl (Table 4.1). 
Sufficient quantities of 4.2b were not generated to react with all hydrazides, so this compound 
was only condensed with hydrazides 1.6 and 2.16, to give PAC-1 derivatives 4.24 and 4.25. 
However, each of the other four aldehydes was condensed with each of the six hydrazides, to 
give a total of 26 PAC-1 derivatives. Reactions were performed on 0.5-1.0 mmol scale and 
purified by chromatography, with the exception of PAC-1 and S-PAC-1, which were 
synthesized on multi-gram scale and purified by recrystallization, as discussed in Chapter 2. 
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Table 4.1. Structures, isolated yields, predicted BBB permeability,
a
 and cytotoxicity
b
 of first-
generation PAC-1 derivatives for the enhancement of metabolic stability. 
(a) Calculated using Equation 3.2:
20
  
predicted logBB = (-0.0148 x PSA) + (0.152 x ClogP) + 0.139. 
(b) U-937 cells treated with compounds (5 µM) for 72 hours. Biomass quantified via 
sulforhodamine B assay.
1
 
 
4.2.2. Evaluation of library 
Because PAC-1 and derivatives are under investigation both for tumors of the central 
nervous system and for the remainder of the body, it is important to determine whether any 
PAC-1 derivative will enter the brain. As discussed in Chapter 3, the ability of a small molecule 
to penetrate the blood-brain barrier (BBB) is commonly represented as logBB, and predicted 
logBB was calculated using Equation 3.2 (reproduced below):
20
 
 
predicted logBB = (-0.0148 x PSA) + (0.152 x AlogP) + 0.139  (Equation 3.2)
20
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 The PSA and AlogP values for PAC-1 and derivatives were calculated using the 
Schrodinger software, and insertion of these values into Equation 3.2 gave the predicted logBB 
values (Table 4.1). PAC-1 has a predicted logBB value of -0.37, which is very close to the 
experimentally determined value of -0.36.
21
 As expected, substitution with polar groups, 
including the pyridyl, dihydroxypropyl, and sulfonamide, leads to a decrease in predicted BBB 
permeability, while substitution with nonpolar substituents, including dichloro and propyl, leads 
to an increase in predicted BBB permeability. 
 The compounds were then evaluated for their ability to induce apoptosis in cell culture. 
U-937 human lymphoma cells were incubated with each compound at 5 μM for 72 hours; PAC-1 
and S-PAC-1 each induce approximately 50% cell death under these conditions. The results of 
the screen are shown in Table 4.1. Of the 24 novel analogues, 11 compounds were at least as 
potent as PAC-1 and S-PAC-1. Each of these analogues contains a relatively hydrophobic 
substituent (allyl, propyl, or chlorine), and cell permeability likely contributes to the potency of 
these analogues relative to the less potent compounds. Because most of the compounds derived 
from aldehydes 4b, 4c, and 4d induced apoptosis to a minimal degree, these analogues were not 
included in further biological evaluation. 
 The remaining 12 compounds (PAC-1, S-PAC-1, and 4.8-4.17) were evaluated in rat 
liver microsomes. Compounds were incubated for 3 hours at 10 µM, and products were analyzed 
by LC/MS. The metabolites observed from PAC-1 matched well with the reported 
transformations from the experiment in rats:
4
 there was a metabolite corresponding to removal of 
the benzyl group, a metabolite corresponding to dihydroxylation of the olefin, and several 
metabolites from monooxygenation of PAC-1. In general, most of the modifications were 
successful in blocking the undesired transformations; the amide substitution eliminated the 
oxidative N-dealkylation, no dihydroxylated species were observed from propyl-substituted 
compounds, and the nitrile substitution reduced the number of monooxygenated species. 
However, the dichloro substitution was not successful in preventing N-dealkylation, as the 
dealkylated metabolite was still observed for these compounds (4.11 and 4.17). Further, the 
degree of monooxygenation increased, and metabolites were observed containing two additional 
oxygen atoms for these derivatives, unlike any of the other 10 compounds evaluated. For this 
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reason, PAC-1 derivatives containing the dichlorobenzyl substituent were not evaluated in 
further experiments. 
 
4.3. Second-generation library for enhancement of metabolic stability 
 
4.3.1. Compound design and synthesis 
 The experiments performed with the initial set of PAC-1 derivatives allowed for a greater 
understanding of the structure-activity relationships and guided an improved library design. 
Because of the poor in vitro metabolic stability, compounds containing the 2,6-dichlorobenzyl 
substituent were removed, and due to reduced cell culture potency, compounds constructed from 
aldehydes 4.2b-d were removed, and increased solubility was no longer a criterion for 
advancement of compounds. Additional strategies for blocking arene oxidation were desired, and 
it appeared that polar substituents tended to reduce potency, so fluorine and trifluoromethyl 
substituents were added to the aromatic rings. 
 The new library for the enhancement of metabolic stability (Figure 4.3) consisted of 45 
PAC-1 analogues, constructed from nine hydrazides and five aldehydes. Five hydrazides (1.6, 
2.16 and 4.1a-c) and two aldehydes (2.1 and 4.2a) remained from the previous library. Added 
hydrazides included those containing 4-fluorobenzyl (4.1e), 4-fluorobenzoyl (4.1f), 4-
(trifluoromethyl)benzyl (3.1{15}), and 4-(trifluoromethyl)benzoyl (4.1g) substituents. Added 
salicylaldehydes contained a fluorine in the 5-position, either with no other substitution on the 
ring (4.2e), or with allyl (4.2f) or n-propyl (4.2g) substituents in the 3-position. 
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Figure 4.3. Nine hydrazides and five aldehydes were used to construct a library of 45 PAC-1 
derivatives designed to display enhanced metabolic stability by blocking oxidative N-
dealkylation, olefin oxidation, and/or arene oxidation.
1
 
 
 Synthesis of the added building blocks (Scheme 4.3) was adapted from previous routes. 
The added hydrazides were synthesized according to Scheme 4.3A. Alkylation of 2.8 with 
substituted benzyl chlorides 4.3e and 3.4{15} gave dialkylated piperazines 4.4e and 3.6{15}, 
respectively, while acylation of 2.8 with substituted benzoyl chlorides 4.3f-g gave amides 4.4f-g, 
respectively. Reaction of these four esters with anhydrous hydrazine gave the four new 
hydrazides. The additional aldehydes (Scheme 4.3B) were synthesized beginning with the 
alkylation of commercially available building block 5-fluorosalicylaldehyde (4.2e) with allyl 
bromide to give ether 4.32. This compound underwent a Claisen rearrangement upon heating to 
give 4.2f, and chemoselective hydrogenation gave 4.2g. Each of the nine hydrazides was 
condensed with each of the five aldehydes to give a total of 45 PAC-1 derivatives, including 10 
from the initial library (Table 4.2). 
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Scheme 4.3. A. Synthesis of hydrazide building blocks. B. Synthesis of aldehyde building 
blocks.
1
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Table 4.2. Synthesis of 45 PAC-1 derivatives designed to display enhanced metabolic stability.
1
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4.3.2. Evaluation of library in silco, in cell culture, and in vitro 
 With the 45 compounds in hand, evaluation of the library was initiated, beginning with 
calculation of the predicted BBB permeability. Calculation of these values was performed as 
previously; the PSA and AlogP values for the compounds were calculated using the Schrodinger 
software, and Equation 3.2 was used to calculate the predicted logBB values (Table 4.3). 
Replacement of hydrogen with fluorine led to a minimal increase in predicted logBB, as 
demonstrated by PAC-1 and 1.14a. However, replacement of hydrogen with a trifluoromethyl 
group, as with compound 4.34, led to a larger increase in predicted BBB permeability. 
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Table 4.3. Predicted BBB permeability,
a
 cytotoxicity,
b
 rat liver microsome stability,
c
 and mouse 
toxicity
d
 of PAC-1 derivatives for the enhancement of metabolic stability. 
(a) Calculated using Equation 3.2:
20
  
predicted logBB = (-0.0148 x PSA) + (0.152 x ClogP) + 0.139. 
(b) U-937 cells treated with compounds for 72 hours. Biomass quantified via sulforhodamine B 
assay. IC50 values shown are mean ± s.e.m. (n = 3).  
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(c) Rat liver microsomes treated with compounds (10 µM) for 3 hours. Percent stability values 
shown are mean ± s.e.m. (n = 3). 
(d) Compounds formulated at 5 mg/mL in 200 mg/mL aqueous HPβCD (pH 5.5). Mice dosed 
with compounds via i.p. injection at 200 mg/kg (except as noted: *100 mg/kg, **10 mg/mL 
solution, ***125 mg/kg). E = excitatory, D = depressive, N.D. = not determined.
1
 
 
 Following these calculations, the biological activity of the compounds was evaluated. 
First, the ability of the compounds to induce cell death in U-937 (human lymphoma) cells in 
culture was determined (Table 4.3). Each of the compounds was found to induce dose-dependent 
cell death under these conditions, and most of the compounds were approximately as potent as 
PAC-1 and S-PAC-1, confirming the previously determined SAR.
3, 5, 6, 8
 
 Next, the metabolic stability of the compounds was evaluated in rat liver microsomes. 
The compounds were evaluated after a 3 hour treatment at 10 µM, and metabolites were 
observed by LC/MS. The beta-adrenergic antagonist (±)-propranolol hydrochloride was included 
as a positive control;
22
 approximately 20% of the control remained. The results of this assay are 
shown in Table 1. Compounds that contained benzoyl substituents were significantly more stable 
than analogous compounds containing benzyl groups; for example, compound 4.8 was more 
stable than PAC-1, and compound 4.53 was more stable than compound 4.52. The propyl-
containing compounds were less stable than the allyl-containing compounds (e.g., PAC-1 was 
more stable than compound 4.12), although the dihydroxylated metabolites were not observed 
for propyl-substituted compounds. In addition, S-PAC-1 was relatively stable in the liver 
microsomes, despite the short in vivo half-life of the compound,
3
 suggesting that clearance 
mechanisms other than oxidative metabolism play a greater role in the elimination of S-PAC-1 
from treated animals. 
 The results of selected liver microsome experiments are shown in Figure 4.4. PAC-1 
(Figure 4.4A) was 38% stable in the assay, and several metabolites, including an N-dealkylated 
product, a dihydroxylated product, and multiple monooxygenated products, were observed. S-
PAC-1 (Figure 4.4B) was found to be more stable than PAC-1, and fewer metabolites were 
observed. One of the modifications that improved stability to the greatest degree was the addition 
of the benzoyl in place of the benzyl substituent, as demonstrated with compound 4.8 (Figure 
4.4C). This modification prevented the N-dealkylation completely and increased stability to 89% 
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during the three-hour incubation. In addition, compounds with a benzoyl substituent had fewer 
monooxygenated species than PAC-1, as the amide likely acted to deactivate the aromatic ring 
towards oxidation. The addition of fluorine to the benzylidene ring, as in compound 4.40 (Figure 
4.4D), was also successful in reducing the number of monooxygenated metabolites, and as 
expected, dihydroxylated metabolites were not formed from compounds lacking the allyl group. 
Finally, combining multiple modifications, as in compounds 4.33 (Figure 4.4E) and 4.53 (Figure 
4.4F), led to highly stable compounds that gave significantly fewer metabolites in the liver 
microsome experiment. 
 
 
 
135 
 
 
Figure 4.4. Metabolic stability of PAC-1 and derivatives was evaluated in rat liver microsomes 
at 10 µM for 3 hours. LC/MS results of liver microsome experiments for A. PAC-1, B. S-PAC-
1, C. 4.8, D. 4.40, E. 4.33, and F. 4.53 are shown. Data shown are representative of three 
independent experiments.
1
 
 
4.3.3. Compound tolerability in mice 
 After determination of the cytotoxicity and in vitro metabolic stability of the 45 
compounds, several of the compounds were evaluated in mice (C57BL/6) to determine the 
tolerability (Table 4.3); compounds with improved tolerability would be considered for further 
evaluation. Compounds were formulated at 5 mg/mL in 200 mg/mL aqueous HPβCD (pH 5.5), 
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and a dose of 200 mg/kg was administered to mice via i.p. injection (exceptions to this protocol 
are noted in Table 4.3). This dose of PAC-1 induces severe but transient neuroexcitation; no 
adverse effects to S-PAC-1 are observed at this dose. Responses to compounds were graded as 
mild, moderate, or severe; compounds that were lethal are also noted. Responses above mild 
toxicity were classified as excitatory (E) or depressive (D). 
 In general, most of the compounds predicted to be BBB permeable were not well 
tolerated. Every compound with a predicted logBB value above -0.55 was evaluated in mice, 
because of the desire for a BBB-permeable compound for the treatment of brain tumors. Each of 
these compounds induced the excitatory phenotype in animals, with the exception of compound 
4.35; however, this compound was lethal at the lower dose of 100 mg/kg. Further, no compound 
that induced neuroexcitation had a predicted logBB value below -0.55. Compound 4.57, with a 
predicted logBB value of -0.55, induced a depressive phenotype. The only compound with a 
predicted logBB value above -0.55 that showed improved tolerability as compared to PAC-1 was 
compound 4.12, with moderate toxicity; all others induced severe toxicity or were lethal to the 
animals. 
 Because of promising results from cell culture and liver microsome experiments, several 
compounds with lower predicted BBB permeability were also evaluated in mice. Each 
compound with a predicted logBB value below -0.55 that was evaluated in mice induced the 
depressive phenotype similar to elevated doses of S-PAC-1. However, the relationship between 
predicted BBB permeability and degree of toxicity was less clear for these compounds. Six 
additional compounds (4.33, 4.48, 4.51, 4.53, 4.60, and 4.62) were found to be tolerated better 
than PAC-1 at the 200 mg/kg dose. 
 
4.4. Evaluation of compound 4.12 
 Because it had slightly improved tolerability as compared to PAC-1, but it was still 
predicted to cross the BBB, compound 4.12 (structure in Figure 4.5C) was evaluated further as a 
potential agent for the treatment of brain tumors. The ability of PAC-1 and 4.12 to induce 
apoptosis was evaluated in five glioma-derived cell lines from human and murine origin, as well 
as a diverse array of human cell lines from six other cancer types. As shown in Table 4.4, 
compound 4.12 displayed comparable potency to that of PAC-1 in all 12 cell lines tested. The 
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compounds showed low micromolar IC50 values against all cell lines, providing support for the 
evaluation of these compounds as anticancer agents. 
 
 
Table 4.4. PAC-1 and 4.12 are potent in a variety of cancer cell lines. Cells treated with 
compounds for 72 hours. Biomass quantified by sulforhodamine B assay. IC50 values shown are 
mean ± s.e.m. (n = 3). 
 
4.5. Blood-brain barrier permeability of selected derivatives 
 In order to determine whether compound 4.12 would be a promising candidate as a 
therapeutic agent for the treatment of brain tumors, the BBB permeability of this compound was 
assessed in mice (Figure 4.5A). Mice were administered compound at 75 mg/kg via i.v. injection 
and sacrificed after 5 minutes. Brain and blood samples were collected, and concentrations were 
determined by HPLC. PAC-1 shows a 30:70 distribution between brain and blood, while S-
PAC-1 shows a distribution of less than 1:99.
21
 The brain:blood distribution of compound 4.12 
was 23:77. The compound is slightly less BBB permeable than PAC-1, which may be sufficient 
to explain the lower toxicity of this compound. For this reason, development of compound 4.12 
was not pursued further. 
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Figure 4.5. BBB permeability in vivo for PAC-1 and derivatives. A. Brain/blood distribution for 
derivatives. B. Comparison of predicted and experimentally determined BBB permeability. Red 
line indicates indentical predicted and experimental logBB values. C. Structures of derivatives 
evaluated. C57BL/6 mice received compound at 75 mg/kg (dissolved in HPβCD) via lateral tail 
vein injection. Concentrations of compounds within serum and brain tissue determined 5 minutes 
post-injection. Results from PAC-1 and S-PAC-1 were reported previously.
21
 Error bars indicate 
standard deviation (n ≥ 4). 
 
 In addition, the BBB permeability of compounds 4.8 and 4.57 was evaluated via the same 
method (Figure 4.5A). Compound 4.8 differs from PAC-1 only by the replacement of the benzyl 
with a benzoyl substituent, so the effect of this substitution on BBB permeability was assessed. 
The brain:blood distribution of compound 4.8 was 8:92, indicating that the amide-containing 
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compounds should be less BBB permeable than analogous compounds containing benzyl 
substituents. Further, compound 4.57 was of interest due to cell culture potency, liver microsome 
stability, and improved tolerability as compared to PAC-1, so the BBB permeability was 
assessed to determine whether compound 4.57 would be a promising candidate for the treatment 
of brain tumors. The brain:blood distribution of 4.57 was 18:82; while this is lower than the BBB 
permeability of PAC-1, it is possible that this level of compound in the brain could be sufficient 
for treatment of brain tumors. However, compound 4.57 was found to induce hemolysis in the 
treated animals, so the compound was not evaluated further. 
 The experimentally determined brain:blood distribution ratios were converted to logBB 
values and compared to the predicted values calculated previously (Figure 4.5B). The red 
diagonal line in Figure 4.5B indicates a case in which the predicted values match the 
experimental values, and the farther away a data point lies from the diagonal, the farther the 
predicted value is from the experimental value. The algorithm was highly predictive for PAC-1, 
as the predicted value of -0.37 was very close to the experimental value of -0.36. S-PAC-1 was 
predicted to show very low permeability (approximately 2.5%), and the experiment 
demonstrated that less than 1% enters the brain. Each of the other three compounds evaluated 
was relatively close to the diagonal, although the concentration of each compound in the brain 
was less than what was predicted. 
 
4.6. Secondary biological assays 
As discussed in Section 4.3.3, six compounds (4.33, 4.48, 4.51, 4.53, 4.60, and 4.62; 
structures in Table 4.5) were identified that were metabolically stable in vitro, and well tolerated 
in vivo. However, due to the high toxicity at lower doses of compounds 4.35 and 4.39, as well as 
the hemolysis induced by 4.57, compounds containing the 4-(trifluoromethyl)benzoyl 
substituent, including compound 4.48, were not pursued further. In addition, compound 4.60 was 
removed from consideration due to slightly decreased potency compared to the rest of the well-
tolerated derivatives. 
Because of their high stability, comparable potency, and improved in vivo tolerability as 
compared to PAC-1, compounds 4.33, 4.51, 4.53, and 4.62 were selected for further 
investigation. In order to confirm that the hit compounds act similarly to PAC-1, the compounds 
were evaluated for their ability to chelate zinc in vitro, activate executioner caspases in whole 
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cells, and induce apoptosis in cancer cells. Zinc binding was determined using an EGTA titration 
experiment.
23
 In this experiment, varying concentrations of Zn(OTf)2 were added to each well of 
a 96-well plate with a HEPES-buffered solution containing EGTA and PAC-1 derivative, and 
the fluorescence of the complex was analyzed, a slight variant of our previous protocol for 
assessment of zinc binding.
6
 As shown in Table 4.5, PAC-1 binds zinc with a Kd of 1.28 ± 0.03 
nM, while S-PAC-1 binds zinc with a Kd of 2.72 ± 0.13 nM. Each of the four new compounds 
displays affinity for zinc in the range of 1-2 nM. Inactive derivative PAC-1a does not bind zinc, 
as shown previously.
6
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Table 4.5. Zinc chelation,
a
 caspase activation,
 b
 and predicted BBB permeability of PAC-1 
derivatives. 
(a) Increasing amounts of Zn(OTf)2 added to a buffered solution of EGTA (7.3 mM) and PAC-1 
derivative (100 µM). Kd was determined by comparing fluorescence intensity (ex. 410 nm, em. 
475 nm) and free zinc concentration. 
(b) U-937 cells treated with compounds (30 µM) for 16 hours, then lysed. Caspase-3/7 activity 
assessed by cleavage of fluorogenic substrate Ac-DEVD-AFC.
1
 
(c) Calculated using Equation 3.2:
20
  
predicted logBB = (-0.0148 x PSA) + (0.152 x ClogP) + 0.139. 
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In addition, the ability of compounds to activate executioner caspases in whole cells was 
evaluated. Cells were treated with compound for 0 or 16 hours, then the cells were lysed, and 
cleavage of the fluorescent caspase-3/-7 substrate Ac-DEVD-AFC was analyzed via kinetic 
reads. The percent activity at 16 hours was normalized to the slope of each compound at 0 hours 
(0% activity) and the slope of the positive control compound staurosporine at 16 hours (100% 
activity). As shown in Table 4.5 and Figure 4.6, PAC-1 induces nearly 90% caspase activation, 
while each of the other active compounds induces greater than 60% activation of the executioner 
caspases. As expected, treatment with DMSO alone or PAC-1a induces minimal caspase activity 
in the cells. 
 
 
Figure 4.6. PAC-1 and active derivatives activate executioner caspases in cells. U-937 cells 
were treated with compounds (30 µM for PAC-1 derivatives, 1 µM for staurosporine) for 16 
hours, and then lysed. Caspase-3/7 activity was assessed by cleavage of the fluorogenic substrate 
Ac-DEVD-AFC. Cells treated with vehicle alone or inactive derivative PAC-1a show minimal 
caspase activity after 16 hours. Values shown are mean ± s.e.m. (n = 3).
1
 
 
In order to confirm that the compounds induced cell death via apoptosis, U-937 cells 
were treated with compounds at 50 μM for 12 hours, and cells were assessed by Annexin V-
FITC/propidium iodide staining (Figure 4.7). Each of these compounds induced approximately 
50% cell death under these conditions, and the presence of large populations in the lower right 
quadrants of the histograms (Annexin V-FITC positive, propidium iodide negative) confirms that 
the compounds induce apoptosis in these cancer cells. 
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Figure 4.7. PAC-1 and derivatives induce apoptosis in U-937 cells. Cells were treated for 12 
hours at 50 µM, and viability was assessed by Annexin V-FITC/propidium iodide staining. Data 
shown are representative of three independent experiments.
1
 
 
As many PAC-1 derivatives show activity against white blood cell cancer lines
3, 5, 6, 8, 10, 
13-16, 24
 and patient-derived leukemic lymphocytes
25
 in culture, the compounds were evaluated for 
their ability to induce cell death in a panel of lymphoma and leukemia cell lines, including Jurkat 
(human leukemia), GL-1 (dog lymphoma), OSW (dog lymphoma), and EL4 (mouse lymphoma) 
cells, in order to complement the previously determined IC50 values in U-937 (human 
lymphoma) cells. As shown in Table 4.6, the compounds displayed comparable potency against 
each given cell line. These results provide further support to the previously determined structure-
activity relationships, as the modifications to improve metabolic stability had minimal effect on 
the activity of the new compounds, and further suggest the potential of PAC-1 and derivatives 
for the treatment of white blood cell cancers. 
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Table 4.6. PAC-1 and derivatives are cytotoxic to white blood cell cancer lines in culture.
 
Cells 
treated with compounds for 72 hours. Biomass quantified by sulforhodamine B assay. IC50 
values shown are mean ± s.e.m. (n = 3).
1 
 
4.7. Pharmacokinetics 
Because compounds 4.34, 4.52, 4.54, and 4.63 all chelate zinc in vitro and activate 
executioner caspases to induce apoptosis in cancer cell lines, all four of the hit compounds were 
studied further in vivo. The pharmacokinetics of the four compounds plus PAC-1 and S-PAC-1 
were evaluated in mice at a dose of 25 mg/kg (IV injection), and the results are shown in Figure 
4.8 and Table 4.7. PAC-1 and S-PAC-1 were cleared rapidly and were no longer detectable after 
5 and 6 hours post-treatment, respectively. In contrast, detectable levels of each of the four new 
derivatives remained in circulation for at least 8 hours post-treatment. 
 The elimination half-life of PAC-1 was 24.6 ± 0.9 minutes, and the half-life of S-PAC-1 
was 38.1 ± 3.3 minutes. Each of the four new derivatives displayed half-lives of at least 88 
minutes, with compound 4.62 having the longest half-life at 122.3 ± 1.4 minutes. In addition, 
AUC values from intravenous administration for the four new derivatives were all considerably 
higher than that of PAC-1. Compounds 4.33, 4.53, and 4.62 were also found to display increased 
oral bioavailability as compared to PAC-1 and S-PAC-1. 
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Figure 4.8. Pharmacokinetic profiles of PAC-1 and selected derivatives following 25 mg/kg 
intravenous dose (n = 2). Detectable levels of the novel derivatives are present in serum for at 
least 8 hours post-treatment, while PAC-1 and S-PAC-1 are no longer detectable after 5 and 6 
hours post-treatment, respectively.
1
 
 
 
Table 4.7. Pharmacokinetic parameters and predicted BBB permeability for PAC-1 and selected 
derivatives. 
25 mg/kg dose was administered via intravenous injection or oral gavage. Values shown are 
mean ± standard deviation (n = 2).
1
 
 
4.8. Discussion 
 The introduction of substituents designed to block oxidative metabolism is among the 
most attractive methods to improve the pharmacokinetic profile for a compound of interest, as 
the drug can pass through the liver without being modified and remain in circulation for longer 
periods of time. The knowledge of the metabolites formed from PAC-1 in vivo facilitated the 
design of a library of PAC-1 derivatives whose members lacked many of the metabolic liabilities 
present on the parent compound. The flexible, modular nature of the PAC-1 synthesis allowed 
for the rapid generation of 61 derivatives from ten hydrazides and eight aldehydes. 
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 Cell culture evaluation confirmed previously determined structure-activity relationships, 
in that substituents could be introduced to the aromatic rings without abolishing activity if the 
core ortho-hydroxy-N-acylhydrazone remained intact. In general, removal of the allyl group led 
to a decrease in cell culture potency, consistent with previous reports,
5, 6
 although reduction to 
the fully saturated propyl group was tolerated in the cell culture experiment. It is likely that the 
increased hydrophobicity of the alkyl chain contributes to increased cell permeability, as the allyl 
group does not affect the ability of PAC-1 to bind zinc.
6
 This was especially apparent in the 
initial library, as compounds derived from aldehydes 4b, 4c, and 4d induced minimal cell death 
under the conditions evaluated. 
The benzoyl-containing compounds displayed similar cell culture activity to PAC-1. This 
substitution changes the electronics at both the arene and the piperazine nitrogen; the role of the 
benzylpiperazine in PAC-1 activity merits further evaluation. Evaluation of the metabolic 
stability of the library members in rat liver microsomes suggested that N-dealkylation was the 
main route of metabolism in vitro; the PAC-1 derivatives containing benzoyl substituents were 
more stable than those containing benzyl substituents. These substitutions also reduced the extent 
of arene oxidation, providing further support for advancement of these compounds. In contrast, 
the dichloro substitution was unsuccessful in preventing N-dealkylation, and the extent of arene 
oxidation increased for these compounds relative to derivatives containing an unsubstituted 
benzyl ring. 
Experiments in mice demonstrated that most compounds with predicted logBB values 
above -0.55 induced neuroexcitation, and responses to most of these compounds were at least as 
severe as the toxicity induced by PAC-1. In contrast, no compound with a logBB value of -0.55 
or lower induced neuroexcitation in mice, suggesting this level as a threshold for induction of 
neuroexcitation. Compound 4.12 was slightly less neurotoxic than PAC-1, but it was also 
slightly less BBB permeable. This concentration difference in the brain may represent a second 
threshold for the severity of neurotoxicity, or 4.12 may interact more weakly with the biological 
macromolecule responsible for neuroexcitation. Further experiments are necessary to fully 
understand the nature of this toxicity; preliminary efforts toward this goal will be discussed in 
Chapter 5. 
Four compounds (4.33, 4.51, 4.53, and 4.62) were identified with favorable cell culture 
potency, in vitro metabolic stability, and in vivo tolerability. Each of these compounds contained 
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the benzoyl substitution, as well as at least one arene substituent (fluorine and/or nitrile) not 
present on PAC-1. The introduction of fluorine is common in medicinal chemistry, especially 
the use of aryl fluorides to block undesired metabolic arene oxidation, as in the cholesterol-
lowering drug ezetimibe.
26
 Aryl nitriles are also commonly employed to accomplish this goal, as 
nitriles typically pass through the body unmodified, and the electron-withdrawing nature of the 
group deactivates the arene towards oxidative metabolism at other sites.
18
 Trifluoromethyl 
groups can deactivate arenes similarly in certain cases,
27
 and in vitro results with the 
(trifluoromethyl)benzoyl-containing PAC-1 derivatives were encouraging. However, these 
compounds were not evaluated further due to unacceptable levels of toxicity in vivo. 
Further evaluation of the four lead compounds demonstrated that they chelate zinc, 
activate executioner caspases in whole cells, and induce apoptosis similarly to PAC-1 and S-
PAC-1. The four derivatives displayed three- to five-fold higher elimination half-lives and up to 
two-fold higher AUC values compared to PAC-1. Results from the liver microsome experiment 
were mostly consistent with the observed in vivo pharmacokinetic profiles from experiments in 
mice: fewer metabolites formed from the new derivatives than from PAC-1 in vitro, and the 
compounds remained in serum for longer periods of time than PAC-1. In contrast, S-PAC-1 was 
stable in the liver microsome assay but had a relatively short in vivo half-life. This suggests that 
the main mode of clearance for S-PAC-1 may not be via oxidative metabolism; instead, the 
compound may be excreted without modification. A more thorough understanding of this 
phenomenon may allow for the design of PAC-1 derivatives that improve upon the 
pharmacokinetics even further than those described in this report. The rapid clearance of PAC-1 
and S-PAC-1 from circulation makes them challenging to evaluate in certain efficacy models in 
vivo; these studies typically require large doses of compound, thereby increasing the potential for 
toxicity. The four novel derivatives remain in circulation for longer than either PAC-1 or S-
PAC-1, and thus offer promise as novel therapeutic agents for the treatment of cancer. 
 
4.9. Materials and methods 
 
4.9.1. Chemical information 
General All reactions requiring anhydrous conditions were conducted under a positive 
atmosphere of nitrogen or argon in oven-dried glassware. Standard syringe techniques were used 
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for anhydrous addition of liquids. Unless otherwise noted, all starting materials, solvents, and 
reagents were acquired from commercial suppliers and used without further purification. Flash 
chromatography was performed using 230-400 mesh silica gel. Experimental details for 
compounds not in literature
1
 are provided below. 
Compound Analysis All NMR experiments were recorded in CDCl3 (Sigma or Cambridge) or 
(CD3)2CO (Sigma or Cambridge) on a Varian Unity 500 MHz spectrometer with residual 
undeuterated solvent as the internal reference for 
1
H-NMR (CDCl3 – 7.26 ppm; (CD3)2CO – 2.04 
ppm) and 
13
C-NMR (CDCl3 – 77.23 ppm; (CD3)2CO – 29.80 ppm). Chemical shift, δ (ppm); 
coupling constants, J (Hz); multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, quint = 
quintet, sext = sextet, m = multiplet, br = broad); and integration are reported. High-resolution 
mass spectral data was recorded on a Micromass Q-Tof Ultima hybrid quadrupole/time-of-flight 
ESI mass spectrometer or a Micromass 70-VSE at the University of Illinois Mass Spectrometry 
Laboratory. 
Ethyl 2-(4-(2,6-dichlorobenzyl)piperazin-1-yl)acetate (4.4d) 
 
To a round-bottom flask were added 2,6-dichlorobenzyl bromide (4.3d, 2.0 g, 8.34 mmol, 1.0 
equiv.), 2.8 (2.15 g, 12.5 mmol, 1.5 equiv.), K2CO3 (3.46 g, 25.0 mmol, 3.0 equiv.), and acetone 
(40 mL, 0.2 M). The reaction mixture was stirred at reflux overnight. The reaction mixture was 
then cooled to rt. The solid was filtered and washed with acetone, and the filtrate was 
concentrated. Purification by silica gel column chromatography (25-50% EtOAc/hexanes) gave 
4.4d (2.54 g, 92.0%) as a colorless oil. 
1
H-NMR (500 MHz, CDCl3) δ 7.29 (d, 2H, J = 8.0 Hz), 
7.13 (t, 1H, J = 8.0 Hz), 4.17 (q, 2H, J = 7.0 Hz), 3.76 (s, 2H), 3.17 (s, 2H), 2.66 (br s, 4H), 2.55 
(br s, 4H), 1.26 (t, 3H, J = 7.0 Hz). 
13
C-NMR (125 MHz, CDCl3) δ 170.6, 137.2, 134.6, 129.0, 
128.6, 60.8, 59.8, 56.6, 53.4, 52.9, 14.5. 
2-(4-(2,6-dichlorobenzyl)piperazin-1-yl)acetohydrazide (4.1d) 
 
To a round-bottom flask were added 4.4d (2.54 g, 7.67 mmol, 1.0 equiv.), EtOH (15 mL, 0.5 M), 
and anhydrous hydrazine (0.97 mL, 30.7 mmol, 4.0 equiv.). The reaction mixture was stirred at 
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reflux overnight. The reaction mixture was cooled to rt and concentrated. The crude residue was 
partitioned between CH2Cl2 (20 mL)/1:1 brine:0.1M KOH (20 mL). The layers were separated, 
and the aqueous layer was extracted with CH2Cl2 (2 x 20 mL). The combined organic layers 
were dried over MgSO4, filtered, and concentrated. 4.1d (2.01 g, 82.6%) was obtained as a white 
solid after extraction without further purification. 
1
H-NMR (500 MHz, CDCl3) δ 8.17 (s, 1H), 
7.30 (d, 2H, J = 8.0 Hz), 7.14 (t, 1H, J = 8.0 Hz), 3.85 (br s, 2H), 3.75 (s, 2H), 3.08 (s, 2H), 2.60 
(br s, 4H), 2.50 (br s, 4H). 
13
C-NMR (125 MHz, CDCl3) δ 170.8, 137.2, 134.3, 129.1, 128.6, 
60.8, 56.5, 53.9, 53.1. 
3-formyl-4-methoxybenzonitrile (4.6) 
 
To an oven-dried round-bottom flask were added 5-bromo-2-methoxybenzaldehyde (4.5, 4.30 g, 
20.0 mmol, 1.0 equiv.), Zn(CN)2 (2.35 g, 20.0 mmol, 1.0 equiv.), Pd(PPh3)4 (924 mg, 0.80 
mmol, 0.040 equiv.), and anhydrous DMF (50 mL). The mixture was deoxygenated by the 
freeze-pump-thaw method. The reaction mixture was then stirred overnight at 100°C under N2. 
The reaction mixture was cooled to room temperature, diluted with H2O (100 mL), and extracted 
with EtOAc (4 x 100 mL). The combined organic layers were washed with H2O (4 x 50 mL) and 
brine (50 mL), dried over MgSO4, filtered, and concentrated. The product was purified by silica 
gel column chromatography (20-30% EtOAc/hexanes) to yield 4.6 (1.91 g, 59.2%) as a white 
solid. 
1
H-NMR (500 MHz, CDCl3) δ 10.40 (s, 1H), 8.08 (d, 1H, J = 2.0 Hz), 7.81 (dd, 1H, J = 
2.0, 9.0 Hz), 7.10 (d, 1H, J = 9.0 Hz), 4.01 (s, 3H). 
13
C-NMR (125 MHz, CDCl3) δ 187.8, 164.3, 
139.2, 133.0, 125.3, 118.2, 113.0, 104.8, 56.5. 
3-formyl-4-hydroxybenzonitrile (4.2b) 
 
To a round-bottom flask were added 4.6 (1.61 g, 10.0 mmol, 1.0 equiv.), LiCl (1.27 g, 30.0 
mmol, 3.0 equiv.), and DMF (25 mL, 0.4 M). The reaction mixture was stirred at reflux 
overnight. The reaction mixture was cooled to room temperature, acidified (pH ≤ 1) with 1 M 
HCl (25 mL), and extracted with EtOAc (6 x 25 mL). The combined organic layers were washed 
with H2O (3 x 25 mL) and brine (25 mL), dried over MgSO4, filtered, and concentrated. The 
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crude product was purified by silica gel column chromatography (gradient, 10-30% 
EtOAc/hexanes) to yield 4.2b (274 mg, 18.7%) as a white solid. 
1
H-NMR (500 MHz, CDCl3) δ 
11.46 (br s, 1H), 9.93 (s, 1H), 7.94 (d, 1H, J = 2.0 Hz), 7.77 (dd, 1H, J = 2.0, 8.0 Hz), 7.11 (d, 
1H, J = 8.0 Hz). 
13
C-NMR (125 MHz, CDCl3) δ 195.5, 164.8, 139.6, 138.5, 120.8, 119.6, 117.9, 
104.1. 
3-hydroxypicolinaldehyde (4.2c) 
 
To a round-bottom flask were added 85% pure 3-hydroxy-2-(hydroxymethyl)pyridine 
hydrochloride (4.7, 5.0 g, 26.3 mmol, 1.0 equiv.), water (75 mL), and CHCl3 (100 mL). The 
mixture was stirred, and activated MnO2 (6.86 g, 78.9 mmol, 3.0 equiv.) was added. 
Concentrated H2SO4 (0.70 mL, 13.2 mmol, 0.5 equiv.) in water (25 mL) was added dropwise to 
the mixture. The reaction mixture was stirred at reflux for 2.5 hours. The mixture was cooled to 
room temperature. Brine (100 mL) was added, and the layers were separated. The aqueous layer 
was extracted with CHCl3 (4 x 100 mL). The combined organic layers were dried over Na2SO4, 
filtered, and concentrated to yield 4.2c (2.28 g, 70.4%) as a brown solid. 
1
H-NMR (500 MHz, 
CDCl3) δ 10.70 (br s, 1H), 10.04 (s, 1H), 8.32 (d, 1H, J = 3.5 Hz), 7.42 (dd, 1H, J = 4.0, 9.0 Hz), 
7.34 (d, 1H, J = 8.5 Hz). 
13
C-NMR (125 MHz, CDCl3) δ 198.9, 158.8, 142.7, 136.9, 130.2, 
126.2. 
3-(2,3-dihydroxypropyl)-2-hydroxybenzaldehyde (4.2d) 
 
To a round-bottom flask were added 2.1 (2.43 g, 15.0 mmol, 1.0 equiv.), 4-methylmorpholine N-
oxide (3.51 g, 30.0 mmol, 2.0 equiv.), and 1:1 t-BuOH:H2O (150 mL, 0.1 M). The mixture was 
stirred, and a solution of OsO4 (2.5% w/w in t-BuOH, 1.9 mL, 0.15 mmol, 0.010 equiv.) was 
added dropwise. The reaction mixture was capped and stirred overnight at room temperature. 
The reaction was quenched by the addition of saturated Na2SO3, capped, and stirred overnight at 
room temperature. The reaction mixture was then extracted with EtOAc (6 x 50 mL). The 
combined organic layers were washed with brine (50 mL), dried over MgSO4, filtered, and 
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concentrated. Purification by silica gel column chromatography (gradient, 25-100% 
EtOAc/hexanes) afforded 4.2d (2.32 g, 78.9%) as a white solid. 
1
H-NMR (500 MHz, CDCl3) δ 
11.39 (br s, 1H), 9.85 (s, 1H), 7.46-7.43 (m, 2H), 6.97 (t, 1H, J = 7.5 Hz), 3.97 (m, 1H), 3.61 (dd, 
1H, J = 2.5, 11.5 Hz), 3.48 (dd, 1H, J = 6.5, 11.5 Hz), 3.18 (br s, 1H), 3.03 (br s, 1H), 2.87 (dd, 
1H, J = 5.5, 13.5 Hz), 2.81 (dd, 1H, J = 7.5, 13.5 Hz). 
13
C-NMR (125 MHz, CDCl3) δ 197.0, 
159.8, 138.9, 132.5, 126.8, 120.5, 120.1, 71.9, 66.0, 33.3. 
General Procedure A: Synthesis of PAC-1 analogues 
To a 16 x 150 mm test tube were added hydrazide (1.0 equiv.), aldehyde (1.0 equiv.), EtOH or 
2:1 MeOH:MeCN (0.15 M), and 1.2 M HCl (7 mol%). The reaction mixture was shaken 
overnight at reflux on a Büchi Syncore parallel synthesizer. The reaction mixture was cooled to 
room temperature, concentrated, and purified by silica gel column chromatography or 
recrystallization to yield pure PAC-1 analogue. 
N'-(3-allyl-2-hydroxybenzylidene)-2-(4-(2,6-dichlorobenzyl)piperazin-1-yl)acetohydrazide 
(4.11) 
 
Synthesized according to General Procedure A, but in a round-bottom flask: 4.1d (317 mg, 1.0 
mmol, 1.0 equiv.), 2.1 (162 mg, 1.0 mmol, 1.0 equiv.), 1.2 M HCl (58 μL, 0.070 mmol, 0.070 
equiv.), EtOH (7 mL, 0.15 M). Purification by silica gel column chromatography (0-5% 
MeOH/EtOAc) yielded 4.11 (392 mg, 85.1%) as an off-white solid. 
1
H-NMR (500 MHz, CDCl3) 
δ 11.25 (s, 1H), 10.10 (br s, 1H), 8.45 (s, 1H), 7.32 (d, 2H, J = 8.0 Hz), 7.19 (dd, 1H, J = 1.0, 7.5 
Hz), 7.16 (t, 1H, J = 8.0 Hz), 7.11 (dd, 1H, J = 1.5, 8.0 Hz), 6.86 (t, 1H, J = 7.5 Hz), 6.04 (tdd, 
1H, J = 6.5, 10.0, 16.5 Hz), 5.11-5.05 (m, 2H), 3.80 (s, 2H), 3.46 (d, 2H, J = 6.5 Hz), 3.19 (br s, 
2H), 2.68 (br s, 4H), 2.62 (br s, 4H). 
13
C-NMR (125 MHz, CDCl3) δ 166.0, 156.7, 151.6, 137.2, 
136.8, 134.2, 132.5, 129.4, 129.2, 128.6, 128.5, 119.2, 117.1, 115.8, 61.2, 56.5, 54.0, 53.1, 34.1. 
HRMS (ESI): 461.1514 (M+1); calcd. for C23H27Cl2N4O2: 461.1511. 
2-(4-(2,6-dichlorobenzyl)piperazin-1-yl)-N'-(2-hydroxy-3-propylbenzylidene)acetohydrazide 
(4.17) 
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Synthesized according to General Procedure A: 4.1d (159 mg, 0.50 mmol, 1.0 equiv.), 4.2a (82 
mg, 0.50 mmol, 1.0 equiv.), 1.2 M HCl (29 μL, 0.035 mmol, 0.070 equiv.), EtOH (3 mL, 0.15 
M). Purification by silica gel column chromatography (50-75% EtOAc/hexanes) yielded 4.17 
(124 mg, 53.3%) as a white solid. 
1
H-NMR (500 MHz, CDCl3) δ 11.20 (s, 1H), 10.05 (br s, 1H), 
8.40 (s, 1H), 7.31 (d, 2H, J = 8.0 Hz), 7.18-7.14 (m, 2H), 7.08 (dd, 1H, J = 1.5, 8.0 Hz), 6.84 (t, 
1H, J = 7.5 Hz), 3.79 (s, 2H), 3.17 (s, 2H), 2.68-2.65 (m, 6H), 2.59 (br s, 4H), 1.66 (sext, 2H, J = 
7.5 Hz), 0.96 (t, 3H, J = 7.5 Hz). 
13
C-NMR (125 MHz, CDCl3) δ 166.0, 156.9, 151.6, 137.1, 
134.2, 132.7, 130.9, 129.2, 129.0, 128.6, 119.0, 116.9, 61.1, 56.5, 53.9, 53.2, 32.1, 22.9, 14.3. 
HRMS (ESI): 463.1670 (M+1); calcd. for C23H29Cl2N4O2: 463.1668. 
2-(4-benzylpiperazin-1-yl)-N'-(5-cyano-2-hydroxybenzylidene)acetohydrazide (4.18) 
 
Synthesized according to General Procedure A: 1.6 (248 mg, 1.0 mmol, 1.0 equiv.), 4.2b (147 
mg, 1.0 mmol, 1.0 equiv.), 1.2 M HCl (58 μL, 0.070 mmol, 0.070 equiv.), EtOH (7 mL, 0.15 M). 
Purification by silica gel column chromatography (gradient, 0-20% MeOH/EtOAc) yielded 4.18 
(319.2 mg, 84.7%) as a yellow solid. 
1
H-NMR (500 MHz, CDCl3) δ 11.54 (br s, 1H), 10.24 (br s, 
1H), 8.47 (s, 1H), 7.55-7.51 (m, 2H), 7.34-7.30 (m, 4H), 7.28-7.25 (m, 1H), 7.04 (d, 1H, J = 9.5 
Hz), 3.55 (s, 2H), 3.21 (s, 2H), 2.63 (br s, 4H), 2.54 (br s, 4H). 
13
C-NMR (125 MHz, CDCl3) δ 
166.5, 162.1, 148.8, 137.7, 135.2, 135.1, 129.3, 128.5, 127.4, 118.8, 118.8, 118.4, 103.0, 63.0, 
61.1, 53.9, 53.0. HRMS (ESI): 378.1925 (M+1); calcd. for C21H24N5O2: 378.1930. 
4-((4-(2-(2-(5-cyano-2-hydroxybenzylidene)hydrazinyl)-2-oxoethyl)piperazin-1-
yl)methyl)benzenesulfonamide (4.19) 
 
Synthesized according to General Procedure A: 2.16 (327 mg, 1.0 mmol, 1.0 equiv.), 2.1 (147 
mg, 1.0 mmol, 1.0 equiv.), 1.2 M HCl (58 μL, 0.070 mmol, 0.070 equiv.), 2:1 MeOH:MeCN (7 
mL, 0.15 M). Purification by silica gel column chromatography (gradient, 0-20% MeOH/EtOAc) 
yielded 4.19 (343 mg, 75.0%) as a yellow solid. 
1
H-NMR (500 MHz, (CD3)2CO) δ 12.31 (br s, 
1H), 11.09 (br s, 1H), 8.56 (s, 1H), 7.84 (d, 2H, J = 8.0 Hz), 7.77 (s, 1H), 7.64 (d, 2H, J = 8.0 
Hz), 7.50 (d, 2H, J = 8.5 Hz), 7.06 (d, 1H, J = 8.5 Hz), 6.59 (br s, 2H), 3.58 (s, 2H), 3.21 (s, 2H), 
2.60 (br s, 4H), 2.51 (br s, 4H). 
13
C-NMR (125 MHz, (CD3)2CO) δ 167.0, 162.6, 148.5, 143.8, 
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143.7, 135.9, 135.3, 129.9, 126.8, 119.9, 119.2, 119.0, 103.3, 62.5, 61.5, 54.1, 53.4. HRMS 
(ESI): 457.1655 (M+1); calcd. for C21H25N6O4S: 457.1658. 
2-(4-benzylpiperazin-1-yl)-N'-((3-hydroxypyridin-2-yl)methylene)acetohydrazide (4.20) 
 
Synthesized according to General Procedure A: 1.6 (124 mg, 0.50 mmol, 1.0 equiv.), 4.2c (62 
mg, 0.50 mmol, 1.0 equiv.), 1.2 M HCl (29 μL, 0.035 mmol, 0.070 equiv.), EtOH (3 mL, 0.15 
M). Purification by silica gel column chromatography (gradient, 0-25% MeOH/EtOAc) yielded 
4.20 (141 mg, 79.4%) as a yellow solid. 
1
H-NMR (500 MHz, CDCl3) δ 10.84 (br s, 1H), 10.31 
(br s, 1H), 8.41 (s, 1H), 8.18 (dd, 1H, J = 1.5, 4.5 Hz), 7.34-7.30 (m, 4H), 7.28-7.24 (m, 1H), 
7.21 (dd, 1H, J = 4.5, 8.0 Hz), 7.10 (dd, 1H, J = 1.5, 7.5 Hz), 3.54 (s, 2H), 3.21 (s, 2H), 2.63 (br 
s, 4H), 2.52 (br s, 4H). 
13
C-NMR (125 MHz, CDCl3) δ 166.2, 155.8, 151.1, 141.4, 137.8, 136.4, 
129.3, 128.5, 127.4, 125.8, 124.9, 63.0, 61.0, 53.8, 53.2. HRMS (ESI): 354.1927 (M+1); calcd. 
for C19H24N5O2: 354.1930. 
4-((4-(2-(2-((3-hydroxypyridin-2-yl)methylene)hydrazinyl)-2-oxoethyl)piperazin-1-
yl)methyl)benzenesulfonamide (4.21) 
 
Synthesized according to General Procedure A: 2.16 (164 mg, 0.50 mmol, 1.0 equiv.), 4.2c (62 
mg, 0.50 mmol, 1.0 equiv.), 1.2 M HCl (29 μL, 0.035 mmol, 0.070 equiv.), 2:1 MeOH:MeCN (3 
mL, 0.15 M). Purification by silica gel column chromatography (gradient, 0-30% MeOH/EtOAc) 
yielded 4.21 (169 mg, 78.2%) as a yellow solid. 
1
H-NMR (500 MHz, (CD3)2CO) δ 11.46 (br s, 
1H), 11.12 (br s, 1H), 8.57 (s, 1H), 8.16 (dd, 1H, J = 1.5, 4.5 Hz), 7.84 (d, 2H, J = 8.5 Hz), 7.51 
(d, 2H, J = 8.0 Hz), 7.31 (dd, 1H, J = 1.5, 8.5 Hz), 7.28 (dd, 1H, J = 4.5, 8.5 Hz), 6.57 (br s, 2H), 
3.58 (s, 2H), 3.21 (s, 2H), 2.60 (br s, 4H), 2.51 (br s, 4H). 
13
C-NMR (125 MHz, CDCl3) δ 166.9, 
156.1, 151.1, 144.0, 143.8, 141.9, 137.9, 129.9, 126.8, 126.0, 124.7, 62.6, 61.7, 54.2, 53.5. 
HRMS (ESI): 433.1656 (M+1); calcd. for C19H25N6O4S: 433.1658. 
2-(4-benzoylpiperazin-1-yl)-N'-((3-hydroxypyridin-2-yl)methylene)acetohydrazide (4.22) 
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Synthesized according to General Procedure A: 4.1a (131 mg, 0.50 mmol, 1.0 equiv.), 4.2c (62 
mg, 0.50 mmol, 1.0 equiv.), 1.2 M HCl (29 μL, 0.035 mmol, 0.070 equiv.), EtOH (3 mL, 0.15 
M). Purification by silica gel column chromatography (gradient, 0-20% MeOH/EtOAc) yielded 
4.22 (169 mg, 91.8%) as a yellow solid. 
1
H-NMR (500 MHz, CDCl3) δ 10.96 (br s, 1H), 10.59 
(br s, 1H), 8.44 (s, 1H), 8.13 (dd, 1H, J = 4.0, 11.5 Hz), 7.42-7.37 (m, 5H), 7.29 (d, 1H, J = 8.0 
Hz), 7.19 (dd, 1H, J = 4.5, 8.5 Hz), 3.82 (br s, 2H), 3.50 (br s, 2H), 3.23 (s, 2H), 2.64 (br s, 2H), 
2.54 (br s, 2H). 
13
C-NMR (125 MHz, CDCl3) δ 170.7, 165.8, 155.8, 151.3, 147.7, 141.3, 136.3, 
135.3, 130.2, 128.8, 127.1, 125.8, 125.0, 60.8, 53.7 (br), 47.8 (br), 42.2 (br). HRMS (ESI): 
368.1720 (M+1); calcd. for C19H22N5O3: 368.1723. 
2-(4-(4-cyanobenzyl)piperazin-1-yl)-N'-((3-hydroxypyridin-2-yl)methylene)acetohydrazide 
(4.23) 
 
Synthesized according to General Procedure A: 4.1b (273 mg, 1.0 mmol, 1.0 equiv.), 4.2c (123 
mg, 1.0 mmol, 1.0 equiv.), 1.2 M HCl (58 μL, 0.070 mmol, 0.070 equiv.), EtOH (7 mL, 0.15 M). 
Purification by silica gel column chromatography (gradient, 0-30% MeOH/EtOAc) yielded 4.23 
(229 mg, 60.6%) as a yellow solid. 
1
H-NMR (500 MHz, CDCl3) δ 10.82 (br s, 1H), 10.36 (br s, 
1H), 8.42 (s, 1H), 8.17 (d, 1H, J = 4.0 Hz), 7.59 (d, 2H, J = 8.0 Hz), 7.42 (d, 1H, J = 8.0 Hz), 
7.31 (d, 1H, J = 8.0 Hz), 7.21 (d, 1H, J = 4.5, 8.5 Hz), 3.57 (s, 2H), 3.24 (s, 2H), 2.64 (br s, 4H), 
2.52 (br s, 4H). 
13
C-NMR (125 MHz, CDCl3) δ 166.2, 155.8, 151.2, 143.6, 141.4, 136.3, 132.3, 
129.6, 125.8, 125.0, 119.0, 111.2, 62.3, 60.8, 53.7, 53.2. HRMS (ESI): 379.1881 (M+1); calcd. 
for C20H23N6O2: 379.1882. 
2-(4-(4-cyanobenzoyl)piperazin-1-yl)-N'-((3-hydroxypyridin-2-yl)methylene)acetohydrazide 
(4.24) 
 
Synthesized according to General Procedure A: 4.1c (287 mg, 1.0 mmol, 1.0 equiv.), 4.2c (123 
mg, 1.0 mmol, 1.0 equiv.), 1.2 M HCl (58 μL, 0.070 mmol, 0.070 equiv.), EtOH (7 mL, 0.15 M). 
Purification by silica gel column chromatography (gradient, 0-30% MeOH/EtOAc) yielded 4.24 
(279 mg, 71.1%) as a dark yellow solid. 
1
H-NMR (500 MHz, CDCl3) δ 10.91 (br s, 1H), 10.47 
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(br s, 1H), 8.44 (s, 1H), 8.17-8.09 (m, 1H), 7.69 (d, 2H, J = 7.0 Hz), 7.50-7.47 (m, 1H), 7.29-
7.26 (m, 1H), 7.23-7.20 (m, 1H), 3.83 (br s, 2H), 3.42 (br s, 2H), 3.27 (s, 2H), 2.69 (br s, 2H), 
2.56 (br s, 4H). 
13
C-NMR (125 MHz, CDCl3) δ 168.5, 165.6, 155.7, 151.4, 141.3, 139.7, 136.2, 
132.7, 127.9, 125.9, 125.0, 118.1, 113.9, 60.7, 53.7 (br), 47.5 (br), 42.2 (br). HRMS (ESI): 
393.1672 (M+1); calcd. for C20H21N6O3: 393.1675. 
2-(4-(2,6-dichlorobenzyl)piperazin-1-yl)-N'-((3-hydroxypyridin-2-
yl)methylene)acetohydrazide (4.25) 
 
Synthesized according to General Procedure A: 4.1d (159 mg, 0.50 mmol, 1.0 equiv.), 4.2c (62 
mg, 0.50 mmol, 1.0 equiv.), 1.2 M HCl (29 μL, 0.035 mmol, 0.070 equiv.), EtOH (3 mL, 0.15 
M). Purification by silica gel column chromatography (gradient, 0-20% MeOH/EtOAc) yielded 
4.25 (177 mg, 83.7%) as a yellow solid. 
1
H-NMR (500 MHz, CDCl3) δ 10.82 (br s, 1H), 10.40 
(br s, 1H), 8.43 (s, 1H), 8.18 (dd, 1H, J = 1.0, 4.5 Hz), 7.32 (d, 1H, J = 8.0 Hz), 7.29 (d, 2H, J = 
8.0 Hz), 7.22 (dd, 1H, J =4.5, 8.5 Hz), 7.14 (t, 1H, J = 8.0 Hz), 3.77 (s, 2H), 3.20 (s, 2H), 2.64 
(br s, 4H), 2.59 (br s, 4H). 
13
C-NMR (125 MHz, CDCl3) δ 166.4, 155.8, 151.1, 141.4, 137.1, 
137.1, 134.1, 129.2, 128.6, 125.8, 125.0, 60.9, 56.4, 53.9, 53.1. HRMS (ESI): 422.1152 (M+1); 
calcd. for C19H22Cl2N5O2: 422.1151. 
2-(4-benzylpiperazin-1-yl)-N'-(3-(2,3-dihydroxypropyl)-2-
hydroxybenzylidene)acetohydrazide (4.26) 
 
Synthesized according to General Procedure A: 1.6 (124 mg, 0.50 mmol, 1.0 equiv.), 4.2d (98 
mg, 0.50 mmol, 1.0 equiv.), 1.2 M HCl (29 μL, 0.035 mmol, 0.070 equiv.), EtOH (3 mL, 0.15 
M). Purification by silica gel column chromatography (gradient, 0-20% MeOH/EtOAc) yielded 
4.26 (178.9 mg, 84.0%) as an off-white solid. 
1
H-NMR (500 MHz, CDCl3) δ 11.49 (br s, 1H), 
10.16 (br s, 1H), 8.36 (s, 1H), 7.34-7.30 (m, 4H), 7.28-7.25 (m, 1H), 7.21 (dd, 1H, J = 1.5, 7.5 
Hz), 7.12 (dd, 1H, J = 1.5, 7.5 Hz), 6.86 (t, 1H, J = 7.5 Hz), 4.00-3.95 (m, 1H), 3.61 (dd, 1H, J = 
4.0, 11.5 Hz), 3.54 (s, 2H), 3.50 (dd, 1H, J = 6.0, 11.5 Hz) 3.18 (s, 2H), 2.92 (dd, 1H, J = 6.0, 
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13.5 Hz), 2.87 (dd, 1H, J = 7.0, 13.5 Hz), 2.62 (br s, 4H), 2.53 (br s, 4H). 
13
C-NMR (125 MHz, 
CDCl3) δ 166.2, 156.6, 151.0, 137.8, 134.0, 129.8, 129.4, 128.5, 127.4, 126.3, 119.7, 117.3, 72.4, 
66.0, 63.1, 61.1, 53.9, 53.1, 34.2. HRMS (ESI): 427.2336 (M+1); calcd. for C23H31N4O4: 
427.2345. 
4-((4-(2-(2-(3-(2,3-dihydroxypropyl)-2-hydroxybenzylidene)hydrazinyl)-2-
oxoethyl)piperazin-1-yl)methyl)benzenesulfonamide (4.27) 
 
Synthesized according to General Procedure A: 2.16 (164 mg, 0.50 mmol, 1.0 equiv.), 4.2d (98 
mg, 0.50 mmol, 1.0 equiv.), 1.2 M HCl (29 μL, 0.035 mmol, 0.070 equiv.), 2:1 MeOH:MeCN (3 
mL, 0.15 M). Purification by silica gel column chromatography (gradient, 0-20% MeOH/EtOAc) 
yielded 4.27 (183 mg, 72.2%) as a yellow solid. 
1
H-NMR (500 MHz, (CD3)2CO) δ 11.86 (br s, 
1H), 10.82 (br s, 1H), 8.49 (s, 1H), 7.84 (d, 2H, J = 8.0 Hz), 7.51 (d, 2H, J = 8.0 Hz), 7.25 (dd, 
1H, J = 1.5, 7.5 Hz), 7.17 (dd, 1H, J = 1.5, 8.0 Hz), 6.83 (t, 1H, J = 7.5 Hz), 6.57 (br s, 2H), 
3.96-3.92 (m, 1H), 3.58 (s, 2H), 3.51 (dd, 1H, J = 4.0, 11.0 Hz), 3.43 (dd, 1H, J = 6.5, 11.0 Hz) 
3.17 (s, 2H), 2.90 (dd, 1H, J = 5.5, 13.5 Hz), 2.74 (dd, 1H, J = 7.5, 13.5 Hz), 2.59 (br s, 4H), 
2.51 (br s, 4H). 
13
C-NMR (125 MHz, (CD3)2CO) δ 166.5, 157.3, 150.7, 144.0, 143.8, 134.2, 
129.9, 129.9, 127.6, 126.8, 119.7, 118.4, 72.4, 66.8, 62.6, 61.6, 54.2, 53.5, 34.8. HRMS (ESI): 
506.2072 (M+1); calcd. for C23H32N5O6S: 506.2073. 
2-(4-benzoylpiperazin-1-yl)-N'-(3-(2,3-dihydroxypropyl)-2-
hydroxybenzylidene)acetohydrazide (4.28) 
 
Synthesized according to General Procedure A: 4.1a (131 mg, 0.50 mmol, 1.0 equiv.), 4.2d (98 
mg, 0.50 mmol, 1.0 equiv.), 1.2 M HCl (29 μL, 0.035 mmol, 0.070 equiv.), EtOH (3 mL, 0.15 
M). Purification by silica gel column chromatography (gradient, 0-20% MeOH/EtOAc) yielded 
4.28 (121 mg, 55.0%) as a white solid. 
1
H-NMR (500 MHz, (CD3)2CO) δ 11.86 (br s, 1H), 10.93 
(br s, 1H), 8.47 (s, 1H), 7.44-7.39 (m, 5H), 7.25 (dd, 1H, J = 1.5, 7.5 Hz), 7.16 (dd, 1H, J = 1.5, 
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7.5 Hz), 6.83 (t, 1H, J = 7.5 Hz), 3.98-3.95 (m, 1H), 3.74 (br s, 2H), 3.64 (br s, 2H), 3.52-3.49 
(m, 1H), 3.44-3.41 (m, 1H), 3.24 (s, 2H), 2.92 (dd, 2H, J = 6.0, 13.0 Hz), 2.74 (dd, 2H, J = 7.5, 
13.0 Hz), 2.63 (br s, 4H). 
13
C-NMR (125 MHz, (CD3)2CO) δ 170.2, 166.2, 157.3, 150.8, 137.3, 
134.2, 130.3, 129.9, 129.2, 127.9, 127.6, 119.7, 118.3, 72.4, 66.8, 61.4, 54.1 (br), 48.2 (br), 42.5 
(br), 34.8. HRMS (ESI): 441.2143 (M+1); calcd. for C23H29N4O5: 441.2138. 
2-(4-(4-cyanobenzyl)piperazin-1-yl)-N'-(3-(2,3-dihydroxypropyl)-2-
hydroxybenzylidene)acetohydrazide (4.29) 
 
Synthesized according to General Procedure A: 4.1b (273 mg, 1.0 mmol, 1.0 equiv.), 4.2d (196 
mg, 1.0 mmol, 1.0 equiv.), 1.2 M HCl (58 μL, 0.070 mmol, 0.070 equiv.), EtOH (7 mL, 0.15 M). 
Purification by silica gel column chromatography (gradient, 0-20% MeOH/EtOAc) yielded 4.29 
(391 mg, 86.5%) as a light yellow solid. 
1
H-NMR (500 MHz, CDCl3) δ 11.45 (br s, 1H), 10.23 
(br s, 1H), 8.31 (s, 1H), 7.59 (d, 2H, J = 8.5 Hz), 7.43 (d, 1H, J = 8.0 Hz), 7.17 (dd, 1H, J = 1.0, 
7.5 Hz), 7.08 (dd, 1H, J = 1.0, 7.5 Hz), 6.81 (t, 1H, J = 7.5 Hz), 3.99-3.94 (m, 1H), 3.59 (dd, 1H, 
J = 3.5, 11.5 Hz), 3.56 (s, 2H), 3.47 (dd, 1H, J = 6.0, 11.5 Hz) 3.18 (s, 2H), 2.87 (dd, 1H, J = 6.0, 
14.0 Hz), 2.82 (dd, 1H, J = 7.0, 13.5 Hz), 2.61 (br s, 4H), 2.50 (br s, 4H). 
13
C-NMR (125 MHz, 
CDCl3) δ 166.2, 156.5, 151.0, 143.9, 134.0, 132.3, 129.8, 129.6, 126.3, 119.7, 119.1, 117.2, 
111.1, 72.3, 66.0, 62.4, 61.0, 53.7, 53.1, 34.1. HRMS (ESI): 452.2296 (M+1); calcd. for 
C24H30N5O4: 452.2298. 
2-(4-(4-cyanobenzoyl)piperazin-1-yl)-N'-(3-(2,3-dihydroxypropyl)-2-
hydroxybenzylidene)acetohydrazide (4.30) 
 
Synthesized according to General Procedure A: 4.1c (287 mg, 1.0 mmol, 1.0 equiv.), 4.2d (196 
mg, 1.0 mmol, 1.0 equiv.), 1.2 M HCl (58 μL, 0.070 mmol, 0.070 equiv.), EtOH (7 mL, 0.15 M). 
Purification by silica gel column chromatography (gradient, 0-20% MeOH/EtOAc) yielded 4.30 
(341 mg, 73.4%) as a light yellow solid. 
1
H-NMR (500 MHz, (CD3)2CO) δ 11.85 (br s, 1H), 
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10.95 (br s, 1H), 8.47 (s, 1H), 7.85 (d, 2H, J = 8.0 Hz), 7.61 (d, 2H, J = 8.5 Hz), 7.25 (d, 1H, J = 
7.5 Hz), 7.15 (dd, 1H, J = 1.5, 7.5 Hz), 6.82 (t, 1H, J = 7.5 Hz), 3.96-3.92 (m, 1H,), 3.78 (br s, 
2H), 3.52-3.41 (m, 4H, CH2-N), 3.25 (s, 2H), 2.90 (dd, 1H, J = 6.0, 13.5 Hz), 2.74 (dd, 1H, J = 
7.0, 13.5 Hz), 2.68 (br s, 2H), 2.61 (br s, 2H). 
13
C-NMR (125 MHz, (CD3)2CO) δ 168.5, 166.2, 
157.3, 150.8, 141.6, 134.2, 133.2, 129.9, 128.8, 127.6, 119.7, 118.8, 118.3 113.8, 72.4, 66.8, 
61.3, 54.1 (br), 53.6 (br), 48.1 (br), 42.5 (br), 34.8. HRMS (ESI): 466.2088 (M+1); calcd. for 
C24H28N5O5: 466.2090. 
2-(4-(2,6-dichlorobenzyl)piperazin-1-yl)-N'-(3-(2,3-dihydroxypropyl)-2-
hydroxybenzylidene)acetohydrazide (4.31) 
 
Synthesized according to General Procedure A: 4.1d (159 mg, 0.50 mmol, 1.0 equiv.), 4.2d (98 
mg, 0.50 mmol, 1.0 equiv.), 1.2 M HCl (29 μL, 0.035 mmol, 0.070 equiv.), EtOH (3 mL, 0.15 
M). Purification by silica gel column chromatography (gradient, 0-20% MeOH/EtOAc) yielded 
4.31 (225 mg, 90.6%) as a light yellow solid. 
1
H-NMR (500 MHz, CDCl3) δ 11.47 (br s, 1H), 
10.24 (br s, 1H), 8.34 (s, 1H), 7.29 (d, 2H, J = 8.0 Hz), 7.19 (dd, 1H, J = 1.5, 7.5 Hz), 7.14 (t, 
1H, J = 8.0 Hz), 7.10 (dd, 1H, J = 1.5, 7.5 Hz), 6.83 (t, 1H, J = 7.5 Hz), 3.99-3.95 (m, 1H), 3.76 
(s, 2H), 3.60 (dd, 1H, J = 3.5, 11.5 Hz), 3.48 (dd, 1H, J = 6.0, 11.5 Hz) 3.16 (s, 2H), 2.90 (dd, 
1H, J = 6.0, 13.5 Hz), 2.84 (dd, 1H, J = 7.0, 13.5 Hz), 2.64 (br s, 4H), 2.57 (br s, 4H). 
13
C-NMR 
(125 MHz, CDCl3) δ 166.3, 156.6, 151.0, 137.1, 134.1, 134.0, 129.8, 129.2, 128.6, 126.3, 119.7, 
117.3, 72.3, 66.0, 61.0, 56.4, 53.9, 53.0, 34.2. HRMS (ESI): 495.1563 (M+1); calcd. for 
C23H29Cl2N4O4: 495.1566. 
 
4.9.2. Biological evaluation 
Materials All reagents were obtained from Fisher unless otherwise indicated. All buffers 
were made with MilliQ purified water. Annexin V Binding Buffer contains 10 mM HEPES (pH 
7.4), 140 mM NaCl, 2.5 mM CaCl2. Bifunctional cell lysis/caspase activity buffer contains 200 
mM HEPES (pH 7.4), 400 mM NaCl, 40 mM DTT, 0.4 mM EDTA disodium salt dihydrate, 1% 
Triton-X-100, and 20 μM Ac-DEVD-AFC (Enzo Life Sciences). 
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Liver Microsome Stability Assay A mixture of 0.1 M potassium phosphate buffer pH 7.4, 
NADP
+
 (final concentration 1.3 mM), MgCl2 (final concentration 3.3 mM), glucose-6-phosphate 
(final concentration 3.3 mM), glucose-6-phosphate dehydrogenase (final concentration 0.4 
U/mL), and a 10 mM solution of compound in DMSO (final concentration 10 μM; 0.1% DMSO) 
was incubated at 37°C in a shaking incubator for 5 min. The reactions were initiated by the 
addition of ice-cold liver microsomes (final protein concentration 1 mg/mL), to bring the total 
volume to 1 mL. A 450 μL aliquot was immediately removed, quenched with 450 μL of a 10 μM 
solution of B-PAC-1
8, 25
 in MeCN, mixed by inversion, and centrifuged at 10,000 x g for 3 min. 
750 μL of the supernatant was removed for LC/MS analysis. The reactions were incubated at 
37°C in a shaking incubator for 3 h. A second 450 μL aliquot was removed, quenched with 450 
μL of a 10 μM solution of B-PAC-1 in MeCN, mixed by inversion, and centrifuged at 10,000 x g 
for 3 min. 750 μL of the supernatant was removed for LC/MS analysis. Samples from the liver 
microsome assay were analyzed by LC/MS using an Agilent 1200 HPLC with DAD (monitoring 
at 280 nm) and an Agilent 6230 TOF MS, with an Agilent C18 column, 3.0 x 50 mm. Mobile 
phase A was 0.1% HCO2H in H2O, B was 0.1% HCO2H in MeCN. A gradient was run from 5-
50% B over 18 min, then 50-95% B for 2 min, then constant 95% B for 4 min, then 95-5% B for 
1 min, then constant 5% B for 2 min. The ratio of the areas of analyte:internal standard at 3 hours 
was compared to the ratio at 0 hours to determine the percent compound remaining after 3 hours. 
 
Cell Culture U-937, Jurkat, and EL4 cells were obtained from the American Type Culture 
Collection. GL-1 cells were provided by Dr. Steve Suter (North Carolina State University, 
Raleigh, NC).  All cultures were maintained at low passage number in RPMI 1640 supplemented 
with 10% fetal bovine serum and 1% penicillin-streptomycin and grown at 37°C and 5% CO2. 
 
72hr IC50 Cell Death Assay To each inner well of a 96-well plate was added 49 μL of RPMI 
1640 complete growth media. To each inner well was added 1 µL of compound stock solutions 
in DMSO at nine concentrations such that the cells were treated with half-log concentrations 
between 0.01 µM and 100 µM compound. 50 μL of a suspension of cells at 300,000 cells/mL 
(for U-937, EL4, GL-1, and OSW cells) or 500,000 cells/mL (for Jurkat cells) were plated into 
the wells, for a final density of 15,000 or 25,000 cells per well, respectively. Each concentration 
was tested in triplicate per plate. In each plate 3 wells received 1 μL of a positive death control 
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and 3 wells received 1 μL DMSO as a live cell vehicle control. The outer wells were filled with 
sterile PBS pH 7.4 (100 or 200 µL), and the plates were then incubated at 37°C with 5% CO2 for 
72 hours.  After the 72 hour incubation period, the plates were analyzed using a Sulforhodamine 
B assay.
28
 Specifically, to each well of the plate 25 µL of a 50% (w/v) solution of trichloroacetic 
acid in H2O was added and the plates were incubated for 4 hours at 4°C. The plates were then 
washed gently with H2O five times. The plates were allowed to air dry after which 100 µL of a 
0.057% (w/v) Sulforhodamine B in a 1% (v/v) acetic acid solution was added to each well for 30 
minutes at room temperature. The plates were gently washed 5 times with 1% (v/v) acetic acid 
and air dried. 200 µL of 10 mM Tris base (pH 10.4) was added to each well and the plates were 
placed on a shaker for thirty minutes. For U-937 cells, the level of SRB was quantified 
fluorometrically (ex. 488 nm, em. 585 nm) on a Gemini EM Microplate Reader (Molecular 
Devices) plate reader. For all other cell lines, the level of SRB was quantified by absorbance at 
510 nm on a SpectraMax Plus 384 Microplate Reader (Molecular Devices). The percent cell 
death was calculated and normalized to the positive control (100% cell death) and the negative 
control (0% cell death). The percent cell death was averaged for each compound concentration 
and plotted as a function of compound concentration. The data were fit to a logistical dose 
response curve using TableCurve 2D and the IC50 value was calculated. The experiment was 
repeated three times and the average of the calculated IC50 values was reported. The standard 
error of the mean (s.e.m.) was determined and reported for the triplicate experiments.  
 
Induction of Apoptosis by Hit Compounds To each well of a 24-well plate for compound 
treatment was added 490 μL of RPMI-1640 complete growth media. To each well was then 
added 10 µL of 5 mM DMSO solutions to achieve a final compound concentration of 50 μM. 10 
µL of DMSO was added to one well as a live cell vehicle control. 500 μL of a suspension of cells 
at 1.2 x 10
6
 cells/mL were plated into the wells, for a final density of 600,000 cells per well. 
Wells not containing compounds were filled with 1 mL RPMI-1640 complete growth media, and 
spaces between wells were filled with 1 mL sterile PBS. The cells were incubated at 37 ºC with 
5% CO2 for 12 hours. The cells were harvested via centrifugation (200 x g for 5 min), washed 
with PBS (2 mL), and resuspended in 450 μL Annexin V Binding Buffer containing 3.5 μL of 
FITC-conjugated Annexin V stain (Southern Biotech) and 2.25 μL of a 1 mg/mL solution of 
propidium iodide (Sigma) to a final concentration of 5 μg/mL. Samples were stored on ice until 
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assessment. Cell populations were analyzed on a Becton Dickinson LSR II cell flow cytometer. 
10,000 events per sample were recorded. 
 
EGTA Fluorescence Titration Assay  This titration assay is based on a published 
protocol.
23
 Buffer (50 mM HEPES, 100 mM KNO3, 8.1 mM EGTA, pH 7.2) and solutions of 
compounds (1 mM in DMSO) and Zn(OTf)2 (100 µM-1 M in H2O) were prepared. The 
compound solutions were diluted ten-fold with buffer (final [compound] = 100 µM, final 
[EGTA] = 7.3 mM), and 198 µL of the resulting solution was added to each well of a 96-well 
plate. Each of 24 Zn(OTf)2 solutions was added to four wells in each plate. The wells were 
allowed to equilibrate for 5 minutes, and the plates were analyzed via a Molecular Devices 
SpectraMax M3 fluorescent plate reader (ex. 410 nm, em. 475 nm). Fluorescence intensity at 475 
nm of each of four technical replicates was plotted against free Zn
2+
 concentration ([Zn
2+
]F), 
calculated using the MaxChelator program (maxchelator.stanford.edu). The data were analyzed 
using OriginPro 9.1 and fitted to a formation curve based on Equation 4.1:
23
 
 
I = (IminKd + Imax[Zn
2+
]F)/(Kd + [Zn
2+
]F)  (Equation 4.1) 
 
where Imin and Imax were defined as the fluorescence intensity of the free probe (PAC-1 or 
derivative) and that of the Zn
2+
-probe complex, respectively. 
 
Caspase Activity in Cell Lysate To each inner well of two 96-well plates was added 100 μL 
of a suspension of U-937 cells in phenol red-free RPMI-1640 complete growth media at 500,000 
cells/mL (50,000 cells/well). Inner wells without compound were filled with 200 μL of media, 
and outer wells were filled with 200 μL of sterile PBS. The plates were incubated at 37°C with 
5% CO2 for 15 hours. Solutions of compounds (PAC-1, S-PAC-1, 4.33, 4.51, 4.53, 4.62, PAC-
1a, staurosporine, or DMSO alone) in media were prepared at 3x final concentrations (3% 
DMSO), and 50 μL of each solution was added to the appropriate wells. Each compound was 
tested in six wells per plate. In the first plate, 50 μL of bifunctional cell lysis/caspase activity 
buffer was added to each treatment well. Fluorescence (ex. 400 nm, em. 505 nm) was monitored 
on an Analyst AD 96-384 plate reader via a 60-minute kinetic read, and the slope was used to 
determine caspase activity. The second plate was incubated at 37°C with 5% CO2 for 16 hours, at 
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which time 50 μL of bifunctional cell lysis/caspase activity buffer was added to each treatment 
well, and fluorescence was monitored as above. The slopes at 16 hours were normalized to the 
slopes of each compound at 0 hours (0% activity) and the staurosporine-treated samples at 16 
hours (100% activity) to give percent caspase activity. 
 
Evaluation of Compound Tolerability in vivo. All experimental procedures were reviewed 
and approved by the University of Illinois Institutional Animal Care and Use Committee. 8-10 
week old C57BL/6 mice were used in all experiments (Charles River). Mice (n = 3/cohort) were 
evaluated for their ability to tolerate a single 200 mg/kg intraperitoneal dosage of compounds, 
formulated at 5 mg/mL in 200 mg/mL hydroxypropyl-β-cyclodextrin (HPβCD) at pH 5.5. Mice 
were treated and observed for clinical signs over 24 hours; specifically, they were observed 
continuously for the first hour, then at hours 2, 4, 6, 8, 12 and 24 hours post-treatment. Mice 
were further allowed 1 week to demonstrate delayed effects of treatment. Toxicity was classified 
as inducing either an ‘excitatory’ or a ‘depressive’ phenotype. The extent of response was graded 
from mild to severe. 
 
Pharmacokinetics of PAC-1 and Derivatives in Mice. Compounds were formulated at 5 mg/mL 
in 200 mg/mL HPβCD at pH 5.5. C57BL/6 mice (n = 2 per cohort per time point) were treated 
with a 25 mg/kg dose of PAC-1 or derivative via tail vein injection or oral gavage. At specified 
time points, mice were sacrificed and blood was collected, centrifuged, and the EDTA plasma 
was frozen at -80°C until analysis. 
 
Assessment of serum concentrations of PAC-1 and derivatives. 2 μL of a 10 μg/mL solution of 
internal standard in 60:40 methanol:water (PAC-1 was used as an internal standard for analysis 
of S-PAC-1; S-PAC-1 was used as an internal standard for analysis of all other compounds) was 
added to a 10 μL aliquot of serum. The proteins were precipitated by the addition of methanol 
(100 μL). The sample was mixed by vortex and centrifuged to remove the proteins. The resulting 
supernatant was evaporated to complete dryness with a SpeedVac. The dried solid was then 
reconstituted in 100 μL 60:40 methanol:water, followed by centrifugation.  The 
supernatant was subject to instrument injection. Samples were analyzed with the 5500 QTRAP 
LC/MS/MS system (AB Sciex, Foster City, CA) in the Metabolomics Lab of the Roy J. Carver 
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Biotechnology Center, University of Illinois at Urbana-Champaign.  The 1200 series HPLC 
system (Agilent Technologies, Santa Clara, CA) includes a degasser, an autosampler, and a 
binary pump. The LC separation was performed on a Phenomenex 4u Polar-RP 80A column (4.6 
x 100mm, 4μm, Torrance, CA) with mobile phase A (0.1% formic acid in water) and mobile 
phase B (methanol). The flow rate was 0.8 mL/min. The linear gradient was as follows: 0-1 min, 
0% B; 5 min, 70% B; 7.5-10.5 min, 100% B; 10.6-15 min, 0% B. The autosampler was set at 
5°C. The injection volume was 2 μL. Mass spectra were acquired under negative electrospray 
ionization (ESI) with the ion spray voltage of -4500 V. The source temperature was 600°C. The 
curtain gas, ion source gas 1, and ion source gas 2 were 35, 50, and 65, respectively. Multiple 
reaction monitoring (MRM) was used for quantitation: PAC-1: m/z 391.1-->m/z 232.0; S-PAC-
1: m/z 470.2-->m/z 311.1; compound 7: m/z 423.1-->m/z 264.1; compound 30: m/z 423.1-->m/z 
246.1; compound 32: m/z 448.1-->m/z 271.1; compound 41: m/z 450.1-->m/z 271.1.  
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4.9.3. Spectra 
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Chapter 5. Investigation of Neurotoxicity Induced by PAC-1 
 
Cell culture evaluation was performed in collaboration with Jessie Peh. Initial animal 
experiments were performed by Dr. Quinn P. Peterson. The second set of animal experiments 
was performed by Prof. Timothy M. Fan and Rachel C. Botham. 
 
5.1. PAC-1 neurotoxicity is most likely not mechanism-based 
 As discussed in Chapter 1, neurotoxicity was observed in early animal studies when 
PAC-1 was dosed at high levels. Animals treated with PAC-1 experienced reversible 
neuroexcitatory symptoms at doses as low as 20 mg/kg via i.v. injection, and symptoms 
increased in severity with increasing doses.
1
 The biochemical basis of this toxicity was not well 
understood, but it was hypothesized that PAC-1 crosses the blood-brain barrier (BBB) and 
chelates inhibitory zinc from NMDA receptors within the central nervous system (CNS);
1
 
structurally unrelated zinc chelators have been shown to elicit neurological responses similar to 
those observed upon treatment with PAC-1.
2, 3
 Initial attempts toward developing a non-
neurotoxic PAC-1 derivative involved the design of compounds that would not cross the BBB; 
these efforts produced S-PAC-1, as discussed in Chapter 1.
1
 Less than 1% of the total dose of S-
PAC-1 administered to mice enters the brain,
4
 as the highly polar sulfonamide group prevents 
the compound from crossing the BBB. 
 While initial results with S-PAC-1 were promising, recent studies have demonstrated the 
potential for PAC-1 to be used to treat brain tumors,
5
 making a BBB-permeable PAC-1 
derivative desirable, especially if a non-neurotoxic derivative could be developed. One method 
discovered to attenuate the neurological symptoms of PAC-1 was oral administration of 
compound.
5
 Both the peak plasma concentration and the area under the concentration-time curve 
decrease upon oral administration as compared to i.v. or i.p. injections, indicating decreases to 
both the maximum amount of compound in the brain as well as the total exposure; a slower 
uptake of compound into the bloodstream is also observed for oral administration as compared to 
i.v. or i.p. injections. However, the potential for adverse events still exists, and if the toxicity is 
not related to zinc chelation, it would be most desirable to have a BBB-permeable PAC-1 
derivative that is incapable of producing a neurological response. In order to understand 
determine whether the toxicity is mechanism-based, an experiment was designed in which mice 
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were treated with PAC-1 or inactive derivatives PAC-1a (1.3), which lacks the allyl and 
hydroxyl groups of PAC-1, and the methyl ether of PAC-1, O-Me-PAC-1 (1.11h). Upon 
treatment, mice were monitored for neurological symptoms. Synthetic routes toward the 
compounds are shown in Scheme 5.1. Condensation of hydrazide 1.6 with benzaldehyde (5.1) 
gave PAC-1a. Methylation of the phenol of 2.1 gave aldehyde 5.2, and condensation of this 
aldehyde with hydrazide 1.6 gave O-Me-PAC-1. 
 
 
Scheme 5.1. Synthesis of inactive derivatives of PAC-1 used in initial neurotoxicity study. 
 
 PAC-1, PAC-1a, and O-Me-PAC-1 were formulated at 10 mg/mL in 200 mg/mL 
aqueous 2-hydroxypropyl-β-cyclodextrin (HPβCD) and dosed at 180 mg/kg via i.p. injection, a 
dose at which PAC-1 elicits a strong neuroexcitatory response. Mice treated with PAC-1, PAC-
1a, and O-Me-PAC-1 were indistinguishable between treatment groups; all mice experienced 
severe seizures from the treatment. Given that the derivatives that do not bind zinc lead to the 
same phenotype in vivo, it is likely that the toxicity observed with PAC-1 is not mechanism-
based, and that it is related to a different property of the molecule. Therefore, if the portion 
responsible for the toxicity can be determined, it may be possible to design a non-neurotoxic, 
BBB-permeable PAC-1 derivative for the treatment of brain tumors. 
 The study described herein represents an attempt to further define the functional groups 
responsible for PAC-1-induced neurotoxicity. A series of compounds with minor modifications 
to PAC-1 was designed and synthesized. The compounds were evaluated in vitro and in cell 
culture to confirm and expand upon previously determined structure-activity relationships. 
Finally, the neurological phenotypes induced by compounds were evaluated in mice. 
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5.2. Compound design and synthesis 
 In order to further determine the portion of the molecule responsible for neurotoxicity, a 
series of compounds was designed that contained minimal modifications to the PAC-1 structure 
(Figure 5.1). The compounds were designed either with an intact ortho-hydroxy-N-
acylhydrazone (Figure 5.1B) or with modifications to the ortho-hydroxy-N-acylhydrazone 
(Figure 5.1C). Compound modifications compared to PAC-1 are highlighted in red; for 
reference, PAC-1 is shown in Figure 5.1A. Modifications to portions other than the ortho-
hydroxy-N-acylhydrazone include removal of the allyl group (1.2), reduction (5.3) or removal 
(5.4) of the phenyl group, removal of one (5.5) or both (5.6) of the methylene groups adjacent to 
the piperazine, and removal of the benzylpiperazine (5.7) or the piperazine (5.8). Modifications 
to the ortho-hydroxy-N-acylhydrazone include removal of the allyl and hydroxyl (1.3), 
methylation of the hydroxyl (1.11h), removal of the group entirely (5.9), removal (1.17b) or 
reduction (1.19) of the hydrazone, and changing the benzylidene to an isopropylidene (5.10). 
Previous studies of the structure-activity relationships (SAR)
6
 suggest that the compounds in 
Figure 5.1C should be inactive, while the structures in 5.1B should maintain activity, although 
some may be less potent than PAC-1. 
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Figure 5.1. Structures of compounds used to evaluate neurotoxicty. A. PAC-1. B. PAC-1 
derivatives with intact ortho-hydroxy-N-acylhydrazone. C. PAC-1 derivatives with modified 
ortho-hydroxy-N-acylhydrazone. Modifications to PAC-1 are highlighted in red. 
 
 Scheme 5.2 shows the synthetic routes toward compounds 5.3-5.8, each of which 
involves condensation with 3-allylsalicylaldehyde (2.1) as the last step of the synthesis. 
Synthesis of 5.3 (Scheme 5.2A) involves alkylation of monosubstituted piperazine 2.8 with 
(bromomethyl)cyclohexane (5.11) to form 5.12a. Similarly, formation of 5.4 and 5.5 require first 
reacting 1-methylpiperazine (5.13) and 1-phenylpiperazine (3.5{30}), respectively, with ethyl 
chloroacetate, to form 5.12b and 3.6{30}. Reaction of each of these three ethyl esters with 
hydrazine monohydrate gives hydrazides 5.14a, 5.14b, and 3.1{30}. Condensation of each 
hydrazide with aldehyde 2.1 gives the desired PAC-1 derivatives 5.3-5.5. Synthesis of 
semicarbazone 5.6 (Scheme 5.2B) begins with the reaction of 3.5{30} with 1,1’-
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carbonyldiimidazole (5.15) to form urea 5.16. This compound is then methylated, and reaction 
with hydrazine monohydrate gives the semicarbazide. Condensation of the crude material with 
2.1 gives semicarbazone 5.6. Compounds 5.7 and 5.8 (Scheme 5.2C) were synthesized by the 
condensation of 2.1 commercially available hydrazides 5.14c and 5.14d, respectively. 
 
 
Scheme 5.2. Synthesis of A. 5.3-5.5, B. 5.6, and C. 5.7-5.8. 
 
 Synthetic routes toward 1.2, 5.8, 5.9, 1.17b, and 1.19, which do not require reaction with 
2.1, are shown in Scheme 5.3. Condensation of hydrazide 1.6 with salicylaldehyde (2.4) or 
acetone (5.17) gives 1.2 and 5.10, respectively (Scheme 5.3A). Alkylation of 5.13 with benzyl 
chloride (2.1) gives compound 5.9 (Scheme 5.3B). Synthesis of 1.17b (Scheme 5.3C) begins 
with the lithium aluminum hydride-mediated reduction of nitrostyrene 5.18 to form 
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phenethylamine 5.19. Acylation of the amine with chloroacetyl chloride (5.20) under Schotten-
Baumann conditions gives amide 5.21, and substitution of the chloride with 1-benzylpiperazine 
(1.10) gives 1.17b. Finally, reduction of PAC-1 with sodium borohydride gives hydrazide 1.19 
(Scheme 5.3D). 
 
 
Scheme 5.3. Synthesis of A. 1.2, 5.8, B. 5.9, C. 1.17b, and D. 1.19 
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5.3. Evaluation of PAC-1 derivatives 
 
5.3.1. Predicted blood-brain barrier permeability 
 Because the neurotoxicity induced by PAC-1 is related to its ability to cross the BBB, it 
was important to design the compounds such that the BBB permeability would not differ greatly 
from that of PAC-1. This will be most important to determine whether any compounds are false 
negatives: reductions in neurotoxicity should be due to reduced interactions with the target that 
leads to the neuroexcitation, rather than inability to cross the BBB. As discussed in Chapter 3, 
BBB permeability is frequently represented as logBB, and predicted logBB was calculated using 
Equation 3.2 (reproduced below):
7
 
 
predicted logBB = (-0.0148 x PSA) + (0.152 x AlogP) + 0.139  (Equation 3.2)
7
 
 
 The PSA and AlogP values for PAC-1 and the 13 derivatives were calculated using the 
Schrodinger software, and insertion of these values into Equation 3.2 gave the predicted logBB 
values (Table 5.1). PAC-1 has a predicted logBB value of -0.37, which is very close to the 
experimentally determined value of -0.36.
4
 Most of the other derivatives have predicted logBB 
values between -0.17 and -0.61, which are close to the value of PAC-1. The only compound with 
a significantly different predicted logBB value (+0.32) is compound 5.9. These predictions 
suggest that BBB permeability should not be a significant variable when evaluating the 
neurotoxicity of the compounds in vivo. 
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Table 5.1. Predicted BBB permeability,
a
 cytotoxicity,
b
 and zinc affinity
c
 of PAC-1 derivatives. 
(a) Calculated using Equation 3.2:  
predicted logBB = (-0.0148 x PSA) + (0.152 x ClogP) + 0.139. 
(b) Cells treated with compounds for 72 hours. Biomass quantified by sulforhodamine B assay. 
IC50 values shown are mean ± s.e.m. (n = 3, except *n = 2). 
(c) Increasing amounts of Zn(OTf)2 added to a buffered solution of EGTA (7.3 mM) and PAC-1 
derivative (100 µM, except **10 µM). Kd was determined by comparing fluorescence intensity 
(ex. 410 nm, em. 475 nm) and free zinc concentration. N.D. = not determined (due to 
insolubility). 
 
5.3.2. Cell culture evaluation 
 With the 14 compounds in hand, the cytotoxicity to cancer cells in culture was evaluated. 
The compounds were evaluated in 72-hour experiments in D54 (human glioblastoma) cells, 
because the goal will be to use the compounds to treat brain tumors, as well as U-937 (human 
lymphoma) cells, because of the extensive use of this cell line in previous efforts with PAC-1 
and derivatives.
1, 4, 6, 8-12
 The results of these experiments are shown in Table 5.1. The potency is 
relatively consistent across the two cell lines. PAC-1 is cytotoxic with IC50 values in the single-
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digit micromolar range. Removal of the allyl group (1.2) and most modifications to the 
benzylpiperazine (5.4, 5.5, 5.7, 5.8) led to a slight decrease in potency. However, reduction of 
the phenyl (5.3) or removal of both methylene groups (5.6) gave compounds with equal or 
slightly improved potency. As expected, modification of the ortho-hydroxy-N-acylhydrazone led 
to a significant loss in potency, including several compounds that were not cytotoxic up to the 
highest concentration tested (100 µM). Compounds 5.5 and 5.8 were insoluble above 10 µM and 
were not evaluated in subsequent experiments. 
 The compounds were then evaluated further in D54 cells to determine the mode of cell 
death induced by the compounds. Cells were treated with compounds at 30 µM for 24 hours, and 
cell death was assessed by Annexin V-FITC/propidium iodide staining (Figure 5.2). Treatment 
with DMSO alone induced minimal cell death, while all cytotoxic compounds induced cell death 
via apoptosis. PAC-1 induced approximately 50% cell death under these conditions, while 
compounds 5.3 and 5.6 showed comparable potency. No derivative lacking the ortho-hydroxy-N-
acylhydrazone induced greater than 25% cell death. Compound 5.7, which lacks the 
benzylpiperazine, was minimally cytotoxic under these conditions, suggesting that this 
compound may require longer treatment times for induction of apoptosis. 
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Figure 5.2.  Annexin V-FITC/propidium iodide staining of D54 cells treated with compounds 
(30 µM) for 24 hours. Data shown are representative of three independent experiments. 
 
5.3.3. Zinc binding determination 
 In order to establish with certainty whether the observed neurotoxicity induced by PAC-1 
is due to zinc chelation, the ability of the new derivatives to bind zinc was evaluated (Table 5.1). 
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As with the compounds in Chapter 4, zinc binding was determined using an EGTA titration 
experiment.
13
 Varying concentrations of Zn(OTf)2 were added to each well of a 96-well plate 
with a HEPES-buffered solution containing EGTA and PAC-1 derivative (100 µM, except 10 
µM for compound 5.6), and the fluorescence of the complex was analyzed. PAC-1, 1.2, 5.4, 5.6, 
and 5.7 all bound zinc with affinity in the 1-2 nM range. Each of these compounds contains the 
ortho-hydroxy-N-acylhydrazone, confirming the essential nature of this group for metal binding. 
Cyclohexyl-containing compound 5.3, which also contains the ortho-hydroxy-N-acylhydrazone, 
bound zinc slightly more weakly, but still with low nanomolar affinity. Compounds 1.3, 1.11h, 
5.9, 1.17b, 1.19, and 5.10 all contain modifications to the ortho-hydroxy-N-acylhydrazone, and 
none of these compounds bound zinc at concentrations lower than 1 mM. 
 
5.3.4. Summary of structure-activity relationships 
 The experiments described above confirmed previously determined SAR for PAC-1, 
summarized in Figure 5.3. As shown previously, the ortho-hydroxy-N-acylhydrazone is required 
for zinc binding and cell culture activity. The allyl group and benzylpiperazine both improve cell 
culture potency relative to derivatives that lack these groups: PAC-1 is more potent than 1.2 (p = 
0.0008 (D54); p = 0.02 (U-937)), which lacks the allyl group, as well as 5.4 (p = 0.02 (D54); p = 
0.007 (U-937)) and 5.7 (p = 0.005 (D54); p = 0.02 (U-937)), which lack the phenyl and 
benzylpiperazine groups respectively (p-values calculated via two-tailed Student’s t-test in 
Microsoft Excel). However, the allyl group is not required for zinc binding, as demonstrated by 
the comparable zinc binding constants for PAC-1 and 1.2. It is possible that the increased 
potency in cells may be due to the increased hydrophobicity of the allyl and benzyl groups; this 
trend was observed for the hydrophobic derivatives discussed in Chapter 3.
10
 The effect of the 
benzylpiperazine moiety on zinc binding is not clear; compounds 5.4 and 5.7, which lack the 
benzyl and benzylpiperazine groups, respectively, each bind zinc with affinity comparable to that 
of PAC-1, but compound 5.3, in which the phenyl group is reduced to a cyclohexyl group, has a 
slightly lower affinity for zinc. In total, these results suggest that if the neurotoxicity is not due to 
the presence of the ortho-hydroxy-N-acylhydrazone, it may be possible to design a derivative of 
PAC-1 that is potent but not neurotoxic, thereby increasing the therapeutic window for 
anticancer efficacy. 
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Figure 5.3. Summmary of structure-activity relationships for PAC-1. 
 
5.4. Evaluation of PAC-1 derivatives in mice 
 After evaluation of the compounds in cell culture and in vitro, the 12 PAC-1 derivatives 
were evaluated in vivo to assess the induction of the neurologic phenotype. Compounds were 
formulated at 20 mM in a 200 mg/mL aqueous solution of hydroxypropyl-β-cyclodextrin 
(HPβCD), and mice were administered a dose of 150 μmol/kg via i.v. injection (150 µL 
injection). Three mice were included in each treatment group. Responses were graded on a scale 
of 0-4, with 0 indicating no effect, and 4 indicating the most significant reaction to the dose. 
PAC-1 induces rapid and severe, but transient, neuroexcitation at this dose (grade 3), and the 
mice survive, while no adverse events are observed upon treatment with HPβCD alone (grade 0). 
HPβCD and PAC-1 were used as controls, while the remaining compounds were randomized, 
and the identities of the compounds were not known to the experimenters during the experiment. 
 Table 5.2 shows the graded responses to compounds, along with a brief description of 
symptoms. Predicted logBB values, initially presented in Table 5.1, are reproduced in Table 5.2. 
All responses were initially apparent within the first minute of treatment, although symptoms 
slowly increased in intensity in response to some of the compounds. Responses were identical 
among the three mice for all treatment groups. Several compounds induced neurotoxicity to a 
greater extent than PAC-1, including methyl ether 1.11h and reduced derivative 1.19, while 
semicarbazone 5.6 induced neuroexcitation to the same extent as PAC-1. Cyclohexyl-containing 
compound 5.3 was more neurotoxic than PAC-1, and the dose was lethal to two of the three 
treated mice within 24 hours. Responses to compounds 1.2 (lacking the allyl group), 5.7 (lacking 
the benzylpiperazine), 1.17b (changing the hydrazone to an ethylene linker), and PAC-1a (1.3, 
lacking the allyl and hydroxyl groups) were less severe than responses to PAC-1. Mice treated 
ortho-hydroxy-N-acylhydrazone
required for activity
allyl group improves 
cell culture potency,
not required for zinc 
binding
benzylpiperazine has 
slight positive effect on 
cell culture potency; 
effect on zinc binding 
unclear
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with compounds 5.4 (lacking the phenyl group), 5.9 (lacking the ortho-hydroxy-N-
acylhydrazone), and 5.10 (isopropylidene hydrazone) were asymptomatic following treatment. 
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Table 5.2. Responses to treatment with PAC-1 derivatives. Compounds were formulated at 20 
mM in 200 mg/mL aqueous HPβCD and administered to C57BL/6 mice at 150 μmol/kg via i.v. 
injection (150 µL, n = 3 per compound). Responses are graded on a scale of 0 (no effect) to 4 
(most severe toxicity). Predicted logBB values are also provided. 
compound murine toxicity
Predicted
logBB
HPβCD 0
No effect
N/A
PAC-1
3
Seizure (mild at first, escalating), rapid 
breathing, hind limbs splayed
-0.37
1.11h
4
Immediate seizure, rapid breathing (more 
severe than PAC-1)
-0.17
1.19
4
Immediate seizure, rapid breathing (more 
severe than PAC-1)
-0.44
5.3
4
Immediate seizure, rapid breathing (more 
severe than PAC-1); lethal to 2/3 mice
-0.28
5.6
3
Delayed onset of symptoms from PAC-1.  
Wobbly, rapid breathing, escalating from 
minor seizures to full seizures.  
-0.21
1.17b
2
Wobbly (still active and mobile), slightly 
sedative
-0.30
1.2
1
A little wobbly (still active and mobile)
-0.52
1.3
1
A little wobbly (still active and mobile)
-0.18
5.7
1
A little wobbly (still active and mobile)
-0.51
5.4
0
Asymptomatic
-0.61
5.9
0
Possibly a little hyper or a little wobbly, but 
highly asymptomatic
+0.32
5.10
0
Asymptomatic
-0.46
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 While few general trends were observed for structural features that induce neurotoxicity, 
this experiment appears to confirm previously determined results, in that neurotoxicity is most 
likely not related to zinc affinity. This is most evident for compounds 5.4, which chelates zinc 
but is not neuroexcitatory, and 1.19, which does not bind zinc but induced neurotoxicity more 
severe than that induced by PAC-1. It is possible that the improved tolerability of compound 5.4 
as compared to PAC-1 is due to decreased BBB permeability; further experiments are necessary 
to determine whether compound 5.4 is well tolerated because it does not enter the brain, or 
because it does not interact with the biological macromolecule(s) responsible for induction of 
neuroexcitation. Of note, these experiments do not eliminate the possibility that the ortho-
hydroxy-N-acylhydrazone or a smaller fragment thereof is responsible for neuroexcitation; it is 
possible that this portion of the molecule interacts with a biological macromolecule in the brain, 
but it is unlikely that the mechanism of neurotoxicity involves binding of zinc by this motif. 
 Compound 5.6, which showed favorable activity in cell culture and in vitro, may also be 
of interest. The predicted BBB permeability (predicted 38:62 brain:blood) is higher than that of 
PAC-1 (experimentally 30:70 brain:blood), but the neurological response was comparable, and 
perhaps slightly lessened. It will be important to confirm that 5.6 is more BBB permeable than 
PAC-1. If a higher concentration of compound 5.6 is present in the brain than PAC-1 after 
administration of equivalent doses, this may indicate the potential for improved efficacy in 
animal studies of brain tumors, as a higher dose would reach the site of the tumor, but 
neurological symptoms would not increase in severity. This may also be useful in the design of 
new derivatives that would be better tolerated. 
 
5.5 Comparison of PAC-1 derivatives 
 In the preceding chapters, the design, synthesis, and evaluation of a wide variety of PAC-
1 derivatives have been discussed. Detailed experiments have been performed for many of these 
compounds in order to elucidate mechanism of action and possible in vivo anticancer efficacy. A 
comparison of favorable and unfavorable characteristics, as well as unknown aspects of the 
compounds that merit further study, is presented in Table 5.3. 
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Table 5.3. Comparison of PAC-1 derivatives. 
 
 PAC-1 has been studied extensively; cell culture and in vivo anticancer efficacy have 
been promising,
8
 and the initial efficacy studies combined with the demonstrated BBB 
Compound Favorable 
Characteristics
Unfavorable/
Unknown 
Characteristics
PAC-1
• Anticancer efficacy
• BBB permeable
• Rapid clearance
• Neurotoxicity at 
elevated doses
S-PAC-1
• Well tolerated in mice 
and dogs
• BBB impermeable
• Potential for efficacy
• Rapid clearance
• Efficacy may be lower 
than PAC-1
WF-208/WF-210
• Efficacy in cell culture 
and in vivo
• Selectivity for cancer 
cell death in culture
• Large size
• BBB permeability
unknown
• Pharmacokinetics
unknown
B-PAC-1
• Potency in cell culture
• Selectivity for cancer 
cell death in culture
• Favorable 
pharmacokinetics
• Expanded cancer type 
scope unknown
• Anticancer efficacy in 
vivo unknown
4.62
• Potency similar to 
PAC-1
• Favorable 
pharmacokinetics
• Expanded cancer type 
scope unknown
• Anticancer efficacy in 
vivo unknown
5.6
• Potency in cell culture 
and in vitro
• Safety similar to PAC-
1, but possible higher 
BBB permeability
• Neurotoxicity still 
exists
• BBB permeabilitty
unknown
• Anticancer efficacy in 
vivo unknown
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permeability
4
 suggest the potential for the treatment of CNS cancers.
5
 However, rapid clearance 
from circulation in mice
14
 necessitates the administration of relatively large doses, and the 
observed neurotoxicity
1
 may prove to be unacceptable at therapeutically relevant doses. Further, 
if the PAC-1 mechanism of action proves to be unsuccessful in treating CNS tumors, and other 
cancer types are pursued, it is most likely that a cytotoxic agent entering the brain would lead to 
adverse side effects, in addition to the observed neuroexcitation, and a BBB-impermeable agent 
would be most favorable. 
 With the goal of identifying a BBB-impermeable PAC-1 derivative, S-PAC-1, 
containing a highly polar sulfonamide group, was designed.
1
 In vivo evaluation demonstrated 
that the sulfonamide successfully prevented entry into the brain,
4
 and the compound showed 
promise in a Phase 1 clinical trial in canine lymphoma patients.
1
 However, S-PAC-1 is also 
rapidly cleared from the body, which required a challenging continuous infusion strategy for 
administration to patients.
1
 It is possible that oral administration may give favorable 
pharmacokinetics, although this has not been investigated. In addition, further experiments have 
demonstrated that S-PAC-1 may show decreased efficacy in vivo as compared to PAC-1, and 
toxicity has been observed at doses necessary to elicit a therapeutic effect. 
 Gong, Wu, and coworkers identified WF-208 and WF-210 as highly potent PAC-1 
derivatives in cell culture across a wide variety of cell lines, and with considerably higher 
potency in cancer cells compared to non-cancerous cell lines. Extensive studies of PAC-1 and 
these two derivatives demonstrated the necessity for procaspase-3 on the mechanism of action 
and showed that apoptosis occurs via a non-canonical pathway, with procaspase-3 activation 
prior to cleavage of initiator procaspases-8 or -9. Both compounds showed anticancer efficacy in 
various mouse xenograft models, and both were reported to be well tolerated by mice.
15, 16
 The 
initial studies demonstrate the promise for these two compounds as anticancer agents. However, 
the compounds are both much larger than typical small molecule drugs, with molecular weights 
of approximately 800, which may have detrimental effects on pharmacokinetics and 
bioavailability. Pharmacokinetic evaluation of these two compounds has not been reported, and it 
will be necessary to determine the pharmacokinetic profiles before further analysis is performed. 
WF-210 demonstrated efficacy in two tumor models upon oral administration, so it is possible 
that the bioavailability will be acceptable, although the compound appears to show improved 
efficacy upon i.v. injection as compared to oral administration. If the size of these compounds 
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prevents them from advancing further, it will be useful to determine the structural features 
responsible for the improved activity, to determine if any portion of the molecules can be 
removed without a loss in potency. In addition, it is unknown whether these compounds are BBB 
permeable, but given the large compound sizes, it is unlikely that high concentrations of these 
compounds are present in the brains of treated animals. 
 Six highly potent PAC-1 derivatives were identified from the library of 837 compounds 
discussed in Chapter 3,
10
 and B-PAC-1 was selected for further evaluation.
17
 B-PAC-1 was 
cytotoxic to primary isolates from leukemia patients in culture, and cytotoxicity was higher for 
cancer cells than healthy cells. Studies on the mechanism of action demonstrated the necessity 
for procaspase-3 and zinc, as well as the non-canonical apoptotic pathway that was observed for 
PAC-1, WF-208, and WF-210.
17
 Pharmacokinetic evaluation demonstrated the delayed 
clearance of B-PAC-1 in vivo, although these results were highly unusual, and further evaluation 
may be necessary. The advancement of B-PAC-1 has not faced significant obstacles, but further 
evaluation is necessary to determine the translational potential of the compound. B-PAC-1 is 
potent in cells derived from white blood cancers, but it is not clear whether efficacy would be 
observed in cells derived from other tumor types. In addition, because in vivo toxicity is among 
the most significant challenges in working with PAC-1, it will be necessary to confirm that B-
PAC-1 can be administered safely at therapeutically relevant doses, and anticancer efficacy in 
vivo has yet to be demonstrated for B-PAC-1. 
 As discussed in Chapter 4, a set of compounds was designed to display improved 
pharmacokinetics. Four compounds were identified with extended elimination half-lives as 
compared to PAC-1, with compound 4.62 displaying the longest half-life in mice. All four 
compounds displayed comparable potency in cell culture and improved tolerability in mice. 
Initial studies of the mechanism of action demonstrated that compounds all chelate zinc and 
induce apoptosis in cancer cells.
12
 However, as with B-PAC-1, further experiments are necessary 
to determine the translational potential for these derivatives. The compounds were only 
evaluated in cell lines derived from white blood cell cancers, and further evaluation in cells from 
diverse cancer types will be necessary to define the potential scope of these compounds as 
anticancer agents. In addition, the compounds have not yet shown anticancer efficacy in vivo. 
 Finally, a series of compounds was designed with the goal of understanding the 
neurotoxic phenotype observed in animals treated with PAC-1. Compound 5.6 was identified as 
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a potent derivative that may be more BBB permeable without increasing the degree of toxicity. 
However, the BBB permeability of the compound still remains unknown, and anticancer efficacy 
has not yet been demonstrated. In addition, the neurological symptoms are still present in 
response to treatment with compound 5.6, and it is unclear whether this degree of toxicity can be 
tolerated at therapeutically relevant doses. 
 Initial results from the PAC-1 derivatives discussed above have demonstrated therapeutic 
potential, although challenges exist for all of the compounds. To date, PAC-1 is the most 
promising compound for CNS tumors, and therapeutically relevant doses can be administered 
safely. However, the rapid clearance and observed neurotoxicity may limit the clinical utility of 
the compound; the development of a non-neurotoxic, BBB-permeable PAC-1 derivative would 
represent a significant advance. It is possible that compound 5.6 may have an improved safety 
profile, but the toxicity may still limit the utility of this compound. The most likely application 
for the other compounds discussed, including S-PAC-1, WF-208, WF-210, B-PAC-1, and 4.62, 
would be tumors not present in the CNS. S-PAC-1 was evaluated in canine lymphoma patients 
with promising initial results, although a narrow therapeutic window has limited further studies 
with the compound. B-PAC-1 and 4.62 are cytotoxic to cells derived from white blood cell 
cancers in culture, but in vivo efficacy has not yet been demonstrated. WF-208 and WF-210 
have demonstrated cytotoxicity in a wide variety of cancer cell lines in culture and have shown 
anticancer efficacy in several murine tumor models, although the large size of these compounds 
may limit their translational potential. Further evaluation of these and other agents will help to 
fully define the ability of procaspase activators to treat diverse cancers. 
 
5.6. Summary and future directions 
The flexible, modular synthesis of PAC-1 has facilitated the construction of over 1000 
PAC-1 derivatives. Many of these compounds were produced in order to improve upon the 
potency, pharmacokinetics, and tolerability of PAC-1. In order to discover a more potent 
compound, a combinatorial library of 837 derivatives was synthesized.
10
 Through this effort, six 
highly potent compounds were identified, and one compound, B-PAC-1, is currently under 
evaluation in patient-derived leukemia samples by Gandhi and coworkers at MD Anderson 
Cancer Center.
17
 In order to improve pharmacokinetics, several derivatives were synthesized 
containing modifications designed to block oxidative metabolism, and four derivatives were 
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identified with extended serum half-lives as compared to PAC-1.
12
 In order to better understand 
the neurotoxicity of PAC-1, a series of derivatives was synthesized containing small 
modifications or deletions, in order to identify functional groups responsible for induction of 
neuroexcitation. In addition, an improved process-scale synthesis of PAC-1 was developed. The 
improvements to the synthesis were general, and if an improved derivative is identified, the 
lessons learned from the PAC-1 synthesis should be applicable to most other derivatives as well. 
 The most significant challenge to be overcome for the translation of PAC-1 remains the 
neuroexcitation observed at elevated doses. The tolerability is greatly improved for many 
compounds that do not enter the brain, such as S-PAC-1, but a BBB-permeable compound will 
be necessary for treatment of tumors of the CNS, as well as the many cancer types for which 
metastases to the brain are common. The experiments described herein provide preliminary 
evidence that the ability of PAC-1 to bind zinc is most likely not responsible for the observed 
neurotoxicity in vivo. Further experiments will be necessary to confirm that reduction in 
neurotoxicity in response to certain compounds, such as compounds 5.4 and 5.10, is not due to 
reduced BBB permeability. With a greater understanding of the mechanism of PAC-1-induced 
neurotoxicity, it may be possible to design a potent, safe, BBB-permeable PAC-1 derivative, 
which would represent a significant advance in the development of procaspase-activating 
anticancer compounds. 
 
5.7. Materials and Methods 
 
5.7.1. Chemical Information 
General All reactions requiring anhydrous conditions were conducted under a positive 
atmosphere of nitrogen or argon in oven-dried glassware. Standard syringe techniques were used 
for anhydrous addition of liquids. Unless otherwise noted, all starting materials, solvents, and 
reagents were acquired from commercial suppliers and used without further purification. Flash 
chromatography was performed using 230-400 mesh silica gel. 
Compound Analysis All NMR experiments were recorded in CDCl3 (Sigma or Cambridge), 
(CD3)2CO (Sigma or Cambridge), or (CD3)2SO (Sigma or Cambridge) on a Varian Unity 500 
MHz spectrometer with residual undeuterated solvent as the internal reference for 
1
H-NMR 
(CDCl3 – 7.26 ppm; (CD3)2CO – 2.04 ppm; (CD3)2SO – 2.48 ppm) and 
13
C-NMR (CDCl3 – 
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77.23 ppm; (CD3)2CO – 29.80 ppm; (CD3)2SO – 39.50 ppm). Chemical shift, δ (ppm); coupling 
constants, J (Hz); multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, quint = quintet, 
sext = sextet, m = multiplet, br = broad); and integration are reported. High-resolution mass 
spectral data was recorded on a Micromass Q-Tof Ultima hybrid quadrupole/time-of-flight ESI 
mass spectrometer or a Micromass 70-VSE at the University of Illinois Mass Spectrometry 
Laboratory. Copies of NMR spectra for compounds not available in the literature are provided 
below. 
 
General Procedure A: Alkylation of monoalkyl piperazines. A mixture of monoalkylated 
piperazine, alkyl halide, and base in acetone or THF was stirred at reflux overnight. The reaction 
mixture was filtered, and the solid was washed with acetone. The filtrate was concentrated and 
purified by silica gel column chromatography to yield pure dialkylated piperazine. 
General Procedure B: Synthesis of hydrazides. A solution of the ester (1.0 equiv.) and hydrazine 
monohydrate (4.0 equiv.) in EtOH (0.5 M) was stirred at reflux overnight. The reaction mixture 
was cooled to room temperature and concentrated. The residue was partitioned between CH2Cl2 
(20 mL)/1:1 brine:0.1 M KOH (20 mL). The layers were separated, and the aqueous layer was 
extracted with CH2Cl2 (2 x 20 mL). The combined organic layers were dried over MgSO4, 
filtered, and concentrated to yield hydrazide, which was used without further purification. 
General Procedure C: Synthesis of hydrazones. A solution of hydrazide (1.0 equiv.), aldehyde 
(1.0-2.0 equiv.), and 1.2 M HCl (0.070 equiv.) in EtOH (0.15 M) was stirred at reflux overnight. 
The reaction mixture was cooled to room temperature, concentrated, and purified by silica gel 
column chromatography to yield the hydrazone. 
N'-benzylidene-2-(4-benzylpiperazin-1-yl)acetohydrazide (PAC-1a, 1.3) 
 
Synthesized according to General Procedure C: 1.6 (745 mg, 3.0 mmol, 1.0 equiv.), freshly 
distilled benzaldehyde (5.1, 0.31 mL, 3.0 mmol, 1.0 equiv.), 1.2 M HCl (0.18 mL, 0.21 mmol, 
0.070 equiv.), EtOH (20 mL, 0.15 M). Purification by silica gel column chromatography 
(gradient, 0-20% MeOH/EtOAc) yielded 1.3 (868 mg, 85.9%) as an off-white solid. 
1
H-NMR 
(500 MHz, CDCl3) δ 10.08 (s, 1H), 8.20 (s, 1H), 7.77-7.74 (m, 2H), 7.41-7.38 (m, 3H), 7.34-7.29 
(m, 4H), 7.29-7.24 (m, 1H), 3.55 (s, 2H), 3.19 (s, 2H), 2.63 (br s, 4H), 2.53 (br s, 4H). 
13
C-NMR 
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(125 MHz, CDCl3) δ 166.5, 148.6, 138.0, 133.7, 130.7, 129.3, 128.8, 128.5, 127.9, 127.4, 63.1, 
61.3, 53.9, 53.2. HRMS (ESI): 337.2014 (M+H)
+
; calcd. for C20H25N4O: 337.2023. 
3-allyl-2-methoxybenzaldehyde (5.2) 
 
To a round-bottom flask were added 2.1 (487 mg, 3.0 mmol, 1.0 equiv.), K2CO3 (1.24 g, 9.0 
mmol, 3.0 equiv.), and acetone (6 mL, 0.5 M). The mixture was stirred, and iodomethane (0.23 
mL, 3.6 mmol, 1.2 equiv.) was added. The reaction mixture was stirred at rt overnight. The solid 
was filtered and washed with acetone, and the filtrate was concentrated. Purification by silica gel 
column chromatography (0-5% EtOAc/hexanes) yielded 5.3 (419 mg, 79.2%) as a pale yellow 
oil. 
1
H-NMR (500 MHz, CDCl3) δ 10.38 (s, 1H), 7.73 (dd, 1H, J = 2.0, 7.5 Hz), 7.47 (dd, 1H, J = 
2.0, 7.5 Hz), 7.20 (t, 1H, J = 7.5 Hz), 5.98 (tdd, 1H, J = 6.5, 10.0, 16.5 Hz), 5.15-5.06 (m, 2H), 
3.90 (s, 3H), 3.48 (d, 2H, J = 6.5 Hz). 
13
C-NMR (125 MHz, CDCl3) δ 190.4, 161.6, 137.1, 136.6, 
134.5, 129.6, 127.5, 124.8, 116.8, 64.5, 33.4. HRMS (ESI): 177.0919 (M+H)
+
; calcd. for 
C11H13O2: 177.0916. 
N'-(3-allyl-2-methoxybenzylidene)-2-(4-benzylpiperazin-1-yl)acetohydrazide (1.11h) 
 
Synthesized according to General Procedure C: 1.6 (124 mg, 0.50 mmol, 1.0 equiv.), 5.2 (88 mg, 
0.50 mmol, 1.0 equiv.), 1.2 M HCl (29 µL, 0.035 mmol, 0.070 equiv.), EtOH (3 mL, 0.15 M). 
Purification by silica gel column chromatography (0-10% MeOH/EtOAc) yielded 1.11h (165 
mg, 81.0%) as an off-white solid. 
1
H-NMR (500 MHz, CDCl3) δ 10.12 (s, 1H), 8.44 (s, 1H), 7.95 
(dd, 1H, J = 1.5, 8.0 Hz), 7.33-7.29 (m, 4H), 7.29-7.22 (m, 2H), 7.10 (t, 1H, J = 7.5 Hz), 5.98 
(tdd, 1H, J = 6.5, 10.0, 16.5 Hz), 5.11-5.04 (m, 2H), 3.78 (s, 3H), 3.54 (s, 2H), 3.43 (d, 2H, J = 
6.5 Hz), 3.19 (s, 2H), 2.63 (br s, 4H), 2.53 (br s, 4H). 
13
C-NMR (125 MHz, CDCl3) δ 166.5, 
157.8, 144.5, 138.0, 136.9, 133.3, 133.0, 129.2, 128.4, 127.3, 126.9, 125.8, 124.7, 116.3, 63.2, 
63.0, 61.2, 53.8, 53.2, 33.7. HRMS (ESI): 403.2447 (M+H)
+
; calcd. for C24H31N4O2: 407.2442. 
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Ethyl 2-(4-(cyclohexylmethyl)piperazin-1-yl)acetate (5.12a) 
 
Synthesized according to General Procedure A: (bromomethyl)cyclohexane (5.11, 1.4 mL, 10.0 
mmol, 1.0 equiv.), 2.8 (2.58 g, 15.0 mmol, 1.5 equiv.), K2CO3 (4.15 g, 30.0 mmol, 3.0 equiv.), 
acetone (20 mL, 0.5 M). The reaction mixture was stirred at reflux for four days. Purification by 
silica gel column chromatography (50-75% EtOAc/hexanes) gave 5.12a (1.68 g, 62.5%) as a 
yellow oil. 
1
H-NMR (500 MHz, CDCl3) δ 4.13 (q, 2H, J = 7.0 Hz), 3.14 (s, 2H), 2.53 (br s, 4H), 
2.41 (br s, 4H), 2.07 (d, 2H, J = 7.0 Hz), 1.73-1.67 (m, 2H), 1.67-1.57 (m, 3H), 1.46-1.37 (m, 
1H), 1.22 (t, 3H, J = 7.0 Hz), 1.18-1.05 (m, 3H), 0.84-0.76 (m, 2H). 
13
C-NMR (125 MHz, 
CDCl3) δ 170.4, 65.7, 60.6, 59.7, 53.5, 53.3, 35.1, 32.0, 26.9, 26.3, 14.4. HRMS (ESI): 269.2224 
(M+H)
+
; calcd. for C15H29N2O2: 269.2229. 
2-(4-(cyclohexylmethyl)piperazin-1-yl)acetohydrazide (5.14a) 
 
Synthesized according to General Procedure B: 5.12a (1.68 g, 6.3 mmol, 1.0 equiv.), hydrazine 
monohydrate (1.3 mL, 25.2 mmol, 4.0 equiv.), EtOH (13 mL, 0.5 M). After extraction, 5.14a 
(1.24 g, 77.4%) was isolated as a white solid, which was used without further purification. 
1
H-
NMR (500 MHz, CDCl3) δ 8.15 (br s, 1H), 3.83 (br s, 2H), 3.02 (s, 2H), 2.48 (br s, 4H), 2.35 (br 
s, 4H), 2.06 (d, 2H, J = 7.5 Hz), 1.73-1.57 (m, 5H), 1.45-1.37 (m, 1H), 1.22-1.06 (m, 3H), 0.85-
0.75 (m, 2H). 
13
C-NMR (125 MHz, CDCl3) δ 170.7, 65.6, 60.8, 53.9, 53.8, 35.1, 32.0, 26.9, 26.2. 
HRMS (ESI): 255.2186 (M+H)
+
; calcd. for C13H27N4O: 255.2179 
N'-(3-allyl-2-hydroxybenzylidene)-2-(4-(cyclohexylmethyl)piperazin-1-yl)acetohydrazide 
(5.3) 
 
Synthesized according to General Procedure C: 5.14a (127 mg, 0.50 mmol, 1.0 equiv.), 2.1 (81 
mg, 0.50 mmol, 1.0 equiv.), 1.2 M HCl (29 μL, 0.035 mmol, 0.070 equiv.), EtOH (3 mL, 0.15 
M). Purification by silica gel column chromatography (gradient, 75-100% EtOAc/hexanes, then 
5-10% MeOH/EtOAc) yielded 5.3 (165 mg, 82.8%) as a light yellow solid. 
1
H-NMR (500 MHz, 
CDCl3) δ 11.12 (s, 1H), 10.13 (br s, 1H), 8.32 (s, 1H), 7.15 (d, 1H, J = 7.0 Hz), 7.04 (d, 1H, J = 
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7.0 Hz), 6.81 (t, 1H, J = 7.5 Hz), 6.01 (tdd, 1H, J = 6.5, 10.0, 16.5 Hz), 5.09-5.01 (m, 2H), 3.43 
(d, 2H, J = 6.5 Hz), 3.16 (s, 2H), 2.59 (br s, 1H), 2.44 (br s, 1H), 2.12 (d, 2H, J = 7.5 Hz), 1.77-
1.60 (m, 5H), 1.49-1.40 (m, 1H), 1.26-1.08 (m, 3H), 0.89-0.78 (m, 2H). 
13
C-NMR (125 MHz, 
CDCl3) δ 166.1, 156.4, 151.0, 136.6, 132.3, 129.2, 128.2, 119.1, 117.0, 115.7, 65.6, 61.1, 53.8, 
53.7, 35.1, 33.9, 31.9, 26.9, 26.2.  HRMS (ESI): 399.2754 (M+H)
+
; calcd. for C23H35N4O2: 
399.2755. 
Ethyl 2-(4-methylpiperazin-1-yl)acetate (5.12b) 
 
Synthesized according to general procedure A: 1-methylpiperazine (5.13, 1.1 mL, 10.0 mmol, 
1.0 equiv.), ethyl chloroacetate (2.3, 1.6 mL, 15.0 mmol, 1.5 equiv.), NaHCO3 (2.52 g, 30.0 
mmol, 3.0 equiv.), acetone (20 mL, 0.5 M). The reaction mixture was stirred at reflux overnight. 
Purification by silica gel column chromatography (gradient, 0-20% MeOH/EtOAc) gave 5.12b 
(993 mg, 53.4%) as a yellow oil. 
1
H-NMR (500 MHz, CDCl3) δ 4.05 (q, 2H, J = 7.0 Hz), 3.07 (s, 
2H), 2.48 (br s, 4H), 2.37 (br s, 4H), 2.16 (s, 3H), 1.13 (t, 3H, J = 7.0 Hz). 
13
C-NMR (125 MHz, 
CDCl3) δ 171.1, 61.5, 60.4, 55.8, 53.9, 47.0, 15.2. HRMS (ESI): 187.1443 (M+H)
+
; calcd. for 
C9H19N2O2: 187.1441. 
2-(4-methylpiperazin-1-yl)acetohydrazide (5.14b) 
 
A solution of 5.12b (990 mg, 5.3 mmol, 1.0 equiv.), hydrazine monohydrate (1.6 mL, 31.8 
mmol, 6.0 equiv.), and EtOH (10 mL, 0.5 M) was stirred at reflux overnight. The reaction 
mixture was cooled to room temperature and concentrated. The residue was dissolved in CHCl3 
(20 mL), dried over MgSO4, filtered, concentrated, and dried under high vacuum to afford 5.14b 
(471 mg, 51.5%) as a white solid, which was used without further purification.
 1
H-NMR (500 
MHz, CDCl3) δ 8.10 (br s, 1H), 3.78 (br s, 2H), 2.90 (s, 2H), 2.38 (br s, 4H), 2.27 (br s, 4H), 2.11 
(s, 3H). 
13
C-NMR (125 MHz, CDCl3) δ 170.2, 60.4, 54.9, 53.4, 45.9. HRMS (ESI): 173.1405 
(M+H)
+
; calcd. for C7H17N4O: 173.1397. 
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N'-(3-allyl-2-hydroxybenzylidene)-2-(4-methylpiperazin-1-yl)acetohydrazide (5.4) 
 
Synthesized according to General Procedure C: 5.14b (172 mg, 1.0 mmol, 1.0 equiv.), 2.1 (162 
mg, 1.0 mmol, 1.0 equiv.), 1.2 M HCl (58 μL, 0.070 mmol, 0.070 equiv.), EtOH (7 mL, 0.15 M). 
Purification by silica gel column chromatography (gradient, 0-60% MeOH/EtOAc) yielded 5.4 
(277 mg, 87.6%) as a light yellow solid. 
1
H-NMR (500 MHz, CDCl3) δ 11.33 (br s, 1H), 10.23 
(br s, 1H), 8.18 (s, 1H), 7.05 (d, 1H, J = 7.5 Hz), 6.91 (d, 2H, J = 7.0 Hz), 6.69 (t, 1H, J = 7.5 
Hz), 5.91 (tdd, 1H, J = 6.5, 10.0, 16.5 Hz), 5.03-4.91 (m, 2H), 3.32 (d, 2H, J = 6.5 Hz), 2.52 (br 
s, 4H), 2.38 (br s, 4H), 2.18 (s, 3H). 
13
C-NMR (125 MHz, CDCl3) δ 165.8, 156.0, 150.7, 136.3, 
132.0, 129.0, 127.8, 118.9, 116.7, 115.5, 60.7, 54.8, 53.4, 45.8, 33.6. HRMS (ESI): 317.1981 
(M+H)
+
; calcd. for C17H25N4O2: 317.1972. 
Ethyl 2-(4-phenylpiperazin-1-yl)acetate (3.6{30}) 
 
Synthesized according to general procedure A: 1-phenylpiperazine (3.5{30}, 1.62 g, 10.0 mmol, 
1.0 equiv.), ethyl chloroacetate (2.3, 1.6 mL, 15.0 mmol, 1.5 equiv.), NaHCO3 (2.52 g, 30.0 
mmol, 3.0 equiv.), acetone (20 mL, 0.5 M). The reaction mixture was stirred at reflux overnight. 
Purification by silica gel column chromatography (25-50% EtOAc/hexanes) gave 3.6{30} (2.38 
g, 96.1%) as a yellow oil. 
1
H-NMR (500 MHz, CDCl3) δ 7.26 (dd, 2H, J = 7.5, 9.0 Hz), 6.93 (d, 
2H, J = 9.0 Hz), 6.85 (t, 1H, J = 7.5 Hz), 4.20 (q, 2H, J = 7.0 Hz), 3.27 (s, 2H), 3.25 (t, 4H, J = 
5.0 Hz), 2.74 (t, 2H, J = 5.5 Hz), 1.28 (t, 3H, J = 7.0 Hz). 
13
C-NMR (125 MHz, CDCl3) δ 170.3, 
151.3, 129.2, 119.9, 116.2, 60.8, 59.6, 53.2, 49.1, 14.4. HRMS (ESI): 249.1605 (M+H)
+
; calcd. 
for C14H21N2O2: 249.1598. 
2-(4-phenylpiperazin-1-yl)acetohydrazide (3.1{30}) 
 
Synthesized according to General Procedure B: 3.6{30} (2.38 g, 9.6 mmol, 1.0 equiv.), 
hydrazine monohydrate (1.9 mL, 38.4 mmol, 4.0 equiv.), EtOH (20 mL, 0.5 M). After extraction, 
213 
 
3.1{30} (1.72 g, 76.3%) was isolated as a white solid, which was used without further 
purification.
 1
H-NMR (500 MHz, CDCl3) δ 8.21 (br s, 1H), 7.28 (dd, 2H, J = 7.5, 8.5 Hz), 6.92 
(d, 2H, J = 8.5 Hz), 6.88 (t, 1H, J = 7.5 Hz), 3.92 (br s, 2H), 3.19 (t, 4H, J = 5.0 Hz), 3.14 (s, 
2H), 2.68 (t, 2H, J = 5.0 Hz). 
13
C-NMR (125 MHz, CDCl3) δ 170.3, 151.0, 129.2, 120.1, 116.2, 
60.7, 53.7, 49.3. HRMS (ESI): 235.1558 (M+H)
+
; calcd. for C12H19N4O: 235.1553. 
N'-(3-allyl-2-hydroxybenzylidene)-2-(4-phenylpiperazin-1-yl)acetohydrazide (5.5) 
 
Synthesized according to General Procedure C: 3.1{30} (117 mg, 0.50 mmol, 1.0 equiv.), 2.1 
(81 mg, 0.50 mmol, 1.0 equiv.), 1.2 M HCl (29 μL, 0.035 mmol, 0.070 equiv.), EtOH (3 mL, 
0.15 M). Purification by silica gel column chromatography (gradient, 25-100% EtOAc/hexanes) 
yielded 5.5 (133 mg, 70.4%) as a yellow solid. 
1
H-NMR (500 MHz, CDCl3) δ 11.34 (s, 1H), 
10.14 (br s, 1H), 8.34 (s, 1H), 7.30 (t, 2H, J = 7.5 Hz), 7.20 (d, 1H, J = 7.0 Hz), 7.06 (d, 1H, J = 
7.0 Hz), 6.95 (d, 2H, J = 8.0 Hz), 6.91 (t, 1H, J = 7.0 Hz), 6.85 (t, 1H, J = 7.5 Hz), 6.04 (tdd, 1H, 
J = 6.5, 10.0, 17.0 Hz), 5.13-5.04 (m, 2H), 3.46 (d, 2H, J = 6.5 Hz), 3.31-3.23 (m, 6H), 2.76 (br 
s, 4H). 
13
C-NMR (125 MHz, CDCl3) δ 165.8, 156.4, 151.3, 151.0, 136.6, 132.4, 129.3 (2 
signals), 128.3, 120.2, 119.2, 116.9, 116.3, 115.8, 61.1, 53.8, 49.3, 34.0. HRMS (ESI): 379.2131 
(M+H)
+
; calcd. for C22H27N4O2: 379.2129. 
(1H-imidazol-1-yl)(4-phenylpiperazin-1-yl)methanone (5.16) 
 
To a round-bottom flask were added 1-phenylpiperazine (3.5{30}, 406 mg, 2.5 mmol, 1.0 
equiv.), CH2Cl2 (25 mL, 0.1 M), and 1,1’-carbonyldiimidazole (5.15, 454 mg, 2.8 mmol, 1.1 
equiv.). The reaction mixture was stirred at room temperature overnight. The reaction mixture 
was diluted with H2O (25 mL). The layers were separated, and the aqueous layer was extracted 
with CH2Cl2 (2 x 25 mL). The combined organic layers were washed with brine (25 mL), dried 
over MgSO4, filtered, and concentrated. Purification by silica gel column chromatography 
(gradient, 50-100% EtOAc/hexanes, then 5% MeOH/EtOAc) yielded 5.16 (578 mg, 90.2%) as a 
white solid. 
1
H-NMR (500 MHz, CDCl3) δ 7.89 (s, 1H), 7.28 (t, 2H, J = 8.0 Hz), 7.22 (s, 1H), 
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7.10 (s, 1H), 6.94-6.90 (m, 3H), 3.75 (t, 4H, J = 5.0 Hz), 3.22 (t, 4H, J = 5.0 Hz). 
13
C-NMR (125 
MHz, CDCl3) δ 150.9, 150.6, 137.0, 130.0, 129.4, 121.1, 118.0, 116.9, 49.5, 46.4. HRMS (ESI): 
257.1402 (M+H)
+
; calcd. for C14H17N4O: 257.1397. 
N'-(3-allyl-2-hydroxybenzylidene)-4-phenylpiperazine-1-carbohydrazide (5.6) 
 
To a round-bottom flask were added 5.16 (570 mg, 2.2 mmol, 1.0 equiv.), MeCN (11 mL, 0.2 
M), and iodomethane (0.55 mL, 8.8 mmol, 4.0 equiv.). The reaction mixture was stirred at rt 
overnight. The reaction mixture was then concentrated. The crude residue was resuspended in 
MeCN (5 mL, 0.5 M), and hydrazine monohydrate (1.1 mL, 22.0 mmol, 10.0 equiv.) was added. 
The reaction mixture was stirred at rt overnight. The reaction mixture was diluted with 1:1 
brine:1M NaOH (20 mL) and extracted with CH2Cl2 (3 x 20 mL). The combined organic layers 
were dried over MgSO4, filtered, concentrated, and dried under high vacuum. The crude material 
was dissolved in EtOH (15 mL, 0.15 M), and 2.1 (357 mg, 2.2 mmol, 1.0 equiv.) was added. The 
reaction mixture was stirred at reflux overnight. The reaction mixture was cooled to rt and 
concentrated. Purification by silica gel column chromatography (25-50% EtOAc/hexanes) 
yielded 5.6 (479 mg, 59.8%) as a light brown solid. 
1
H-NMR (500 MHz, CDCl3) δ 11.58 (s, 1H), 
9.79 (s, 1H), 8.26 (s, 1H), 7.22 (t, 2H, J = 7.5 Hz), 7.11 (d, 1H, J = 7.5 Hz), 7.01 (d, 1H, J = 6.5 
Hz), 6.88 (t, 1H, J = 7.5 Hz), 6.79 (t, 1H, J = 7.0 Hz), 6.79 (d, 2H, J = 8.0 Hz), 5.96 (tdd, 1H, J = 
6.5, 10.0, 17.0 Hz), 5.07-4.97 (m, 2H), 3.72 (s, 4H), 3.40 (d, 2H, J = 6.5 Hz), 3.15 (s, 4H). 
13
C-
NMR (125 MHz, CDCl3) δ 155.9, 155.1, 150.9, 147.9, 136.6, 131.6, 129.3, 128.7, 128.1, 120.5, 
119.2, 117.7, 116.6, 115.9, 49.3, 44.5, 33.9. HRMS (ESI): 365.1972 (M+H)
+
; calcd. for 
C21H25N4O2: 365.1972. 
N'-(3-allyl-2-hydroxybenzylidene)acetohydrazide (5.7) 
 
Synthesized according to General Procedure C: acetohydrazide (5.14c, 146 mg, 2.0 mmol, 1.0 
equiv.), 2.1 (324 mg, 2.0 mmol, 1.0 equiv.), 1.2 M HCl (0.12 mL, 0.14 mmol, 0.070 equiv.), 
EtOH (13 mL, 0.15 M). Purification by silica gel column chromatography (gradient, 25-75% 
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EtOAc/hexanes) yielded 5.7 (66 mg, 15.1%) as a white solid.  
1
H-NMR (500 MHz, CDCl3) δ 
10.54 (s, 1H), 10.50 (br s, 1H), 8.01 (s, 1H), 7.20 (d, 1H, J = 7.0 Hz), 7.14 (dd, 1H, J = 1.0, 7.5 
Hz), 6.89 (t, 1H, J = 7.5 Hz), 6.04 (tdd, 1H, J = 6.5, 9.5, 16.0 Hz), 5.12-5.05 (m, 2H), 3.46 (d, 
2H, J = 6.5 Hz), 2.37 (s, 3H). 
13
C-NMR (125 MHz, CDCl3) δ 173.2, 155.7, 148.0, 136.5, 132.6, 
129.6, 128.0, 119.8, 117.1, 116.0, 33.9, 20.8. HRMS (ESI): 219.1131 (M+H)
+
; calcd. for 
C12H15N2O2: 219.1128. 
N'-(3-allyl-2-hydroxybenzylidene)-2-phenylacetohydrazide (5.8) 
 
Synthesized according to General Procedure C: phenylacetohydrazide (5.14d 150 mg, 1.0 mmol, 
1.0 equiv.), 2.1 (162 mg, 1.0 mmol, 1.0 equiv.), 1.2 M HCl (58 μL, 0.070 mmol, 0.070 equiv.), 
EtOH (7 mL, 0.15 M). Purification by silica gel column chromatography (25-50% 
EtOAc/hexanes) yielded 5.8 (203 mg, 68.9%) as a light brown solid.  
1
H-NMR (500 MHz, 
(CD3)2SO) δ 11.97 (br s, 1H), 11.81 (s, 1H), 8.33 (s, 1H), 7.32-7.21 (m, 6H), 7.14 (d, 1H, J = 7.0 
Hz), 6.85 (t, 1H, J = 7.5 Hz), 5.94 (tdd, 1H, J = 6.5, 10.0, 17.0 Hz), 5.06-4.97 (m, 2H), 3.57 (s, 
2H), 3.33 (d, 2H, J = 6.5 Hz). 
13
C-NMR (125 MHz, (CD3)2SO) δ 166.4, 155.4, 148.9, 136.5, 
135.3, 131.5, 129.14, 129.09, 128.4, 127.0, 126.7, 119.0, 117.3, 115.7, 40.8, 33.3. HRMS (ESI): 
295.1447 (M+H)
+
; calcd. for C18H19N2O2: 295.1441. 
2-(4-benzylpiperazin-1-yl)-N'-(2-hydroxybenzylidene)acetohydrazide (1.2) 
 
Synthesized according to General Procedure C: 1.6 (124 mg, 0.50 mmol, 1.0 equiv.), 
salicylaldehyde (2.4, 0.11 mL, 1.0 mmol, 2.0 equiv.), 1.2 M HCl (29 μL, 0.035 mmol, 0.070 
equiv.), EtOH (3 mL, 0.15 M). Purification by silica gel column chromatography (gradient, 0-
15% MeOH/EtOAc) yielded 1.2 (146 mg, 83.1%) as a white solid. 
1
H-NMR (500 MHz, CDCl3) 
δ 11.06 (br s, 1H), 10.13 (br s, 1H), 8.38 (s, 1H), 7.34-7.25 (m, 6H), 7.19 (d, 1H, J = 7.5 Hz), 
6.98 (d, 2H, J = 8.5 Hz), 6.88 (t, 1H, J = 7.5 Hz), 6.85 (t, 1H, J = 7.5 Hz), 3.54 (s, 2H), 3.18 (s, 
2H), 2.62 (br s, 4H), 2.53 (br s, 4H). 
13
C-NMR (125 MHz, CDCl3) δ 166.1, 158.6, 151.1, 137.8, 
131.9, 131.0, 129.2, 128.4, 127.3, 119.4, 117.5, 117.2, 62.9, 61.0, 53.8, 53.0. HRMS (ESI): 
353.1982 (M+H)
+
; calcd. for C20H25N4O2: 353.1972. 
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2-(4-benzylpiperazin-1-yl)-N'-(propan-2-ylidene)acetohydrazide (5.10) 
 
Synthesized according to General Procedure C, but at room temperature: 1.6 (248 mg, 1.0 mmol, 
1.0 equiv.), acetone (5.17, 0.15 mL, 2.0 mmol, 2.0 equiv.), 1.2 M HCl (58 μL, 0.070 mmol, 
0.070 equiv.), EtOH (7 mL, 0.15 M). Purification by silica gel column chromatography 
(gradient, 0-20% MeOH/EtOAc) yielded 5.10 (224 mg, 77.7%) as a yellow oil.  
1
H-NMR (500 
MHz, CDCl3) δ 9.86 (s, 1H), 7.23-7.19 (m, 4H), 7.18-7.13 (m, 1H), 3.42 (s, 2H), 3.06 (s, 2H), 
2.51 (br s, 4H), 2.39 (br s, 2H), 2.01 (s, 3H), 1.80 (s, 3H). 
13
C-NMR (125 MHz, CDCl3) δ 165.6, 
154.4, 137.7, 128.8, 128.1, 127.0, 62.6, 60.6, 53.3(2), 53.2(5), 25.2, 16.4. HRMS (ESI): 
289.2028 (M+H)
+
; calcd. for C16H25N4O: 289.2023. 
1-benzyl-4-methylpiperazine (5.9) 
 
Synthesized according to General Procedure A: benzyl chloride (1.2 mL, 10.0 mmol, 1.0 equiv.), 
1-methylpiperazine (1.7 mL, 15.0 mmol, 1.5 equiv.), K2CO3 (4.15 g, 30.0 mmol, 3.0 equiv.), 
THF (20 mL, 0.5 M). The reaction mixture was stirred at reflux overnight. Purification by silica 
gel column chromatography (gradient, 50-100% EtOAc/hexanes, then 10-20% MeOH/EtOAc) 
gave 5.9 (1.57 g, 82.8%) as a yellow oil. 
1
H-NMR (500 MHz, CDCl3) δ 7.34-7.28 (m, 4H), 7.26-
7.22 (m, 1H), 3.51 (s, 2H), 2.46 (br s, 8H), 2.29 (s, 3H). 
13
C-NMR (125 MHz, CDCl3) δ 138.2, 
129.2, 128.2, 127.0, 63.1, 55.2, 53.2, 46.1. HRMS (ESI): 191.1543 (M+H)
+
; calcd. for C12H19N2: 
191.1543. 
2-(2-aminoethyl)-phenol (5.19) 
 
To an oven-dried round-bottom flask were added lithium aluminum hydride (569 mg, 15.0 
mmol, 3.0 equiv.) and anhydrous THF (5 mL). The mixture was stirred at 0°C under N2, and a 
solution of 2-hydroxy-β-nitrostyrene (5.18, 826 mg, 5.0 mmol, 1.0 equiv.) in anhydrous THF (10 
mL) was added dropwise via addition funnel. The reaction mixture was stirred at rt for 2h. The 
reaction mixture was cooled to 0°C and quenched by the dropwise addition of H2O (20 mL). The 
solid was filtered and washed with THF. The filtrate was acidified with 1 M HCl (20 mL) and 
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extracted with EtOAc (2 x 20 mL). The combined organic layers were extracted with 1 M HCl (2 
x 20 mL). The combined aqueous layers were treated with L-tartaric acid (3.0 g, 20.0 mmol, 4.0 
equiv.), basified with 28% aqueous NH3 (20 mL), and extracted with CHCl3 (3 x 20 mL). The 
combined organic layers from the CHCl3 extraction were washed with brine (20 mL), dried over 
MgSO4, filtered, and concentrated. Purification by silica gel column chromatography (gradient, 
0-60% MeOH/EtOAc) yielded 5.19 (165 mg, 24.1%) as a light yellow solid. 
1
H-NMR (500 
MHz, CDCl3) δ 7.13 (dt, 1H, J = 1.5, 7.5 Hz), 7.01 (dd, 1H, J = 1.5, 7.5 Hz), 6.91 (dd, 1H, J = 
1.0, 8.0 Hz), 6.77 (dt, 1H, J = 1.5, 7.5 Hz), 5.25 (br s, 3H), 3.05 (t, 2H, J = 5.0 Hz), 2.78 (t, 2H, J 
= 5.0 Hz). 
13
C-NMR (125 MHz, CDCl3) δ 156.9, 131.1, 128.3, 128.1, 119.3, 117.8, 42.4, 36.5. 
2-chloro-N-(2-hydroxyphenethyl)acetamide (5.21) 
 
To a round-bottom flask were added 5.19 (165 mg, 1.2 mmol, 1.0 equiv.), CH2Cl2 (2 mL), sat. 
Na2CO3 (2 mL), and chloroacetyl chloride (5.20, 0.16 mL, 2.4 mmol, 2.0 equiv.). The reaction 
mixture was stirred vigorously at rt overnight. The reaction mixture was diluted with 1 M HCl 
(10 mL) and extracted with CH2Cl2 (3 x 10 mL). The combined organic layers were washed with 
brine (10 mL), dried over MgSO4, filtered, and concentrated. Purification by silica gel column 
chromatography (gradient, 10-40% EtOAc/hexanes) yielded 5.21 (100 mg, 39.1%) as a white 
solid. 
1
H-NMR (500 MHz, (CD3)2CO) δ 8.50 (s, 1H), 7.67 (br s, 1H), 7.09 (d, 1H, J = 7.5 Hz), 
7.04 (t, 1H, J = 7.5 Hz), 6.85 (d, 1H, J = 8.0 Hz), 6.75 (t, 1H, J = 7.5 Hz), 4.06 (s, 2H), 3.47 (q, 
2H, J = 6.5 Hz), 2.84 (t, 2H, J = 7.0 Hz). 
13
C-NMR (125 MHz, (CD3)2CO) δ 166.9, 156.1, 131.3, 
128.4, 126.2, 120.4, 115.9, 43.2, 40.8, 30.6. HRMS (ESI): 214.0629 (M+H)
+
; calcd. for 
C10H13NO2: 214.0629. 
2-(4-benzylpiperazin-1-yl)-N-(2-hydroxyphenethyl)acetamide (1.17b) 
 
Synthesized according to General Procedure A: 1.10 (166 mg, 0.94 mmol, 2.0 equiv.), 5.21 (100 
mg, 0.47 mmol, 1.0 equiv.), K2CO3 (130 mg, 0.94 mmol, 2.0 equiv.), THF (2 mL, 0.25 M). 
Purification by silica gel column chromatography (gradient, 0-10% MeOH/EtOAc) gave 1.17b 
(143 mg, 86.0%) as a white solid. 
1
H-NMR (500 MHz, (CD3)2CO) δ 8.83 (br s, 1H), 7.51 (t, 1H, 
J = 5.5 Hz), 7.34-7.31 (m, 4H), 7.29-7.26 (m, 1H), 7.11-7.06 (m, 2H, J = 7.5 Hz), 6.84 (d, 1H, J 
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= 7.5 Hz), 6.79 (t, 1H, J = 7.5 Hz), 3.59 (q, 2H, J = 7.0 Hz), 3.53 (s, 2H), 3.01 (s, 2H), 2.89 (t, 
2H, J = 7.0 Hz), 2.49 (br s, 4H), 2.44 (br s, 4H). 
13
C-NMR (125 MHz, (CD3)2CO) δ 171.4, 155.4, 
137.5, 130.7, 129.4, 128.4, 128.0, 127.3, 125.1, 119.7, 115.8, 62.9, 61.3, 53.3, 52.9, 39.2, 30.5. 
HRMS (ESI): 354.2173 (M+H)
+
; calcd. for C21H28N3O2: 354.2176. 
N'-(3-allyl-2-hydroxybenzyl)-2-(4-benzylpiperazin-1-yl)acetohydrazide (1.19) 
 
To a round-bottom flask were added PAC-1 (196 mg, 0.50 mmol, 1.0 equiv.) and MeOH (2.5 
mL, 0.2 M). The solution was stirred at 0°C, and NaBH4 (95 mg, 2.5 mmol, 5.0 equiv.) was 
added. The reaction mixture was stirred while allowing to gradually warm to rt. After 22 hours, 
an additional portion of NaBH4 (95 mg, 2.5 mmol, 5.0 equiv.) was added, and the solution was 
stirred at rt overnight. The reaction mixture was diluted with H2O (10 mL) and extracted with 
EtOAc (3 x 10 mL). The combined organic layers were washed with brine (10 mL), dried over 
MgSO4, filtered, and concentrated to yield 1.19 (159 mg, 80.9%) as a light yellow solid. 
1
H-
NMR (500 MHz, CDCl3) δ 9.31 (br s, 1H), 8.50 (d, 1H, J = 4.5 Hz), 7.34-7.25 (m, 5H), 7.10 (dd, 
1H, J = 2.0, 7.5 Hz), 6.87 (dd, 1H, J = 2.0, 7.5 Hz), 6.75 (t, 1H, J = 7.5 Hz), 6.06 (tdd, 1H, J = 
6.5, 10.0, 16.5 Hz), 5.14-5.07 (m, 2H), 5.04 (br s, 1H), 4.17 (s, 2H), 3.47-3.45 (m, 4H), 3.02 (s, 
2H), 2.41 (br s, 4H), 2.32 (br s, 2H). 
13
C-NMR (125 MHz, CDCl3) δ 170.0, 154.7, 137.8, 137.1, 
130.0, 129.2, 128.3, 128.0, 127.6, 127.2, 120.4, 119.6, 115.5, 62.9, 60.5, 54.3, 53.5, 52.9, 34.1. 
HRMS (ESI): 395.2428 (M+H)
+
; calcd. for C23H31N4O2: 395.2442. 
 
5.7.2. Biological Evaluation 
Materials All reagents were obtained from Fisher unless otherwise indicated. All buffers 
were made with MilliQ purified water. Annexin V Binding Buffer contains 10 mM HEPES (pH 
7.4), 140 mM NaCl, 2.5 mM CaCl2. 
 
Cell Culture U-937 cells were obtained from the American Type Culture Collection. All 
cultures were maintained at low passage number in RPMI 1640 (U-937) or DMEM (D54) 
supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin and grown at 37°C 
and 5% CO2. 
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72hr IC50 Cell Death Assay – U-937 cells To each inner well of a 96-well plate was added 49 
μL of RPMI 1640 complete growth media. To each inner well was added 1 µL of compound 
stock solutions in DMSO at nine concentrations such that the cells were treated with half-log 
concentrations between 0.01 µM and 100 µM compound. 50 μL of a suspension of cells at 
300,000 cells/mL were plated into the wells, for a final density of 15,000 cells per well. Each 
concentration was tested in triplicate per plate. In each plate 3 wells received 1 μL of a positive 
death control and 3 wells received 1 μL DMSO as a live cell vehicle control. The outer wells 
were filled with sterile PBS pH 7.4 (200 µL), and the plates were then incubated at 37°C with 
5% CO2 for 72 hours.  After the 72 hour incubation period, the plates were analyzed using a 
Sulforhodamine B assay.
18
 Specifically, to each well of the plate 25 µL of a 50% (w/v) solution 
of trichloroacetic acid in H2O was added and the plates were incubated for 4 hours at 4°C. The 
plates were then washed gently with H2O five times. The plates were allowed to air dry after 
which 100 µL of a 0.057% (w/v) Sulforhodamine B in a 1% (v/v) acetic acid solution was added 
to each well for 30 minutes at room temperature. The plates were gently washed 5 times with 1% 
(v/v) acetic acid and air dried. 200 µL of 10 mM Tris base (pH 10.4) was added to each well and 
the plates were placed on a shaker for thirty minutes. The level of SRB was quantified by 
absorbance at 510 nm on a SpectraMax Plus 384 Microplate Reader (Molecular Devices). The 
percent cell death was calculated and normalized to the positive control (100% cell death) and 
the negative control (0% cell death). The percent cell death was averaged for each compound 
concentration and plotted as a function of compound concentration. The data were fit to a 
logistical dose response curve using OriginPro 9.1, and the IC50 value was calculated. The 
experiment was repeated three times and the average of the calculated IC50 values was reported. 
The standard error of the mean (s.e.m.) was determined and reported for the triplicate 
experiments. 
 
72hr IC50 Cell Death Assay – D54 cells To each inner well of a 96-well plate was added 50 
µL of a suspension of cells in DMEM complete growth media at 50,000 cells/mL, for a final 
density of 2500 cells/well. Outer wells were filled with sterile PBS pH 7.4 (200 µL). The plates 
were incubated at 37°C with 5% CO2 for 2-3 hours to allow cells to adhere. Compound solutions 
were prepared in 2% DMSO/DMEM complete growth media at 2x final concentration, and 
solutions were added to the plates (1% DMSO final concentration). Cells were treated at nine 
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concentrations in half-log increments between 0.01 µM and 100 µM compound. Each 
concentration was tested in triplicate per plate. In each plate 3 wells received 1 μL of a positive 
death control and 3 wells received 1 μL DMSO as a live cell vehicle control. The plates were 
then incubated at 37°C with 5% CO2 for 72 hours. After the 72 hour incubation period, the plates 
were analyzed using a Sulforhodamine B assay.
18
 Specifically, to each well of the plate 100 µL 
of a 10% (w/v) solution of trichloroacetic acid in H2O was added and the plates were incubated 
for 4 hours at 4°C. The plates were then washed gently with H2O five times. The plates were 
allowed to air dry after which 100 µL of a 0.057% (w/v) Sulforhodamine B in a 1% (v/v) acetic 
acid solution was added to each well for 30 minutes at room temperature. The plates were gently 
washed 5 times with 1% (v/v) acetic acid and air dried. 200 µL of 10 mM Tris base (pH 10.4) 
was added to each well and the plates were placed on a shaker for thirty minutes. The level of 
SRB was quantified by absorbance at 510 nm on a SpectraMax Plus 384 Microplate Reader 
(Molecular Devices). The percent cell death was calculated and normalized to the positive 
control (100% cell death) and the negative control (0% cell death). The percent cell death was 
averaged for each compound concentration and plotted as a function of compound concentration. 
The data were fit to a logistical dose response curve using OriginPro 9.1, and the IC50 value was 
calculated. The experiment was repeated three times and the average of the calculated IC50 values 
was reported. The standard error of the mean (s.e.m.) was determined and reported for the 
triplicate experiments. 
 
Induction of Apoptosis by Hit Compounds To each well of a 12-well plate for compound 
treatment was added 1 mL of a suspension of D54 cells in DMEM complete growth media at 
70,000 cells/mL. The cells were incubated at 37°C with 5% CO2 for 2-3 hours to allow cells to 
adhere. To each well was then added 10 µL of 3 mM DMSO solutions to achieve a final 
compound concentration of 30 μM. 10 µL of DMSO was added to one well as a live cell vehicle 
control. Wells not containing compounds were filled with 1 mL sterile PBS pH 7.4. The cells 
were incubated at 37 ºC with 5% CO2 for 24 hours. The media was transferred to flow tubes. 
Sterile PBS pH 7.4 (0.5 mL) was then added to the wells to wash and transferred to flow tubes, 
and the remaining cells were harvested with trypsin (0.5 mL, 1-2 min) and transferred to flow 
tubes. The cells were centrifuged (1000 x g for 3 min) and resuspended in 450 μL Annexin V 
Binding Buffer containing 3 μL of FITC-conjugated Annexin V stain (Southern Biotech) and 
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0.25 μL of a 1 mg/mL solution of propidium iodide (Sigma) to a final concentration of 0.56 
μg/mL. Samples were stored on ice until assessment. Cell populations were analyzed on a 
Becton Dickinson LSR II cell flow cytometer. 10,000 events per sample were recorded. 
 
EGTA Fluorescence Titration Assay  This titration assay is based on a published 
protocol.
13
 Buffer (50 mM HEPES, 100 mM KNO3, 8.1 mM EGTA, pH 7.2) and solutions of 
compounds (1 mM in DMSO) and Zn(OTf)2 (100 µM-1 M in H2O) were prepared. The 
compound solutions were diluted ten-fold with buffer (final [compound] = 100 µM, final 
[EGTA] = 7.3 mM), and 198 µL of the resulting solution was added to each well of a 96-well 
plate. Each of 24 Zn(OTf)2 solutions was added to four wells in each plate. The wells were 
allowed to equilibrate for 5 minutes, and the plates were analyzed via a Molecular Devices 
SpectraMax M3 fluorescent plate reader (ex. 410 nm, em. 475 nm). Fluorescence intensity at 475 
nm of each of four technical replicates was plotted against free Zn
2+
 concentration ([Zn
2+
]F), 
calculated using the MaxChelator program (maxchelator.stanford.edu). The data were analyzed 
using OriginPro 9.1 and fitted to a formation curve based on Equation 4.1:
13
 
 
I = (IminKd + Imax[Zn
2+
]F)/(Kd + [Zn
2+
]F)  (Equation 4.1) 
 
where Imin and Imax were defined as the fluorescence intensity of the free probe (PAC-1 or 
derivative) and that of the Zn
2+
-probe complex, respectively. 
 
Evaluation of Compound Tolerability in vivo. All experimental procedures were reviewed 
and approved by the University of Illinois Institutional Animal Care and Use Committee. 8-10 
week old C57BL/6 mice were used in all experiments (Charles River). Mice (n = 3/cohort) were 
evaluated for their ability to tolerate a single 150 μmol/kg intravenous dosage of compounds, 
formulated at 20 mM in 200 mg/mL hydroxypropyl-β-cyclodextrin (HPβCD) at pH 5.5. Mice 
were treated, then videotaped for 30 seconds immediately upon return to their cages. Mice were 
observed for clinical signs continuously for 30 minutes and intermittently over the next 24 hours. 
Mice were further allowed 1 week to demonstrate delayed effects of treatment. The extent of 
initial response was graded from 0 (no effect) to 4 (most severe toxicity). Compounds that 
proved lethal were noted.  
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5.7.3. Spectra 
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